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Background: Approximately 670,000 people in the UK have dementia. Previous literature suggests that
physical exercise could slow dementia symptom progression.
Objectives: To estimate the clinical effectiveness and cost-effectiveness of a bespoke exercise programme,
in addition to usual care, on the cognitive impairment (primary outcome), function and health-related
quality of life (HRQoL) of people with mild to moderate dementia (MMD) and carer burden and HRQoL.
Design: Intervention development, systematic review, multicentred, randomised controlled trial (RCT) with
a parallel economic evaluation and qualitative study.
Setting: 15 English regions.
Participants: People with MMD living in the community.
Intervention: A 4-month moderate- to high-intensity, structured exercise programme designed specifically
for people with MMD, with support to continue unsupervised physical activity thereafter. Exercises were
individually prescribed and progressed, and participants were supervised in groups. The comparator was
usual practice.
Main outcome measures: The primary outcome was the Alzheimer’s Disease Assessment Scale –
Cognitive Subscale (ADAS-Cog). The secondary outcomes were function [as measured using the Bristol
Activities of Daily Living Scale (BADLS)], generic HRQoL [as measured using the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L)], dementia-related QoL [as measured using the Quality of Life in Alzheimer’s
Disease (QoL-AD) scale], behavioural symptoms [as measured using the Neuropsychiatric Inventory (NPI)],
falls and fractures, physical fitness (as measured using the 6-minute walk test) and muscle strength.
Carer outcomes were HRQoL (Quality of Life in Alzheimer’s Disease) (as measured using the EQ-5D-3L) and
carer burden (as measured using the Zarit Burden Interview).
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The economic evaluation was expressed in terms of incremental cost per quality-adjusted life-year (QALY)
gained from a NHS and Personal Social Services perspective. We measured health and social care use with
the Client Services Receipt Inventory. Participants were followed up for 12 months.
Results: Between February 2013 and June 2015, 494 participants were randomised with an intentional
unequal allocation ratio: 165 to usual care and 329 to the intervention. The mean age of participants
was 77 years [standard deviation (SD) 7.9 years], 39% (193/494) were female and the mean baseline
ADAS-Cog score was 21.5 (SD 9.0). Participants in the intervention arm achieved high compliance rates,
with 65% (214/329) attending between 75% and 100% of sessions. Outcome data were obtained for
85% (418/494) of participants at 12 months, at which point a small, statistically significant negative
treatment effect was found in the primary outcome, ADAS-Cog (patient reported), with a mean difference
of –1.4 [95% confidence interval (CI) –2.62 to –0.17]. There were no treatment effects for any of the
other secondary outcome measures for participants or carers: for the BADLS there was a mean difference
of –0.6 (95% CI –2.05 to 0.78), for the EQ-5D-3L a mean difference of –0.002 (95% CI –0.04 to 0.04),
for the QoL-AD scale a mean difference of 0.7 (95% CI –0.21 to 1.65) and for the NPI a mean difference
of –2.1 (95% CI –4.83 to 0.65). Four serious adverse events were reported. The exercise intervention was
dominated in health economic terms.
Limitations: In the absence of definitive guidance and rationale, we used a mixed exercise programme.
Neither intervention providers nor participants could be masked to treatment allocation.
Conclusions: This is a large well-conducted RCT, with good compliance to exercise and research
procedures. A structured exercise programme did not produce any clinically meaningful benefit in function
or HRQoL in people with dementia or on carer burden.
Future work: Future work should concentrate on approaches other than exercise to influence cognitive
impairment in dementia.
Trial registration: Current Controlled Trials ISRCTN32612072.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full programme and will be published in full in Health
Technology Assessment Vol. 22, No. 28. See the NIHR Journals Library website for further project
information. Additional funding was provided by the Oxford NIHR Biomedical Research Centre and the
Oxford NIHR Collaboration for Leadership in Applied Health Research and Care.
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Plain English summary
Dementia is a progressive brain disease for which there is currently no cure. The disease reduces theability to plan thoughts and movements, make decisions and remember things. People with dementia
can feel confused, disorientated and frightened. Many live with the diagnosis for years in the community
and, ultimately, may require nursing care. The causes of the disease are complex and not fully understood.
However, research over the last 10 years suggests that exercise may help, as it improves blood flow to the
brain and releases chemicals from muscles. To see if this is so, we asked nearly 500 people with dementia
and their carers to join this research study. We tracked the thinking abilities of people with dementia, as
well as their independence, body functioning, mental health and enjoyment of life. We also looked at the
costs of all the health and social services they used. We asked two-thirds of the people with dementia to
try out a new exercise programme, which included 4 months of face-to-face sessions that involved going
to a group class twice a week and trying to do more exercise at home. Participants then tried to carry
on the exercise programme at home for 8 months with some support provided by physiotherapists. We
tracked nearly all of the people who signed up for the trial. Two-thirds of those who asked to go to the
exercise classes attended the majority of sessions. One-third of the people did not complete the exercise
classes. The results showed that people enjoyed the exercise classes and that very frail people managed to
join in. Physical fitness and muscle strength improved. However, body functioning, mental health and
enjoyment in life were no different from the group who did not take the exercise programme. Thinking
abilities were a little worse in the group who did the exercise.
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Scientific summary
Background
Dementia prevalence in the UK is estimated to be around 670,000 people. Previous literature suggests that
physical exercise could slow or prevent dementia symptom progression.
Objectives
To undertake a definitive randomised controlled trial (RCT) to estimate the effects of an exercise or physical
activity intervention that is feasible for delivery within the current constraints of NHS delivery, compared
with usual NHS care in community-dwelling adults with mild to moderate dementia (MMD).
The specific objectives of the Dementia and Physical Activity (DAPA) trial were to:
1. refine an exercise intervention for delivery to community-dwelling populations of people with dementia,
including a systematic review to inform intervention development
2. pilot critical procedures in the intervention and trial
3. complete a definitive, individual RCT to estimate the effectiveness of exercise, in addition to usual care,
on cognitive impairment (primary outcome), function and quality of life in people with mild or moderate
dementia, and on carer burden for carers
4. complete a parallel cost study and conduct an economic evaluation from a NHS and Personal Social
Services perspective
5. investigate intervention effects in predefined subgroups of gender and dementia severity
6. undertake a qualitative study into the experiences of participants and carers taking part in the intervention.
Methods
Trial design
A multicentred RCT was undertaken with an embedded systematic review, qualitative study and economic
evaluation. The trial compared treatment as usual with treatment as usual plus a 4-month group exercise
intervention and ongoing support to encourage increased physical activity. We randomised individuals
using a stratified unbalanced randomisation (2 : 1 in favour of the intervention arm).
Setting
The trial took place in 15 regions across England, including NHS primary, secondary and community care
services. The intervention was delivered predominantly in community gym facilities.
Control intervention
Routinely delivered usual care was consistent with the recommendations of the National Institute for Health
and Care Excellence clinical guidance (CG42). We stratified the randomisation by regions (with regions
representing large NHS trusts and/or Clinical Commissioning Groups) to account for regional differences in
standard care. All participants were provided with information sheets detailing the recommended physical
activity levels for their age category.
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Intervention (groups exercise) arm
We developed a prespecified and manualised intervention. Physiotherapists and exercise assistants received
training to deliver the trial intervention and underwent a minimum of two quality assurance checks.
The intervention comprised a 4-month individually tailored intervention that was delivered to groups of,
on average, 6–8 participants. Exercise included moderate- to high-intensity aerobic (fixed cycles) and
resistance (weighted jackets and dumb-bells) training. Exercise sessions lasted for 1 hour and took place
twice per week, in addition to 50 minutes of recommended home exercises at moderate intensity. After
4 months, participants were encouraged to continue exercising in the community, with motivational
support telephone calls and face-to-face review sessions. Behavioural strategies were used throughout
to enhance adherence levels.
Recruitment
Interested people were first contacted to ascertain eligibility, the criteria for which comprised a diagnosis
of dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, as well
as the participant having dementia severity lying between mild and moderate, being community-dwelling,
being able to stand from a chair independently, being able to walk 10 feet without human assistance and
not having any acute, unstable or terminal illness that may have precluded their participation in the exercise.
Follow-up
We collected outcome data from participants and carers in their own homes at baseline and follow-up
data at 6 and 12 months after randomisation.
Randomisation and masking (blinding)
The random allocation sequence was generated by an independent statistician, using a computerised
random number generator, and implemented by a central telephone registration and randomisation service
at the Warwick Clinical Trials Unit. The unit of randomisation was the individual participant. Randomisation
was stratified by region and dementia severity (moderate or mild). Participants were randomised to:
1. usual care
2. usual care plus exercise intervention.
Randomisation was 2 : 1 in favour of the exercise intervention group, to allow exercise groups to be
assembled in a shorter period of time and to reduce the chance of participants withdrawing between
randomisation and the exercise classes commencing. In addition, the baseline measures were taken close
to the exercise classes commencing.
Neither intervention providers nor participants could be masked to treatment allocation. If a research
clinician became unmasked, then follow-up assessments were conducted by different research workers.
All study personnel involved with data entry, follow-up assessments and management were masked until
the final analysis was complete.
Sample size
A sample size of 360 participants provided 80% power to detect a minimum clinical between-group
difference of 2.45 [baseline standard deviation (SD) 7.8 based on n = 66 participants] on the Alzheimer’s
Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) at 12 months with a 5% level of significance
and 2 : 1 randomisation in favour of the intervention. This equated to a standardised effect size of 0.31.
An overall difference of 2–2.5 change points on the ADAS-Cog was considered to be a worthwhile target.
To account for therapist effects, the sample size was inflated using a design effect of 1.04 (intracluster
correlation = 0.01) assuming that there are five participants per group (and recognising that it may not
have been possible to achieve and retain the proposed eight recruits to each group), giving a sample size
of 375. The sample size was then further inflated to account for 20% loss to follow-up, of which 10%
was predicted to be attributable to death. Thus, a final minimum sample size of 468 participants was
required, with 312 participants to be randomly allocated to the intervention arm and 156 participants to
the control arm.
SCIENTIFIC SUMMARY
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Monitoring and ethics
The study benefited from having broad-ranging patient and public involvement at various stages of
the project. The National Institute for Health Research (NIHR) involved people with dementia and their
representatives in the specifying of the question, including methods, selecting important outcome domains
and type of intervention, throughout the commissioning process. The study team involved people with
dementia, their representatives and other stakeholders in the intervention and protocol development,
including receiving detailed feedback on the intervention, questionnaires, approach and invitation,
acceptability of procedures and logistics. Carers of people with dementia were formal members of the study
Trial Steering Committee/Data Monitoring Committee. At the end of the study, people with dementia and
their carers were invited to a joint feedback day with research and clinical staff, and contributed actively to
discussions about the results and interpretation. Trial oversight was undertaken by a Trial Steering
Committee and an independent Data Monitoring Committee. Ethics permission was granted for all
participating sites.
Clinical outcomes and analysis
The primary outcome was the ADAS-Cog with item-level imputation, which measured global cognitive
impairment. The secondary outcomes were the additional subscales of the ADAS-Cog (praxis, memory,
attention and language), the Bristol Activities of Daily Living Scale (BADLS), health-related quality of life
(HRQoL) [EuroQol-5 Dimensions, three-level version (EQ-5D-3L)], dementia-related quality of life [Quality of
Life in Alzheimer’s Disease (QoL-AD) scale] and behavioural symptoms [Neuropsychiatric Inventory (NPI)].
Carer-related outcomes were the carer HRQoL (EQ-5D-3L) and carer burden [Zarit Burden Interview (ZBI)],
the patient’s health- and social-care usage (Client Services Receipt Inventory) and falls and fractures.
For the primary and secondary analyses, multilevel models, adjusted for age, gender, Standardised Mini
Mental State Examination and the baseline measure of the outcome, were used with a random effect for
region to estimate the treatment effects and 95% confidence intervals (CIs). Sensitivity analyses included
(1) excluding participants who were unable to complete all items of the ADAS-Cog, (2) excluding missing
ADAS-Cog scores with the worst score assignment and (3) item response theory to assess the effects
within specific cognitive domains within the primary outcome of ADAS-Cog. Prespecified subgroup
analyses were performed on cognitive impairment severity, type of dementia, physical performance and
gender, with formal tests of interaction.
Economic evaluation
In parallel, the costs of the exercise intervention were estimated, including the costs of training the
health-care professionals, delivering the group supervision, participant monitoring activities and any
follow-up/management. Data were collected on broader health and Personal Social Services and broader
societal resource inputs using a modified version of the Client Services Receipt Inventory, which was
administered via face-to-face interviews at baseline and at 6 and 12 months post randomisation. Resource
inputs were valued using a combination of primary research and data collated from secondary national tariff
sets, using standard accounting methods. The economic evaluation took the form of a cost–utility analysis,
with quality-adjusted life-year (QALY) profiles for DAPA trial participants based on participant and carer
reports of EQ-5D-3L-generated HRQoL outcomes at baseline and at 6 and 12 months post randomisation.
We conducted a bivariate regression of costs and QALYs, with multiple imputation of missing data, to
estimate the incremental cost per QALY gained associated with the exercise intervention. Several sensitivity
analyses were undertaken to assess the impact of uncertainty surrounding aspects of the economic
evaluation. Prespecified subgroup analyses were also conducted for the main cost-effectiveness results to
explore the effects of heterogeneity in the trial population.
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Results
We recruited in 15 different regions in England, using a mixture of NIHR-funded research networks,
dementia research networks, primary care and other third-sector organisations. The intervention
was delivered in 27 different venues. Between February 2013 and June 2015, 494 participants were
randomised: 165 to receive treatment as usual and 329 to receive treatment as usual plus the DAPA
exercise intervention. The mean age of participants was 77 years, 39% (193/494) were female and the
mean baseline ADAS-Cog score was 21.5. Participants in the intervention arm achieved good compliance
rates, with 65% attending > 75% of the scheduled group supervision sessions. Outcome data were
obtained for 85% of participants at 12 months. At 12 months, there was evidence of a small, statistically
significant negative treatment effect in the primary outcome, ADAS-Cog, with a mean difference of –1.4
(95% CI –2.62 to –0.17). There was no evidence of treatment effects for any of the other patient-related
secondary outcomes: for the BADLS there was a mean difference of –0.6 (95% CI –2.05 to 0.78), for the
EQ-5D-3L a mean difference of –0.002 (95% CI –0.04 to 0.04), for the QoL-AD scale a mean difference of
0.7 (95% CI –0.21 to 1.65) and for the NPI a mean difference of–2.1 (95% CI –4.83 to 0.65). Neither was
there evidence of treatment effects for the carer-related secondary outcomes: for the EQ-5D-3L there was
a mean difference of –0.002 (95% CI –0.04 to 0.04), for the ZBI a mean difference of –0.5 (95% CI –2.78
to 1.72) and for falls an incident rate ratio of 1 : 1 (95% CI 0.84 to 1.33). Within-group analyses show that
participants from the intervention arm became fitter over a 6-week period, as measured by the 6-minute
walk test (n = 231) with a mean of 343.7 m walked (SD 112.9 m) pre intervention and a mean of 361.8 m
walked (SD 115.3 m) post intervention, with an estimate of the difference between the two of –18.1
(95% CI –24.6 to –11.6; p < 0.001). Muscle strength and amount of weight lifted increased.
Qualitative study
We conducted a qualitative study in parallel, the aim of which was to provide insight into participants’ and
carers’ experiences of taking part in the experimental intervention, and physiotherapists’ experiences of
delivering it. The qualitative study explored patient, carer and therapist attitudes towards the intervention
while they were participating in it.
Sampling of participants and their carers was consecutive and participants were drawn from five intervention
delivery sites. Sites were selected to reflect a range of settings, and reflexive observations were carried out at
each site. Once observations of the sites were completed, we invited participants and carers to take part in
an interview. Participants had already consented to be approached to take part in the qualitative study as
part of the consent process for the RCT.
Our data comprised:
l notes taken during observations of exercise classes
l interviews with trial participants
l interviews with carers of trial participants
l interviews with physiotherapists delivering the classes.
The data were analysed as a single data set. Identifying information was anonymised to ensure that
interviewees’ confidentiality was maintained.
We observed five sites four times for approximately 1.5 hours each between November 2013 and
March 2015. Settings for the delivery of the intervention included pleasant leisure centres with cafes and
soft seating for carers to use, large warehouse-style gyms situated on industrial estates with very loud
heating systems and rather run-down local authority amenities with no facilities for carers to use. These
were located in a range of urban, suburban and rural settings.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
Eight participants and seven carers agreed to take part in an interview. Six participants chose to be
interviewed on their own and two chose to have their carer or friend present. Six carers chose to
be interviewed on their own and one to be interviewed with the participant. All five physiotherapists
delivering the intervention at the included sites agreed to be interviewed (one via a telephone interview).
The qualitative data reflects the quantitative findings, in that participants and carers did not feel that the
intervention had changed their cognitive functioning but they did feel fitter and stronger and enjoyed
attending the classes.
Economic evaluation results
The mean cost of the exercise programme in participants with complete resource-use data over the
entire follow-up period was £1269 [standard error (SE) £30]. Over the entire follow-up period, and for
participants with complete data, the mean total NHS and Personal Social Service costs, inclusive of the cost
of the intervention, were £5945 (SE £492) in the intervention arm compared with £4597 (SE £444) in the
control arm, generating a mean cost difference of £1347 (bootstrap 95% CI £8 to £2136; p = 0.0426).
There were no (statistically significant) differences in the overall EQ-5D-3L utility scores or EQ-5D-3L visual
analogue scale scores between the exercise intervention and usual-care groups at each of the follow-up
time points. The mean incremental cost-effectiveness of the exercise intervention was estimated at
–£74,227 per QALY gained (north-west quadrant of cost-effectiveness plane), that is, on average, the
intervention was associated with a higher net cost and a lower net effect and was dominated in health
economic terms. The associated mean incremental net monetary benefits at cost-effectiveness thresholds
of £15,000, £20,000 and £30,000 per QALY were –£2158, –£2306 and –£2601, respectively. The
probability that the exercise intervention is cost-effective was < 1% in the baseline analysis, a result that
remained robust to sensitivity and subgroup analyses.
Conclusions
This was a well-conducted, large, pragmatic trial with good intervention compliance and follow-up rates.
The exercise intervention was well tolerated and enjoyed by participants and carers, but did not produce
any clinical impact on function and HRQoL in people with dementia or upon their carer’s burden, or
evidence that it is cost-effective. There was slight worsening of cognitive impairment. The qualitative study
suggests that, although the intervention cannot produce long-term improvements to cognitive impairment,
function and HRQoL, it did provide respite, social interaction and enjoyment for participants and carers
alike during the phase of group supervision of exercise.
Future research
We recommend that future research concentrates on alternative treatments to alter the progress of dementia.
Trial registration
This trial is registered as ISRCTN32612072.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the NIHR.
Additional funding was provided by the Oxford NIHR Biomedical Research Centre and the Oxford NIHR
Collaboration for Leadership in Applied Health Research and Care.
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Chapter 1 Introduction
Definition and prevalence of dementia
Dementia is a syndrome characterised by acquired, progressive deterioration in memory, general cognitive
function, self-care and personality. Probable dementia according to the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV)1 criteria is defined by:
l memory impairment with cognitive disturbance in at least one of the following domains – aphasia
(language impairment), apraxia (motor impairment), agnosia (impairment of object recognition) or
executive functioning (planning, sequencing, abstracting)
l functional decline – increasing impairment in functional ability (social, occupational, personal/self-care)
related to cognitive deficits.
Dementia affects older people to a much greater extent than younger people. As a rule of thumb, the
prevalence of dementia in developed countries doubles in successive 5-year age groups within the age
range of 65–99 years, from under 1% for people aged 65–69 years, to about 35% in people aged
95–99 years.2 Prevalence is similar in men and women.2 About 60% of cases of dementia in developed
countries are caused by Alzheimer’s disease, and about 20% by vascular dementia,3 while mixed
Alzheimer’s/vascular dementia and dementia with Lewy bodies are the other common causes.
Recent reports have suggested that the prevalence of dementia is reducing across Western Europe4 and
in the USA.5 The hypothesised reasons for this reduction are an increase in educational achievements in
successive birth cohorts and other medical, social and behavioural factors that are still under investigation.
However, current prevalence figures indicate that in the UK > 800,000 people have dementia, with an
annual cost to the economy of £23B.6 Although more recent estimates of dementia prevalence have
revised this figure down to 670,000 people,7 this is still a very substantial number of people.
Reducing the burden of dementia is a priority for the UK government. In February 2015, the Prime Minister
reiterated the 2012 dementia statement and set a challenge for the UK to become the best country in the
world for dementia care and research.8
Evidence for the effect of exercise on cognition
There is currently no cure for dementia, only interventions to reduce risk and alleviate symptoms.
The protective effects of moderate levels of physical activity on the progression of subjective memory
impairment and mild cognitive impairment (MCI) to dementia have been observed consistently in several
large-scale epidemiological studies.9–11 Studies of Alzheimer’s disease in transgenic mice and dogs suggest
several potential mechanisms by which exercise may prevent the progression of dementia. Brain-derived
neurotrophic factor is stimulated by exercise in mice with Alzheimer’s disease, leading to increased
concentrations in many areas of the brain including the hippocampus, which is thought to have a key role
in mediating some of the effects of dementia.12 Other effects of exercise observed in murine dementia
models include improved synaptic function,13 attenuated mitochondrial reactive oxygen species production,14
delayed loss of myelinated fibres in the brain15 and a reduction of damaging beta amyloid oligomers.16
Epidemiological studies of the human brain have shown positive associations between physical activity and
the volume of the hippocampus and other areas of the central nervous system sensitive to pathological
change in dementia,17 all of which are targets that are considered important for treatment.18
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These studies provide evidential support for the theoretical model of increasing physical activity and
exercise in people with dementia with the aim of alleviating cognitive symptoms. At the time of finalising
the protocol, the then most recent Cochrane review of exercise programmes for people with dementia
(final search date October 2013)19 included 17 studies, nine of which assessed the effect of exercise on
cognition. No clear conclusions could be drawn regarding the effect of exercise on cognition in people
with dementia because of unexplained heterogeneity in the data, and the review was unable to make
recommendations as to the type and dose of exercise (i.e. intensity, frequency and duration).
The Cochrane review19 ended its searches in October 2013 and we ran an update to this review with
searches ending in September 2016. We identified an additional 14 studies investigating dementia and MCI
patients (reported in Chapter 6) and two other systematic reviews20,21 of patient trials have been reported
during the trial. One of these systematic reviews concluded that exercise was an effective intervention20 and
the other that it was not.21
Current management of dementia in the UK
The treatments for dementia recommended by the National Institute for Health and Care Excellence (NICE)22
are cholinesterase inhibitors (donepezil, galantamine and rivastigmine), but only for mild to moderate
Alzheimer’s disease, not for vascular dementia. Memantine is supported by NICE for limited use in
moderate to severe dementia or in patients who are unable to tolerate cholinesterase inhibitors.22 Many
people with mild to moderate dementia (MMD) and their families require additional services, mainly to
mitigate functional loss, such as carer training, home carers, day care, respite admissions, sitting services
and carer support services.
Potential role of exercise in the management of dementia
Physical exercise is a candidate non-pharmacological treatment for dementia and there is a considerable
amount of literature given to expanding underlying mechanistic hypotheses and rationale.
Although much of the current evidence informing the choice of type of exercise to improve cognition
is derived from animal studies, and studies of healthy humans or people with MCI, it is a widely held
belief that exercise has the potential to be an important intervention in the management of people with
dementia. In addition to any possible effects on cognition, exercise should improve physical fitness and
functioning, and the selection of the right type of exercise stimulus could reduce fall risk, improve mobility
and reduce cardiovascular risk factors, just as in people who are not cognitively impaired. The main
challenge is to design a programme that people with dementia can engage with, and adhere to in the
longer term, which is of sufficient intensity and frequency to achieve the desired effect.
To date there are no recommendations as to which behaviour change techniques (BCTs) are the most
effective for people with dementia. There are, however, recommendations regarding generic BCTs to
increase physical activity adherence in adults23 and for older people without dementia.24,25 The key active
components include self-regulatory BCTs (e.g. goal-setting, self-monitoring), feedback and reviewing of
previously set goals.
The Dementia and Physical Activity trial
The aim was to establish whether or not exercise is effective in slowing or improving cognitive decline in
community-dwelling adults with MMD.
INTRODUCTION
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Research objectives
To undertake a definitive randomised controlled trial (RCT) to estimate the effects of an exercise or physical
activity intervention that is feasible for delivery within the current constraints of NHS delivery.
Our objectives were to:
1. refine an existing intervention for delivery to community-dwelling populations of people with dementia,
including a systematic review to inform intervention development
2. pilot critical procedures in the intervention and trial
3. complete a definitive, individually RCT to estimate the effectiveness of exercise in addition to usual care
on cognitive impairment (primary outcome), function and quality of life in people with mild or moderate
dementia, and on carer burden in carers
4. complete a parallel cost study and conduct an economic analysis from a health-care and
societal perspective
5. investigate intervention effects in predefined subgroups of gender and dementia severity
6. undertake a qualitative study into the experiences of participants and carers taking part in the intervention.
Overview of report
The report is structured in seven chapters. We present the methods, results and a brief discussion of each
of the main components of the study within each chapter. The results of the systematic review, which we
have undertaken as a continual process throughout the trial, are presented in Chapter 6. We finish with an
overarching discussion and conclusion.
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Chapter 2 Intervention development
and description
Parts of this report are based on Brown et al.,26 in which the intervention description has beenpublished. © 2015 Chartered Society of Physiotherapy. Published by Elsevier Inc. All rights reserved.
Reproduced with permission.
Introduction
The development of the intervention followed a pathway and method we established in earlier National
Institute for Health Research (NIHR) Health Technology Assessment (HTA)-funded studies27–30 and in
accordance with the Medical Research Council recommendations for the development of complex
interventions.31 Exercise interventions in older people are underpinned by a well-established physiological
and clinical evidence base and guidelines; however, these do not necessarily include people with cognitive
impairment.32 We examined existing relevant reviews and undertook a systematic review specifically to
identify RCTs that examined the effect of exercise upon cognitive function in people with MCI or dementia,
as summarised in Chapter 6. In addition, we considered the observational and animal study evidence base
specific to exercise and cognitive impairment. Finally, patient, carer and clinician expertise was used to draw the
intervention package together into a programme. The refinement, acceptability and feasibility of trial procedures
and the exercise intervention were tested in pre pilot and pilot studies between June 2011 and July 2012.
Figure 1 demonstrates the various information sources and considerations that were combined to
formulate the final Dementia and Physical Activity (DAPA) intervention.
Rationale and development of the intervention
Evidence review
We defined exercise as ‘a subcategory of leisure time physical activity in which planned, structured and
repetitive bodily movements are performed to improve or maintain one or more components of physical
fitness’.33 Physical activity was taken to mean any activity (including exercise itself) that could mimic the
Pilot study:
feasibility
Deliverable in
NHS
Expert opinion
Animal studies:
mechanisms of
effect
WHO guidance
for cardiovascular
fitness
Review of
previous
interventions
Intervention
design
considerations
Standardised and
reproducible to
allow evaluation
FIGURE 1 Intervention design considerations. WHO, World Health Organization. © 2015 Chartered Society of
Physiotherapy. Published by Elsevier Inc. All rights reserved. Reproduced with permission.
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physiological effects of exercise, for example gardening or housework. From our systematic review of trials
and review of systematic reviews, we developed an evidence-based rationale for the intervention content.
The most recent Cochrane review of exercise programmes for people with dementia19 included 17 studies,
nine of which assessed the effect of exercise on cognition. No clear conclusions could be drawn regarding
the effect of exercise on cognition in people with dementia because of unexplained heterogeneity in the
data. The review was unable to make recommendations as to the type and dose of exercise (i.e. intensity,
frequency and duration).
Exercise type
To inform our decision around the types of exercise to deliver, we examined existing exercise models and
evidence for mechanisms of action. There is evidence that aerobic exercise increases vascularisation of the
brain and triggers the release of neurotrophic substances, which support cognitive functions.34 Studies in
healthy older adults report that increased aerobic fitness is associated with better preservation of grey
matter volume and larger hippocampus volume. The hippocampus contributes to spatial memory and
consolidation of short-term memory.35 In dementia patients, the hippocampus is atrophied. Similarly,
resistance training alters levels of circulating substances (insulin-like growth factor 1, homocysteine)36 in a
manner that may positively affect cognitive function. Supporting evidence is summarised in Table 1. Hence,
it was decided to include both aerobic and resistance training elements in the exercise programme.
Dose of exercise
There is a robust evidence base around the quantity of exercise needed to elicit health benefits in healthy
older people, but these are not specific to cognitive outcomes.32 Our systematic review (see Chapter 6)
found that protocols for exercise interventions ranged from 60 to 210 minutes of exercise per week,
with an average of 122 minutes per week. Although there is no direct evidence to inform dosing for
improvement in cognitive performance, there is a link between cardiovascular status and dementia.
We used the guidance, produced by the World Health Organization (WHO), for the quantity and quality
of exercise required for cardiorespiratory and musculoskeletal good health for adults and older adults.43
This WHO guidance recommends at least 150 minutes per week of moderate-intensity cardiorespiratory
exercise. The same guidance recommends resistance exercises for the major muscle groups two or three
times a week for musculoskeletal good health. Hence, we selected the target intensity as, at least,
moderate to moderate to hard level for both exercise forms for an overall total of 150 minutes per week.
To gauge an individual’s fitness and exertion levels (mild, moderate, hard) we used the 6-minute walk test
(6MWT). This assessment is relatively simple to implement, and an adapted version has been shown to
be reliable in people with Alzheimer’s disease.44 It requires less time to complete than the Incremental
Shuttle Walk Test45 and, unlike the cycle ergometry test,46 requires no special equipment. We selected the
Borg Scale of Perceived Exertion, adapted for use by people with dementia,47 as the primary method of
assessing exercise intensity during sessions, coupled with soft indicators such as sweating, skin colour and
breathing rate. Although heart rate could have been, and was occasionally planned to be, used as an
indicator, these measures are complicated in situations in which, as we expected, there was a higher
prevalence of beta-blockers and drugs/devices/conditions influencing heart rate.
We selected cycling as the core aerobic exercise38 because the cycling action is a simple, intuitive one and
the risk of falls is minimised.
For resistance exercise, the gold standard method for identifying an initial resistance load is the one-repetition
maximum using an isokinetic dynamometer.48 However, exposing untrained individuals to resistance that is
higher than 80% of the one-repetition maximum increases the likelihood of an adverse event (AE) and is
not recommended for older people.49 Given the probable frailty of the participants, we selected a validated
method to prescribe the resistance by estimating the maximum number of lifts that could be made with good
form for a given weight.49 As dyspraxia is common among people with dementia,39 the exercises chosen were
simple, functional movements aimed at enhancing participation and were selected to engage the major
muscle groups, in accordance with the guidance from the WHO.32
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TABLE 1 Evidence to support design of the DAPA intervention. © 2015 Chartered Society of Physiotherapy.
Published by Elsevier Inc. All rights reserved. Reproduced with permission
Evidence References Implications
Element of the DAPA
intervention
Aerobic exercise leads
to increased brain
vascularisation in animal
model
Lista and Sorrentino34 Increased oxygenation to the
brain enhances cognitive
performance
Inclusion of aerobic exercise
Aerobic exercise leads to
release of brain-derived
neurotrophic factor in
animal model
Lista and Sorrentino34 Formation of new neurones and
new synapses in the brain
Inclusion of aerobic exercise
Amount of cardiovascular
exercise required for general
health and fitness
Garber et al.32 The American College of
Sports Medicine recommends
150 minutes per week at
moderate intensity for adults
Dosage of aerobic activity
Resistance training at 50%
1RM leads to decreased
homocysteine levels
Vincent et al.37 High levels of homocysteine
linked to increased risk of
cognitive impairment
Inclusion of resistance exercise
Resistance training leads to
increased levels of insulin-
like growth factor 1
Suetta et al.36 Low levels of insulin-like growth
factor 1 linked to reduced
cognitive performance
Inclusion of resistance exercise
Feasibility of people with
dementia using exercise
bicycles
Yu and Swartwood38 Exercise bicycles can be used by
people with dementia
Use of exercise bicycles for
aerobic exercise
Prevalence of dyspraxia in
people with dementia
Zoltan39 Dyspraxia is not uncommon in
people with dementia
Use of simple, functional
movements, such as
sit-to-stand
Behavioural interventions,
for example goal-setting,
feedback on physical activity
Conn et al.40 These strategies increase physical
activity in healthy adults
Use of behavioural
interventions
Peer support in maintaining
physical activity
Cress et al.41 Peer support is associated with
exercise adherence in older
adults
Use of group exercise,
involvement of carers
Social component of
physical activity
NICE42 The social component of activity
is important to older adults, so
group exercise is recommended
Use of group exercise
Written goal-setting and
planning, recording physical
exercise
Cress et al.41 Written contracts assist exercise
adherence in older adults
Use of written goals and
exercise plans, use of exercise
calendar
Use of exercise logs NICE42 Written exercise logs
recommended for older people
Use of exercise calendar
Performance feedback Cress et al.41 Provision of accurate feedback
and positive reinforcement
assists exercise adherence in
older adults
Use of 6MWT review, verbal
feedback during classes
Feasibility of the DAPA
intervention
DAPA pilot Intervention practicable in this
population
Entire intervention
1RM, one repetition maximum; 6MWT, 6-minute walk test.
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Duration of exercise intervention
Determination of the total duration of an intervention was challenging. Our systematic review (see Chapter 6)
identified intervention duration ranges from 1.5 to 12 months, with an average duration of 5 months. Our
funders requested that the duration of the intervention was 4 months in order to maximise the chance of it
being found to be cost-effective, which is documented in Appendix 1.
To maximise the chance of the intervention being cost-effective, we used group supervision (with each
participant working to their individual prescription) for 4 months, and included BCTs plus suggestions for
continued activities to encourage continued physical activity.
Exercise intervention adherence
Behavioural modification is an important component of the intervention, to make adherence to the exercise
intervention more likely. Simply providing information about the health benefits of exercise is not effective in
increasing older adults’ participation in exercise.41 The BCT taxonomy of Michie et al.50 provides standardised
definitions of 93 techniques used in behaviour change interventions and promotes clarity in the reporting of
intervention content. During our intervention development there was no specific guidance for which BCTs
to use for people with dementia. We adapted guidance for healthy older people32 and the NHS guidance for
behaviour change,51 and examined BCT evidence for healthy older adults. A review identified self-efficacy as
the most consistent predictor of initiation and maintenance of physical activity in adults aged > 50 years.52
The BCTs of ‘goal-setting’ and ‘activity contracts’ are associated with increased physical activity levels and
improved self-efficacy in adults.53 The NHS guidance for behaviour change details how to implement these
BCTs into an intervention. Group exercise, compared with individual home-based exercise, has been shown
to improve exercise adherence in older people.54 Substantial parts of the DAPA behavioural intervention
depended on telephone contact, and there is precedence for this. A study of older women undertaking a
26-week group-based exercise programme found that those who were given a telephone-assisted coping
plan, via a single telephone call, had better adherence to the programme than those who were given only
written advice.55 Staff encouraged a fun atmosphere in the classes, as enjoyment has been shown to
improve exercise adherence in adults attending exercise groups.56 Encouragement from spouses and carers
has been recognised to strengthen self-efficacy and improve adherence.57 Carers were welcome to come
along to the sessions. They had no formal role during the class and did not participate as either coaches or
individuals during the session. A break-out area was organised where carers could chat among themselves.
When they wished to be, carers were involved in identifying activities that the participants were likely to find
enjoyable and in encouraging compliance with home exercise.
Expert opinion
A key part of the intervention development process was the advice received from clinicians and other
experts, including patient groups. The intervention development team gained opinions from specialist
physiotherapy teams and visited exercise or physical activity group programmes that were being run for
the target population. The team members also talked to people with MMD and their carers via local
Alzheimer’s Society activities, as well as within the pre-pilot and pilot studies.
Guidelines
The intervention design was supported by information from a number of guidelines, principally the
American College of Sports Medicine’s guidelines for exercise testing and prescription,32 NICE’s dementia
guidelines58 and the WHO’s Global Recommendations on Physical Activity for Health.43
The pilot studies
We ran two pilot studies. The first tested the feasibility of using the OPERA trial intervention59 (a randomised
trial of an exercise intervention for older people in residential and nursing accommodation based on a
music approach) in the DAPA trial target population. It was found that even the highest level of the OPERA
exercise activities were not able to create an adequate exercise challenge, as the DAPA trial population were
younger and fitter than the OPERA population. As a result, the intervention development team created an
innovative and specially targeted exercise programme.
INTERVENTION DEVELOPMENT AND DESCRIPTION
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The acceptability and feasibility of the new intervention (including the behaviour change support strategies)
was then tested in a second pilot study (n = 6 people with dementia).
Informal feedback interviews were conducted with the participants, carers and physiotherapists involved.
No qualitative analysis was conducted on these data, but the data were used in real time to inform
intervention development. Participants found the DAPA intervention to be acceptable, feasible and
enjoyable. The exercise activities were able to create an adequate exercise challenge for the DAPA trial
target group (using heart rate monitoring). This pilot study also highlighted that some participants needed
more assistance and supervision than others and that the involvement of carers facilitated attendance and
adherence in terms of timings, transport and emotional support, and so this also was accounted for in the
programme design. Participants identified concerns that they held before starting the groups, which were
used to inform our recruitment strategy information documents. Outcome measures and some aspects of
the recruitment processes were also tested during the pilot phases.
The Dementia and Physical Activity intervention
A summary of the final DAPA intervention is provided in Figure 2. The exercise intervention was divided
into two parts: a supervised part lasting 4 months and a supported, unsupervised component lasting an
additional 8 months. The supervised part comprised a pre-exercise assessment, twice-weekly exercise
sessions of approximately 1 hour’s duration (including 50 minutes of exercise at the target intensity) for
4 months with a target of at least 50 minutes of unsupervised activity at moderate intensity, to achieve a
total of 150 minutes per week. The exercises sessions were a combined aerobic and resistance training
schedule at moderate to hard intensity, with supervision in groups of up to eight participants.
Individual pre-exercise assessment
The pre-exercise assessment assessed the participant’s general health, current fitness and activity levels.
The participant and/or carer was asked about cardiovascular, respiratory, neurological, musculoskeletal
and psychiatric conditions, as well as diabetes mellitus and recent acute illnesses (for details please see
Appendix 2). Current and previous physical activity levels, along with any physical, perceptual or sensory
limitations, for example limited range of shoulder movement, were noted and considered in the individual
tailoring of exercises. Carers were encouraged to attend when possible to provide additional information
to the therapist, for example on medications, comorbidities and exercise preferences.
The main element of the pre-exercise assessment was to set the initial intensity of exercise for the sessions.
A 6MWT was completed using two marker cones set up 15 m apart, and the participant was instructed
to walk between and around the cones for 6 minutes, with standardised directions and phrases of
encouragement.44 The distance walked in 6 minutes was noted. The participant also wore a heart rate
monitor, and the resting and average heart rates were recorded. This allowed calculation of the initial
target aerobic intensity according to Luxton.60 For resistance exercises, the maximum weight that could be
lifted in good form over 20 repetitions was estimated.
Exercise sessions
Exercise sessions required a venue with sufficient accessible space and numbers of fixed cycles, weighted
jackets and dumb-bells. The sessions required a physiotherapist and an exercise assistant, unless the
number of participants were substantially fewer than the target of eight. The exercise assistant was usually
an exercise instructor or had worked in health care, for example as a physiotherapy assistant.
Warm-up
A simple warm-up comprising movements of the neck, shoulders, trunk, hips and knees, together with
marching on the spot was performed, lasting about 5 minutes.
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Aerobic
The target intensity for aerobic training was 25 minutes in each session, with at least 15 minutes at
moderate to hard intensity. Intensity was individually tailored to each participant’s baseline fitness,
recognising that a low load may be a moderate challenge to some but a low challenge to others. The
period of cycling was built over the sessions. For all sessions, the first 5 minutes of the aerobic exercise was
spent cycling at low intensity. At the outset of the programme all participants were started at low intensity.
The aerobic challenge was progressed by increasing the total duration spent cycling, up to 25 minutes,
as well as the duration spent exercising at moderate and hard intensity over the ensuing sessions.
Resistance
Progression was individually tailored using recognised methods.61 The resistance exercises always included
sit-to-stand, using weighted belts and jackets, and biceps curls, using dumb-bells as resistance, and were
set according to principles shown in Figure 3. Suppliers are detailed in Appendix 3.
Participant randomised to receive DAPA intervention
Physiotherapist to visit DAPA exercise venue
Pre-exercise
assessments
(sessions 1 and 2)
DAPA exercise
classes
(sessions 3 – 31)
Target-setting meeting to
complete exercise action
planner and present 
DAPA calendar
(between sessions 5 and 10)
Target-setting review
(between sessions 26 and 31)
Telephone follow-up calls
(at 2 – 3,14 – 16 and 22 – 23
weeks post exercise classes)
DAPA exercise classes
finish and participants
begin 8-month period of
unsupervised exercise
Behavioural components
Face-to-face follow-up
(at 2 months  post
exercise classes)
End of trial data collection
(12 months)
6MWT
(between sessions 17 and  22)
FIGURE 2 The DAPA intervention. © 2015 Chartered Society of Physiotherapy. Published by Elsevier Inc. All rights
reserved. Reproduced with permission.
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Role of exercise assistant and physiotherapist
The physiotherapists were responsible for the examination and assessment of the participants, setting the
prescription and reviewing and progressing the exercise prescription. The physiotherapists supervised the
exercise assistants during the sessions. The role of the exercise assistants was to assist in welcoming carers
and participants to the class, to monitor and encourage people during the class and to provide assistance
when required. The physiotherapists undertook the telephone follow-up calls.
Good form = correct postural alignment maintained, contraction is controlled, full range of movement
is used, normal breathing is maintained.
Ratamess et al.61
The initial resistance load was determined on the basis that the lift should be at least moderately hard and
on clinical observations, with the ability to lift 20 repetitions in ‘good’ form being the principal guide.
Table 2 gives typical ranges of initial resistance for the sit-to-stand exercise. The weight lifted was
increased, with participants performing 15 repetitions 3 weeks into classes and 10 repetitions at a higher
weight again at 7 weeks. The weight was subsequently increased if the participant could perform two
additional repetitions with good form, or decreased if the participant could not perform the required
number of repetitions. A further 1–3 exercises (depending on time available) were selected from shoulder
forward raise, shoulder lateral raise and shoulder press, again using dumb-bells as resistance. The
resistance training element of the exercise class lasted approximately 25 minutes. The participants were
congratulated and presented with a certificate at their last exercise class, to reinforce continuation with
unsupervised
exercise.
Every repetition of the exercise
completed in good form?
Can they do two further
repetitions in good form?
Decrease weight
Increase weight Weight correct; no
action needed
Yes No
Yes No
FIGURE 3 Calibrating load for resistance exercises. © 2015 Chartered Society of Physiotherapy. Published by Elsevier Inc.
All rights reserved. Reproduced with permission.
TABLE 2 Typical starting resistance for sit-to-stand. © 2015 Chartered Society of Physiotherapy. Published by
Elsevier Inc. All rights reserved. Reproduced with permission
Sit-to-stand form category
Gender, starting resistance (kg)
Men Women
Excellent: no use of hands, compensations or momentum, good control throughout
the movement
8–12 6–8
Fair: use of hands, compensations or momentum but able to perform movement
without these when prompted, with reasonable control throughout the movement
4–7 3–5
Poor: use of hands, compensations or momentum in order to perform movement,
poor control observed
0–3 0–2
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Unsupervised activity
During the supervised part of the intervention, the participant was encouraged to undertake an additional
50 minutes of activity per week at a moderate intensity at home. The physiotherapist helped the participant
to find an enjoyable or, at least, an acceptable activity, to maximise the likelihood of adherence, and to
signpost the participant to local exercise facilities or groups. After the 4 months of exercise classes, all of the
150 minutes of activity per week at moderate intensity was carried out unsupervised.
Behaviour change techniques
Goal-setting
During the supervised exercise intervention, a system of goal-setting was used that focused on the goals
and activities that were important to the participants. The first goal-setting took place between weeks 3
and 5 of the supervised exercise sessions and focused on an action plan with specific physical activities,
which were to be undertaken at agreed locations and times. The second goal-setting took place between
weeks 13 and 16 and focused on a plan for the transition from the supervised to the unsupervised exercise
period. This focused on how, and where, to perform the unsupervised exercise and included an exercise
opportunities booklet detailing local facilities and opportunities.
Review behavioural goals (objective and subjective)
Between weeks 17 and 22, the 6MWT was used to review participants’ progress and to act as a prompt to
revise goals and identify barriers or facilitators. An exercise calendar was given to participants and carers to
encourage self-monitoring of behaviour, as a visual prompt to remind the participant to undertake physical
activity and to assist the physiotherapist to monitor unsupervised exercise. The face-to-face meeting with
the participant and (if possible) carer was to review the targets from the second target-setting discussion
and amend them if necessary, together with praise and problem-solving assistance.
Behavioural contract
The action plan (goal-setting) was signed by the participant and physiotherapist to reinforce the
commitment to carry it out.
Identification of barriers or facilitators and solutions
Telephone contact was made with participants who did not attend exercise sessions to identify and
problem-solve any barriers to class attendance and encourage the habit of regular attendance. During the
unsupervised part of the intervention, three telephone calls and one face-to-face meeting took place. The
telephone calls were made approximately 2–3 weeks, 14–16 weeks and 22–23 weeks after the supervised
exercise sessions had finished, and were intended to provide praise and encouragement and assist in
solving any difficulties encountered in exercising independently.
Dementia-specific considerations
People with dementia commonly have difficulties with communication,62 as well as poor memory. Using
aids to memory and communication (e.g. name badges for staff, participants and carers), observation
of facial expression and body language, and the use of alternative wording to aid understanding were
included as part of the conduct of the exercise classes. Background noise and distractions were minimised
by having a separate room (not a public gym) for the sessions. Demonstration and instruction on how to
perform the exercises were provided by the physiotherapist or exercise assistant. For participants with
dyspraxia, copying a movement (mirroring) was sometimes easier than following verbal instructions, and
hands-on guidance was appropriate for some individuals.63 In some cases, a modified (but safe) version of
the movement was allowed, if the participant was unable to perform the movement correctly.
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Quality control assessments
The intervention sites were visited by trial research physiotherapists (Nicola Atherton, Deborah Brown,
Katie Spanjers, Lousia Stonehewer and Janet Lowe) to conduct quality control (QC) assessments. The first
QC assessment at each site was conducted during the first few weeks of delivering the interventions.
The aim of these visits was to ensure that the intervention was being delivered in a standardised manner
and that the physiotherapist and exercise assistant could demonstrate competency in all aspects of the
intervention. The QC assessor also provided, as needed, clinical supervision and support to the intervention
staff. Items assessed included:
l correct adherence to the exercise procedures focusing on ensuring effective delivery of an adequate
exercise dose
l correct completion of all paperwork, especially the structured treatment forms that record the exercise
intensity and duration (enabling accurate calculation of the exercise dose delivered)
l evidence of the use of a person-centred care approach with appropriate support given to participants
l communication between the staff regarding participants’ progress and needs
l completion and return of AE documentation (when required).
This visit also allowed the provision of support and advice to staff to enhance their clinical competencies
and assist with the smooth running of the exercise group.
A second QC visit was made after some of the formal behavioural support activities (such as goal-setting)
had commenced. When possible, these activities were observed; when this was not possible, assessment
was made through inspection of the documentation and a discussion with the physiotherapist who
carried out the activity, with corrective guidance being given as needed. The QC assessor also assessed the
continued correct adherence to the exercise procedures, with an emphasis on the use of progressions and
provision of adequate exercise challenges, and the correct completion of clinical records. The QC forms are
available in Appendix 4. At the end of each of these visits, feedback was provided to the staff delivering the
intervention and further visits arranged if problems were found in the QC assessment or if the staff needed
further support. A QC form was completed and signed by both the assessor and the physiotherapist
(provided that the latter agreed with its findings).
Results of the quality control visits
There were 26 physiotherapists and 17 exercise assistants delivering the DAPA intervention across the
DAPA trial sites. Of the physiotherapists, in the first QC assessment, 23 were rated as ‘satisfactory’, two
were rated as ‘minor concerns’ and one had missing forms. Those who were rated as ‘minor concerns’
were followed up within 2 weeks of the initial assessment and both then reached a ‘satisfactory’ rating.
Of the exercise assistants, 13 achieved a rating of ‘satisfactory’, three were rated as ‘minor concerns’ and
one had missing forms. In the follow-up assessment, all three exercise assistants who had been rated as
‘minor concerns’, then reached the ‘satisfactory’ rating.
In the second QC assessment, all physiotherapists were rated as ‘satisfactory’, apart from three who had
a missing assessment, and all exercise assistants were rated as ‘satisfactory’, apart from one who was
rated as ‘minor concerns’ and one who had missing forms (unable to complete the QC visit). The exercise
assistant who was rated as ‘minor concerns’ was rated as the same at their follow-up assessment.
The third and fourth QC assessments were performed only on physiotherapists, as they carried the
predominant load and responsibility for the intervention. At the third QC assessment, all physiotherapists
were rated as ‘satisfactory’ and one had missing forms.
At the fourth QC assessment, 10 physiotherapists were rated as ‘minor concerns’. In the follow-up
assessment, it was not possible to reassess 4 out of these 10 physiotherapists and the remaining therapists
were reclassified as a rating of ‘satisfactory.’
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In all cases where forms were missing, the QC visit could not be completed within the scheduled time
period, before the next QC visit was due.
Manuals are available at www.octru.ox.ac.uk/trials/trials-completed/dapa (accessed 17 April 2018).
Patient and public involvement
The study benefited from broad-ranging patient and public involvement. At the outset of the study people
who had experience of caring with people with dementia were identified and asked to join the Trial
Steering Committee and were independent voting members of the committee. We made broad informal
consultation with carers and people with dementia as we undertook the pilot work for the study both for
the design of the intervention and for research design. We engaged in public meetings on dementia and
research to gain input into the study. At the end of the study, we presented the results to members of the
public, including an invitation for all participants to attend the meeting along with their carers. We had
good attendance and feedback about the study, which we were able to incorporate into our final report.
INTERVENTION DEVELOPMENT AND DESCRIPTION
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Chapter 3 Randomised controlled trial: methods,
results and brief discussion
The protocol for the RCT was published in Atherton et al.64
Aim
The primary aim was to estimate the effect of the exercise intervention on cognitive and functional decline
in community-dwelling adults with MMD.
Randomised controlled trial design
The design was a multicentred, randomised parallel-group trial comparing a 4-month, supervised,
moderate- to hard-intensity exercise training regime with follow-on behavioural support for long-term
physical activity change with usual care.
Methods
Participant recruitment and setting
We recruited adults (aged ≥ 18 years) with a diagnosis of any type of dementia and their carers (when
available). The dementia needed to be mild to moderate at the time of recruitment. Participants were
recruited from 15 regions in the UK.
Approach and initial information
Participants were recruited from four sources:
1. NHS secondary care memory clinics and services: authorised NHS staff identified potential participants
using electronic or case record searches to screen for eligibility. The lists were reviewed by a clinician
involved in the clinical care of the participant and checked for patients who should be excluded.
Potential participants and their carers were approached by their clinician or authorised NHS staff
member either face to face at a clinic or by letter.
2. General practice registers of people with dementia: general practices searched their registers of patients
to identify people with a diagnostic code for dementia. In most practices, this was done by a search of
databases using Read Codes or Quality Outcomes Framework codes. General practitioners approved the
final list of names and sent invitation letters to potential participants.
3. Research network participant-interested databases [e.g. the Dementia and Neurodegenerative Diseases
Research Network (DeNDRoN); Join Dementia Research]: the UK Department of Health and Social Care
has funded a number of networks and projects to enable people with dementia to register their interest
in participating in research and to enable a rapid and simple approach. Participants were identified
by a nursing or clinical staff of DeNDRoN from these databases. Participants deemed as meeting the
inclusion criteria were contacted by DeNDRoN staff by telephone to explain the study and, if potentially
eligible, sent an invitation letter.
4. Other dementia resources (e.g. Alzheimer’s cafes): we approached community-based dementia
resources directly to determine if they were willing to approach potential participants. When service
providers agreed and approached potential participants, a researcher from the team then visited the
centres and provided further explanation about the study to potential participants and their carers.
When participants or carers were interested, the researcher assessed their potential eligibility and
contacted their health-care provider to confirm eligibility.
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All procedures were consistent with relevant legislation to ensure data confidentiality. All invitations
were accompanied by written information about what was involved in the study, supplemented by a
verbal explanation when the opportunity arose. In all instances, the participants indicated their potential
willingness to participate by sending a reply slip to either the local co-ordinating centres or the research
office at the University of Warwick Clinical Trials Unit (WCTU) (depending on the local set-up). Once a
participant confirmed their willingness to participate, they were contacted by a member of the recruitment
team (a registered nurse or allied health professional with appropriate research training) to further assess
eligibility and explain the trial. In all instances, participants received the written and verbal information and
were given a minimum of 48 hours to decide whether or not they wished to join the trial. Potential participants
were visited in their own homes to record consent in writing and to confirm eligibility [Standardised Mini
Mental State Examination (sMMSE) score and functional abilities]. A baseline assessment was carried out
and the participant was registered and randomised.
Eligibility criteria
Participants were required to:
1. have probable dementia according to the DSM-IV criteria1
2. have probable MMD (a score of > 10 on the sMMSE)65
3. be able to participate in a structured exercise programme determined by:
i. being able to sit in a chair and walk 10 feet without human assistance
ii. having no unstable medical conditions, for example unstable angina, or acute or terminal illness
4. live in the community, alone or with a friend, relative or carer, or in sheltered accommodation.
Consent
People with MMD may lack the necessary mental capacity to provide fully informed consent. All potential
participants were assessed for their capacity to consent by the registered research nurses or physiotherapists
conducting the baseline visit. All nurses and physiotherapists were trained specifically in assessing and taking
consent in trials recruiting people with dementia using the principles of the Mental Capacity Act 2005.66
Training was provided by the NIHR Clinical Research Network or DeNDRoN and/or the lead research
physiotherapist responsible for recruitment. When potential participants were assessed as having capacity,
informed consent was obtained from the individual. If potential participants were assessed as lacking
capacity, agreement to participate was still sought from these individuals. In this situation, additional advice
would be sought from the primary carer or personal consultee on whether or not the person who lacked
capacity should take part in the project and what their past and present wishes and feelings would have
been about taking part. If participants were unable to give informed consent, and for whom no personal
consultee was available, a nominated consultee (e.g. health-care professional) who was well-placed and
prepared to act on behalf of the potential participant was sought. When a potential participant lacked
capacity to provide informed consent, and a nominated consultee could not be found, that person was not
recruited. Agreement for continued participation was checked at each follow-up visit. Consent was sought
from carers, for the data on carers, after consent for participation had been secured from the person
with dementia.
Risks and benefits
All participants had access to usual care, and thus no treatment was withheld from trial participants. There
is some limited evidence of a very small increased risk of injury as a result of becoming more physically
active. In our physical activity programme, however, health-care professionals tailored progressive exercises
to individual need/ability and delivered the programme to small groups of participants in a supervised and
safe context.
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Intervention
The usual-care arm
All participants had, or were receiving, usual care consistent with the recommendation of NICE’s clinical
guidance,67 comprising diagnosis, information provision and limited social support. We recognised that the
usual-care interventions vary across the country and, hence, we stratified the randomisation by region to
ensure these effects were randomly distributed. There was no limit on co-interventions during the trial;
medications and other treatments could be initiated, continued or discontinued at the discretion of the
clinical team responsible for the care of the participants. We collected data on treatments provided to both
arms of the trial at baseline and during the follow-up period, and described these in the study reports.
Exercise is not currently part of recommended usual care for people with dementia, but each study participant
(in both the control and intervention groups) was given one of two information sheets produced by the
Department of Health and Social Care, appropriate to their age group. The information sheets recommend
physical activity levels for adults (aged 19–64 years)68 and older adults (aged ≥ 65 years).69
The Dementia and Physical Activity (intervention) arm
The intervention arm is fully described in Chapter 2.
Assessment data
Baseline data on the participants (persons with dementia)
Potential participants were visited at home by a registered research nurse or physiotherapist. Informed
consent was obtained (see Consent), then eligibility was checked, including carrying out the sMMSE. Once
the participant was confirmed as being eligible, descriptive data were collected, including age, gender,
marital status, ethnicity, educational attainment and employment status.
The next stage was to collect the data for the primary and secondary outcomes, as given in Table 3. The
type of dementia (vascular, Alzheimer’s or mixed) was ascertained after the baseline visit by reference to
the participant’s medical notes.
The primary outcome was the global cognition score of the Alzheimer’s Disease Assessment Scale – Cognitive
Subscale (ADAS-Cog).70 The funder’s brief was clear that the primary purpose of the trial and of the exercise
programme should be to determine whether or not exercise can modify cognitive functioning. Cognitive
deficits are central to dementia and widely understood as the most important treatment target.77 The
ADAS-Cog was collected directly from the participant, takes about 30–40 minutes to administer and has
established sensitivity to change. It is widely considered the gold standard primary outcome in treatment
trials for dementia, with relatively well-established treatment effect sizes.78 We also collected the maze and
number of cancellation optional items of the ADAS-Cog as additional items to be reported separately.
Initially, the primary outcome measure was to be the sMMSE, which, although widely used in clinical
evaluation, is a very global, relatively insensitive measure of cognitive function. The ADAS-Cog is
acknowledged to be more sensitive in detecting cognitive change in individuals with MMD than a variety
of other measures, including the sMMSE.79 The use of a valid but more sensitive primary outcome measure
(the ADAS-Cog) made it possible to reduce the sample size of the study.
Secondary outcomes were chosen to reflect the broad impact of dementia on function, behaviour and
quality of life. When possible, we chose instruments that were dementia specific, well validated and not
excessively burdensome. Secondary outcomes are also detailed in Table 3. In all instances we used the
published guidance about who the primary respondent for the questionnaire should be. We used the
Bristol Activities of Daily Living Scale (BADLS).71 This carer-rated instrument of participant ability is dementia
specific, sensitive to change and widely used in clinical trials. We also collected data using the Quality
of Life in Alzheimer’s Disease (QoL-AD) scale.73 This is a 13-item dementia-specific scale that can be
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
completed by a carer or participant; both were collected for the DAPA trial but the participant response
was considered the primary data source. We also collected the EuroQol-5 Dimensions, three-level version
(EQ-5D-3L),72 a 5-dimension generic (i.e. not dementia-specific) measure of health-related quality of life
(HRQoL). The EQ-5D-3L was reported by both the participant and carer, with the participant being the
primary data source, and it allows a calculation of health utilities for application in economic evaluations.
We used the Neuropsychiatric Inventory (NPI),74 which includes important predictors of carer breakdown
such as depression and agitation. We collected cost data using the Client Services Receipt Inventory
TABLE 3 Outcome measures
Domain Measure Description Completed by
Primary
Cognition ADAS-Cog70 Takes 30–40 minutes to complete. Includes
11 tasks targeting three domains (memory,
language and praxis). Scores range from 0 to
70 points, with higher scores indicating greater
cognitive impairment. A 4-point difference is
considered clinically important79
Participant
Secondary
Function BADLS71 Takes 15 minutes to complete. Includes 20 daily
activities. Scores range from 0 to 60 points, with
higher scores indicating greater impairment
Carer (rating participant)
HRQoL EQ-5D-3L72 Takes a few minutes to complete. Includes
health state classification system with five
dimensions and a VAS thermometer. Scores on
the classification system range from 0 to 25,
with higher scores indicating better quality of
life. Scores on the VAS range from 0 to 100,
with 100 equating to the best health state.
These two scores can be combined into an
index value 0.0–1.0, the higher value indicates
better quality of life
Participant (rating self)
Carer (rating self)
Carer (rating participant)a
Dementia quality of life QoL-AD73
QoL-AD proxy
Takes 10–15 minutes to complete. Includes
13 items. Scores range from 13 to 52 points,
with higher scores indicating less impairment
Participant (rating self)
Carer (rating participant)a
Behavioural symptoms NPI74 Takes 10 minutes to complete. Includes
12 behavioural domains. Scores range from
0 to 144 points, with higher scores indicating
greater impairment
Carer (rating participant)
Carer burden ZBI75 Takes 5 minutes to complete. Includes 22 items
regarding direct stress to carers. Scores range
from 0 to 88 points, with higher scores
indicating greater stress
Carer (rating self)
Health- and social-care
usage to inform the
health economics analysis
CSRI76 Administered by trained assessor. Takes
20 minutes to complete. Includes 29 items
covering five domains regarding information
about use of health- and social-care services,
other economic impacts (such as time off work
because of illness) and sociodemographic
information. Used to inform health economic
study
Carer with participant
(rating participant)
ADAS-Cog, Alzheimer’s Disease Assessment Scale – Cognitive Subscale; BADLS, Bristol Activities of Daily Living scale;
CSRI, Client Services Receipt Inventory; EQ-5D-3L, EuroQol-5 Dimensions, three-level version; HRQoL, health-related quality
of life; QoL-AD, Quality of Life in Alzheimer’s Disease; NPI, Neuropsychiatric Inventory; VAS, visual analogue scale; ZBI, Zarit
Burden Interview.
a For use in sensitivity analyses only, not the primary data source.
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(CSRI).76 This detailed questionnaire is designed to be used with a carer and covers all social, health care,
medication use and out-of-pocket expenses. Initially, mood was to be a secondary outcome, as measured
by the Cornell Scale for Depression in Dementia.80 This was removed prior to the collection of any data
as mood is covered by the NPI and it would have added unnecessarily to participant burden during
data collection.
Carer
We recorded carer age, gender, ethnicity, details about the relationship they had with the person with
dementia and how much care they provided. Carers were asked to complete the Zarit Burden Interview
(ZBI)75 and the EQ-5D-3L72 to assess their own HRQoL. These outcomes are all among those recommended
by a consensus recommendation of outcome scales for non-drug interventional studies in dementia.81
Outcome assessment training and quality control
All staff involved in recruitment and baseline assessments received a 1-day face-to-face training session,
supplemented by a detailed operational recruitment manual. The ADAS-Cog is a measure that needs
initial training, shadowing and practise over time to become proficient. Recruitment staff had differing
experience in using this measure; therefore, training was adapted to accommodate this. Those who had a
working knowledge of the measure attended a data collection training day that included rating a video,
discussion around individual items and performing an ADAS-Cog simulation with a trainer to assess practical
competency. Based on competency, it was decided whether or not the rater required further shadowing
and training. Inexperienced raters had an initial introduction to the measure, shadowed experienced raters
and practised until they were ready to undertake the training day. Raters were also required to pass a
competency test. This day included training for the sMMSE screening tool and other outcome measures.
The QC included the observation of at least one baseline home visit per researcher to ensure recruitment
and data collection processes were followed correctly. All questionnaire data were sent to the WCTU,
where it was checked on receipt for discrepancies and errors. Feedback was provided to the research
nurses and therapists by e-mail to improve standards. Further QC visits were used to check source data
collection and completion of paperwork as necessary.
Process evaluation
A range of process evaluation measures was undertaken. Some were trial process evaluation markers,
including time from randomisation to first assessment and first group attendance. In addition, we collected
detailed information about baseline prescription of exercise, assessment variables including comorbidity and
baseline 6MWT, session attendance and the dose of exercise delivered in each session. Dose was collected
on the amount of weight lifted and total number of repetitions in each session. For the cycling activity, we
recorded the amount of time at low-intensity and moderate- to high-intensity exercise. We reassessed
6MWT distance at 6 weeks after the beginning of the group intervention. Data were summarised for each
participant for each session and we report the weight lifted during a session as the product of the number
of repetitions and the amount of weight lifted for each exercise divided by the number of participants who
attended that session number.
Follow-up
Follow-up data collection was also conducted face to face and, in most instances, we were able to
maintain continuity in the personnel who collected the data across all time points. These interviews were
also carried out in the participants’ homes. Data for the primary and secondary outcomes were collected in
the same way as at baseline, together with some additional data. The carer was asked ‘How much benefit
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have you gained from being in the DAPA trial?’ and ‘How much has the dementia of the person you care
for changed in the past 6 months?’. The CSRI was usually completed by the carer for the participant at
these time points, but a person with no carer could give as much information as they were able.
Randomisation and masking
The unit of randomisation was the individual patient. Randomisation was stratified by region and dementia
severity (sMMSE score of ≥ 20 for mild and < 20 for moderate). Participants were randomised to:
1. usual care
2. usual care plus exercise programme (intervention).
Randomisation was 2 : 1 in favour of the intervention group, to allow exercise groups to be assembled in
a shorter period of time and minimise participant withdrawal between randomisation and the exercise
classes commencing.
The random allocation sequence was generated by an independent statistician, using a computerised
random number generator, and implemented by a central telephone registration and randomisation service
at the WCTU.
Research clinicians registered participants after obtaining consent, confirming eligibility and undertaking
the baseline assessment. Once registered, the allocation was generated and, after the researcher had
left the participant’s home, the WCTU trial team informed the participant of their allocation and made
arrangements for treatment referral. Neither the intervention providers nor participants could be masked to
treatment allocation. If a research clinician became unmasked, then follow-up assessments were conducted
by different research workers, and all study personnel who were involved with data entry, follow-up
assessments, and management were masked until the final analysis was complete.
Post-randomisation withdrawals
Participants were able to withdraw from the trial intervention and/or the trial at any time without prejudice.
Participants who withdrew from the intervention were followed up, whenever possible, and data were
collected as per the protocol until the end of the trial, unless they specifically withdrew from follow-up.
Participants who became unable to participate in the exercise intervention were withdrawn from the
intervention by the physiotherapist but followed up at 6 and 12 months, unless they indicated that they
did not wish this. Carers were able to withdraw from the trial without this affecting the inclusion of the
participant with dementia.
Documentation was completed on withdrawal to confirm the date and reason for withdrawal (if available).
Data management
All data were managed within the framework of the Data Protection Act 199882 and the standard
operating procedures of WCTU. Data were entered onto a bespoke application and stored on a secure
WCTU server with daily, weekly and monthly back-ups. All case report forms and accompanying papers
(excluding consent forms) were stored in a lockable cabinet at WCTU in individual, numbered participant
files. The files were kept in numerical order and had restricted access. Consent forms were stored
separately in a different cabinet to the case report forms, as they contained identifiable information.
Intervention forms were anonymised and stored in a lockable cabinet. All data were checked for
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completeness and validity prior to data entry. Researchers were requested to check data for completeness
prior to returning the case report forms to the trial team at WCTU. A further check was made by an
appropriate member of the trial team and queries were clarified by the completing researcher prior to data
entry. Data were not checked and entered by the same trial personnel.
A detailed data management plan was written that provided full details of the management of the data,
including formalising the tracking and collection of data from centres and participants, and guidance on
telephone contact with participants and carers.
Data analyses
Sample size
A sample size of 360 participants would provide 80% power to detect a minimum clinical between-group
difference of 2.45 points [baseline standard deviation (SD) of 7.8 points based on 66 participants] on
the ADAS-Cog at 12 months with a 5% level of significance and 2 : 1 randomisation in favour of the
intervention. This equated to a standardised effect size of 0.31. An overall difference of 2–2.5 change
points on the ADAS-Cog is considered to be a worthwhile target.83 To account for therapist effects, we
inflated the sample size using a design effect of 1.04 (intracluster correlation = 0.01) assuming that there
are five participants per group (recognising that it may not be possible to achieve and retain eight recruits
to each group), which gave a sample size of 375. The sample size was further inflated to account for 20%
loss to follow-up, of which 10% was estimated would be attributable to death. Thus, a final minimum
sample size of 468 participants was required, with 312 participants to be randomly allocated to the
intervention arm and 156 participants to the control arm.
Note that the sample size initially calculated was 728 participants based on the sMMSE score as the
primary outcome. The use of ADAS-Cog score rather than sMMSE score as the primary outcome allowed
the sample size to be reduced to 468. This change in sample size occurred before we started the trial and
was approved as a formal protocol amendment.
Primary analyses
Data were summarised and reported in accordance with Consolidated Standards of Reporting Trials
(CONSORT) guidelines for RCTs,84 and we used intention-to-treat (ITT) analyses as the primary analysis.
For the primary analyses, multilevel models were used with a random effect for region to estimate the
treatment effects and 95% confidence intervals (CIs). The clustering effects of therapist and group were
assessed by measuring the intracluster correlation. Therapist and/or group effects were not included in
the multilevel model if the clustering effects were found to be negligible. The models were adjusted for
important covariates (age, gender, region, sMMSE score and baseline ADAS-Cog score). Owing to the
nature of the population, certain items on the ADAS-Cog were missing and, hence, the missingness was
classed as being not random. Thus, for the primary analyses, participants with missing ADAS-Cog outcome
at each time point in the observed data had their item-level responses reviewed on an individual basis.
If any items were missing as a result of the participant being either cognitively unable, too distressed or
refusing to answer, then we estimated the treatment effects using multiple imputation (MI) methods.
This approach was taken as we are aware that the missing item-level responses for the ADAS-Cog are
non-ignorable. Therefore, doing a complete-case analysis (as done so in the first sensitivity analysis) could
give highly biased results. However, baseline variables, such as baseline ADAS-Cog score and sMMSE
score, are quite likely to be good predictors of missing items. We therefore applied MI methods, which is
considered a plausible approach to address non-ignorable missing data, to impute missing item-level data,
enabling us to compute and analyse the ADAS-Cog scores.85
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Sensitivity analyses
In addition to the primary analysis, three sensitivity analysis data sets were used to carry out sensitivity
analyses. For the first sensitivity analysis, the treatment effect was estimated using the observed data with
missing values present in the ADAS-Cog. This sensitivity analysis data set consisted of participants who
provided complete primary outcome data. For the second sensitivity analysis, participants with missing
ADAS-Cog outcome in the observed data had the worst score assigned at the item level, provided the item
was missing as a result of the participant being either cognitively unable, too distressed or refusing to
answer. For the third sensitivity analysis, an item response theory (IRT) approach was used. Between the
estimation of the sample size and the finalisation of the statistical analysis plan, the literature had moved
to suggest that the ADAS-Cog does not measure a single patient trait (cognitive impairment) but rather it
measures cognitive impairment in multiple cognitive domains.86 Therefore, IRT was used to assess treatment
effects in each of the cognitive domains, namely language, memory and praxis86 (see Appendix 5).
Secondary analyses
For secondary analyses, we estimated treatment effects over the 12-month time period using longitudinal
models adjusting for the same variables used in the primary analysis.
Subgroup analyses
Prespecified subgroup analyses looking at severity of cognitive impairment (sMMSE score of ≥ 20 for mild
and < 20 for moderate), type of dementia (Alzheimer’s vs. other), physical performance (no problems
walking vs. some problems/confined to bed, taken from the EQ-5D-3L) and gender (female vs. male) were
conducted using formal tests of interaction.87
Complier-average causal effect analysis
We measured compliance with the intervention by the number of sessions attended. This information was
collected by the therapist providing the treatment. Complier-average causal effect (CACE) analysis was
used to assess the effect of compliance with the intervention on the primary outcome.88
Data set access
The final data set was accessible to all study members after data lock. The chief investigator assumed
overall responsibility for the data report and had full access to the trial data set. There were no contractual
agreements that limited access for investigators.
Serious adverse event and adverse event reporting
An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a
causal relationship with this treatment. These were most likely to be identified by the physiotherapist
during the exercise sessions, from information at the sign-in, or after completion of the exercise sessions
during support telephone calls or the face-to-face meeting.
As each participant had a pre-exercise assessment done, this provided information on comorbidities.
The trial population included many participants aged > 70 years old and, therefore, they had many of the
common chronic diseases of older age, for example osteoarthritis. It was expected that participants would
experience some uncomfortable effects of participation in the intervention, for example muscle or joint
soreness in response to exercise. Provided that these followed an expected pattern (e.g. as for delayed-onset
muscle soreness), needed simple modifications to the exercise activity (e.g. changes to the bicycle seat
height) or were non-serious exacerbations of existing medical conditions, they were not considered as AEs.
A serious adverse event (SAE) was an AE that fulfilled one or more of the following criteria:
l resulted in death
l was immediately life-threatening
l required hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l required medical intervention to prevent one of the above.
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The SAEs to be reported were defined as those that occurred within 2 hours of completing the exercise
sessions or follow-on physical activities. SAEs were reported to the Trial Co-ordinating Centre within
24 hours of the physiotherapist becoming aware of them. The Trial Co-ordinating Centre was responsible
for reporting AEs to the sponsor and ethics committee within required timelines.
The relationship of SAEs to trial treatment was assessed by the chief investigator and this was recorded on
each SAE form. All SAEs were recorded in the trial database, when appropriate, reported to and reviewed
by the Data Monitoring and Ethics Committee (DMEC) throughout the trial, and were followed up
to resolution.
Monitoring and approval
Trial Steering Committee
A Trial Steering Committee was responsible for monitoring and supervising the progress of the trial
towards its interim and overall milestones.
Data Monitoring and Ethics Committee
The DMEC was independent of the trial and monitored the ethical, safety and data integrity aspects of
the trial.
Formal approvals
The original ethics approval for this project was granted on 19 January 2012. A substantial amendment
for the pre-pilot study was granted on 31 May 2012. Another amendment regarding randomisation was
granted on 17 July 2012. The third amendment for a change to the primary outcome measure to ADAS-Cog
was also granted on 17 July 2012. Amendments 4–6 were changes to the intervention materials based on
the results of the pre-pilot study, and these were granted on 17 January 2013. Amendment 7, regarding
sample size, was granted on 7 July 2014; and the final amendment, to add more elements to the qualitative
study into the project, was granted on 19 January 2015.
Results
Participant flow
The CONSORT flow diagram (Figure 4) describes the overall flow of participants through the study and
Table 53, Appendix 6, describes the flow summarised by each region.
Recruitment
Screening
Recruitment occurred between 1 February 2013 and 24 June 2015 across 15 different regions. A total of
2929 potential participants were identified through the screening process, of whom 1082 were ineligible.
The remaining 63% (1847/2929) of people were approached to participate in the trial through various
organisations within each region (see Appendix 6, Table 54) using different approach methods (Table 4).
Around 41% (750/1847) of these people were sourced through secondary care organisations and the main
approach method was by letter (50%) and telephone (25%). Of the 1847 people approached, 73.3%
(1353/1847) declined and 25.4% (461/1847) were eligible but were unwilling or unable to participate.
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Follow-up completed at 6 months
 (n = 145)
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Excluded from analysis (n = 28)
• Withdrawn from trial completely, n = 21
• Died, n = 5
• Lost to follow-up, n = 2
Follow-up completed at 6 months 
(n = 300)
Allocated to exercise programme 
(n = 329)
    
Ineligible
 (n = 1082)a
Excluded from analysis (n = 48)
• Withdrawn from trial completely, n = 24
• Died, n = 13
• Lost to follow-up, n = 11
Screened
(n = 2929)
Randomised
(n = 494)
• Has probable dementia according to the
   DSM-IV criteria: no, n = 25
• Dementia of mild to moderate severity
   (sMMSE score of >10): no, n = 244
• Able to sit on a chair and walk 10 feet
   without human assistance: no, n = 239
• Medically stable to exercise: no, n = 303
• Lives in the community (not residential or
   nursing home): no, n = 422
   • Not interested, n = 145
   • No reply, n = 65
   • Other health issues, n = 64
   • Participant commitment, n = 40
   • Carer commitment, n = 18
   • Transport, n = 4
   • Other reason, n = 120
   • Not specified, n = 897
Declined 
(n = 1353)
• Withdrawn from intervention but remained 
   for follow-up, n = 0
• Withdrawn from intervention but remained
   for follow-up, n = 38
• Withdrawn from trial completely, n = 17
• Died, n = 1
• Lost to follow-up, n = 2
Follow-up completed at 12 months
 (n = 137)
• Withdrawn from trial completely, n = 4
• Died, n = 4
• Lost to follow-up, n = 0
• Withdrawn from trial completely, n = 18
• Died, n = 5
• Lost to follow-up, n = 6
• Withdrawn from trial completely, n = 6
• Died, n = 8
• Lost to follow-up, n = 5
Follow-up completed at 12 months 
(n = 281)
Analysed at 12 months
 (n = 137)
Analysed at 12 months 
(n = 281)
FIGURE 4 The CONSORT flow diagram for the DAPA trial. a, Participants have more than one reason for ineligibility.
RANDOMISED CONTROLLED TRIAL: METHODS, RESULTS AND BRIEF DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
TABLE 4 Approach method for recruitment summarised for each region
Approach
method
Region (n)
Total
(n)Berkshire
Black
Country Coventry
Devon
and
Exeter
Gloucestershire
& Herefordshire
Greater
Manchester
West Leicester
North
East
London Northampton Nuneaton Oxford Rugby Solent
South
Warwickshire Worcester
Alzheimer’s
Cafe
0 0 0 2 0 2 0 0 0 0 0 0 0 0 1 5
Clinic 0 67 34 0 1 18 69 19 0 14 10 15 18 1 30 277
Letter 2 92 187 13 15 0 0 0 1 131 80 74 0 107 216 918
Telephone 37 0 0 3 0 9 16 22 215 0 165 0 0 0 0 467
Other 6 12 30 6 6 5 16 0 0 0 24 8 1 8 0 122
Unknown 0 0 1 0 0 2 0 0 1 1 0 2 0 32 0 58
Total 45 171 252 24 22 36 101 41 217 146 279 99 19 148 247 1847
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Recruitment
Of the 2929 participants screened, 17% (494/2929) of the participants were deemed eligible and
consented to trial participation (Table 5). The majority of participants were able to provide informed
consent (376/484, 76.1%), some required a personal consultee (117/494, 23.7%), and one required a
nominated consultee (1/494, 0.2%). The personal consultee was the carer in most situations.
Although the original target sample size was set as 468 participants, by the time this target was reached a
further 26 participants had been recruited and randomised because of the nature of recruiting participants to
fill exercise groups. The final recruitment total was, therefore, 494 participants. There were no participants
randomised in error. The proportion of participants in each arm across all regions is listed in Table 6 and
across the randomisation strata is given in Table 55, Appendix 6.
TABLE 5 Summary of method of consent by treatment
Method of consent
Treatment, n (%)
Total (N= 494), n (%)Usual care (N= 165) Exercise programme (N= 329)
Participant 126 (76.4) 250 (76.0) 376 (76.1)
Personal consultee 38 (23.0) 79 (24.0) 117 (23.7)
Nominated consultee 1 (0.6) 0 1 (0.2)
Missing 0 0 0
TABLE 6 Randomised participants by region and treatment
Region
Treatment, n (%)
Total (N= 494), n (%)Usual care (N= 165) Exercise programme (N= 329)
Berkshire 13 (31.7) 28 (68.3) 41 (8.3)
Black Country 15 (33.3) 30 (66.7) 45 (9.1)
Coventry 18 (33.3) 36 (66.7) 54 (10.9)
Devon and Exeter 4 (40.0) 6 (60.0) 10 (2.0)
Gloucestershire & Herefordshire 6 (33.3) 12 (66.7) 18 (3.6)
Greater Manchester West 6 (33.3) 12 (66.7) 18 (3.6)
Leicester 5 (29.4) 12 (70.6) 17 (3.5)
North East London 6 (33.3) 12 (66.7) 18 (3.6)
Northampton 21 (33.9) 41 (66.1) 62 (12.6)
Nuneaton 8 (34.8) 15 (65.2) 23 (4.7)
Oxford 25 (33.3) 50 (66.7) 75 (15.2)
Rugby 8 (33.3) 16 (66.7) 24 (4.9)
Solent 4 (40.0) 6 (60.0) 10 (2.0)
South Warwickshire 12 (33.3) 24 (66.7) 36 (7.3)
Worcester 14 (32.6) 29 (67.4) 43 (8.7)
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Participant baseline data
Participant baseline characteristics
The dementia diagnosis of participants at the baseline assessment has been summarised in Table 7, with
the most common diagnoses being dementia in Alzheimer’s disease with late onset at 35.6% (176/494),
atypical or mixed type at 20.9% (103/494) and unspecified at 15.4% (76/494). The baseline demographic
characteristics and outcome measures of the randomised participants are summarised by treatment group
in Table 8. Overall, the demographic characteristics were well matched across treatment groups, with the
majority of participants being white males with an average age of 77.4 years (SD 7.9 years), who were
married and living with their wife/husband/partner.
Participant baseline medications
Medication use was similar in both treatment groups; the overall mean number of medications being
taken was 5.7 (SD 3.5) and donepezil was the most used medication (50.6%) (see Table 8).
Participant baseline outcome measures
A summary of the baseline outcome measures is given in Table 8. We report only the primary data sources,
as data were sufficiently complete that we did not have to rely on alternative sources (i.e. proxy). All
outcome measures were similar across treatment groups at baseline. The overall mean imputed ADAS-Cog
score (primary outcome) was 21.5 (SD 9.0) out of a possible score of 70, for which a higher score indicates
greater cognitive impairment. The three subscales of the primary outcome, namely language, memory and
praxis, had mean scores of 2.9 (SD 3.4), 16.9 (5.8) and 1.7 (SD 1.6), respectively.
TABLE 7 Summary of the dementia diagnosis of participants
Dementia diagnosis
Treatment, n (%)
Total (N= 494),
n (%)
Usual care
(N= 165)
Exercise programme
(N= 329)
Dementia in Alzheimer’s disease
With early onset 9 (5.5) 25 (7.6) 34 (6.9)
With late onset 56 (33.9) 120 (36.5) 176 (35.6)
Atypical or mixed type 33 (20.0) 70 (21.3) 103 (20.9)
Unspecified 29 (17.6) 47 (14.3) 76 (15.4)
Multi-infarct dementia 3 (1.8) 7 (2.1) 10 (2.0)
Mixed cortical and subcortical vascular dementia 2 (1.2) 0 2 (0.4)
Vascular dementia, unspecified 17 (10.3) 27 (8.2) 44 (8.9)
Dementia in
Pick’s disease 1 (0.6) 3 (0.9) 4 (0.8)
Parkinson’s disease 5 (3.0) 13 (3.9) 18 (3.6)
Other specified diseases classified elsewhere 2 (1.2) 3 (0.9) 5 (1.0)
Unspecified dementia 8 (4.9) 14 (4.3) 22 (4.5)
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TABLE 8 Baseline demographic and clinical characteristics of randomised and the sample providing data for the
analysis of the primary end point (ADAS-Cog at 12 months) primary analysis
Characteristic
Randomised sample
Sample providing primary
outcome
Usual care
(N= 165)
Exercise
programme
(N= 329)
Usual care
(N= 137)
Exercise
programme
(N= 278)
Age (years), mean (SD) 78.4 (7.6) 76.9 (7.9) 78.1 (7.7) 76.9 (7.7)
Gender (male), n (%) 106 (64.2) 195 (59.3) 86 (62.8) 166 (59.7)
Living arrangements, n (%)
Live alone 35 (21.2) 62 (18.8) 29 (21.2) 46 (16.5)
Live with relatives 5 (3.0) 18 (5.5) 4 (2.9) 15 (5.4)
Live with wife/husband/partner 125 (75.8) 248 (75.4) 104 (75.9) 216 (77.7)
Living with friends 0 1 (0.3) 0 1 (0.4)
Ethnicity, n (%)
White 157 (95.2) 321 (97.6) 130 (94.9) 274 (98.6)
Other 8 (4.8) 8 (2.4) 7 (5.1) 4 (1.4)
Highest level of education, n (%)
Degree/degree equivalent (including
higher degree)/NVQ4/NVQ5
24 (14.5) 57 (17.3) 20 (14.6) 51 (18.3)
Higher education below degree 16 (9.7) 28 (8.5) 11 (8.0) 23 (8.3)
NVQ3/GCE A-level equivalent 10 (6.1) 14 (4.3) 9 (6.6) 12 (4.3)
NVQ2/GCE O-level/GCSE-level
equivalent/school certificate
29 (17.6) 60 (18.2) 25 (18.2) 50 (18.0)
Other vocational/work-related
qualifications
35 (21.2) 68 (20.7) 29 (21.2) 57 (20.5)
No qualification 49 (29.7) 99 (30.1) 41 (29.9) 84 (30.2)
Total number of medications, mean (SD) 5.5 (3.1) 5.7 (3.7) 5.6 (3.2) 5.5 (3.5)
Dementia medications, n (%)
Donepezil 84/155 (54.2) 166/318 (52.2) 70/129 (54.3) 148/270 (54.8)
Rivastigmine 0 6/318 (1.9) 0 3/270 (1.1)
Galantamine 1/155 (0.6) 6/318 (1.9) 0 0
Memantine 8/155 (5.2) 10/318 (3.1) 8/129 (6.2) 4/270 (1.5)
ADAS-Cog score, mean (SD) 21.8 (7.7) 21.4 (9.6) 21.4 (7.8) 21.2 (9.5)
Language subscale score, mean (SD) 2.7 (3.0) 3.0 (3.6) 2.7 (3.0) 2.9 (3.6)
Memory subscale score, mean (SD) 17.4 (4.8) 16.7 (6.2) 17.1 (4.9) 16.6 (6.1)
Praxis subscale score, mean (SD) 1.7 (1.5) 1.7 (1.7) 1.6 (1.5) 1.7 (1.6)
sMMSE score, mean (SD) 21.6 (4.6) 22.0 (4.7) 22.1 (4.6) 22.1 (4.6)
EQ-5D-3L score (self-reported), mean (SD) 0.85 (0.18) 0.82 (0.20) 0.86 (0.16) 0.84 (0.19)
EQ-5D-3L score (proxy-reported), mean (SD) 0.70 (0.24) 0.68 (0.24) 0.72 (0.22) 0.69 (0.24)
QoL-AD score (self-reported), mean (SD) 39.3 (5.2) 38.7 (5.6) 39.4 (5.0) 39.1 (5.4)
NPI score (proxy-reported), mean (SD) 13.3 (13.2) 12.8 (15.0) 12.7 (12.2) 12.7 (15.1)
BADLS score (proxy-report), mean (SD) 11.4 (8.5) 12.0 (8.4) 10.9 (8.1) 11.6 (8.1)
Fallen in the last 6 months (yes), n (%) 56 (36.4) 90 (29.5) 41 (31.8) 70 (27.1)
Number of falls in last 6 months, mean (SD) 2.8 (4.9) 2.7 (3.3) 3.1 (5.5) 2.8 (3.7)
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Participant baseline outcome measures
A summary of the baseline outcome measures is given in Table 8. We report only the primary data sources
as data were sufficiently complete that we did not have to rely on alternative sources (i.e. proxy). All
outcome measures were similar across treatment groups at baseline. The overall mean imputed ADAS-Cog
score (primary outcome) was 21.5 (SD 9.0) out of a possible score of 70, for which a higher score indicates
greater cognitive impairment. The three subscales of the primary outcome, namely language, memory and
praxis, had mean scores of 2.9 (SD 3.4), 16.9 (5.8) and 1.7 (SD 1.6), respectively.
Comparing the baseline self-reported and proxy-reported outcome measures
Self-reported and proxy-reported data were available for most of the participants at baseline (see Table 9).
In total, self-reported data were provided by 98.4% (486/494) of the participants for the EQ-5D-3L, 98.0%
(484/494) for the EQ-5D-3L visual analogue scale (VAS) and 85.8% (424/494) for the QoL-AD. The only
reason that most participants with self-reported outcomes did not have proxy data was if their carer did
not give consent to participate and provide data. The self-reported and proxy-outcome measures were
compared for all participants who had both sets of data available at baseline (see Table 10). There is
evidence of a significant difference between the self-reported and proxy-reported outcome measures when
the participants reported a significantly higher quality of life. Therefore, participants rated their quality of
life significantly more highly than their carers did.
TABLE 8 Baseline demographic and clinical characteristics of randomised and the sample providing data for the
analysis of the primary end point (ADAS-Cog at 12 months) primary analysis (continued )
Characteristic
Randomised sample
Sample providing primary
outcome
Usual care
(N= 165)
Exercise
programme
(N= 329)
Usual care
(N= 137)
Exercise
programme
(N= 278)
Broken bones in last 6 months (yes), n (%) 5 (3.3) 9 (3.0) 2 (1.6) 9 (3.5)
Carer age (years), mean (SD) 70.2 (10.5) 69.1 (11.4) 70.1 (10.4) 69.8 (10.7)
Carer gender (male), n (%) 29 (18.8) 87 (28.5) 25 (19.4) 74 (28.7)
Carer relationship, n (%)
Spouse 117 (76.0) 239 (78.4) 98 (76.0) 209 (81.0)
Son/daughter (in law) 32 (20.8) 55 (18.0) 27 (20.9) 42 (16.3)
Other 4 (2.6) 11 (3.6) 3 (2.3) 7 (2.7)
Frequency of caring, n (%)
Daily 120 (77.9) 254 (83.3) 100 (77.5) 217 (84.1)
4–6 times a week 7 (4.6) 14 (4.6) 5 (3.9) 9 (3.5)
1–3 times a week 16 (10.4) 24 (7.9) 15 (11.6) 21 (8.1)
Less than once a month 9 (5.8) 8 (2.6) 7 (5.4) 7 (2.7)
ZBI score, mean (SD) 29.0 (15.7) 30.6 (15.4) 28.5 (15.7) 30.2 (15.0)
Carer EQ-5D-3L score, mean (SD) 0.82 (0.23) 0.79 (0.21) 0.81 (0.23) 0.79 (0.21)
A level, Advanced Level; GCE, General Certificate of Education; GCSE, General Certificate of Secondary Education;
NVQ, National Vocational Qualification; O level, Ordinary Level.
Note
Missing data are presented only when data are missing.
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TABLE 9 Summary of self-reported data and proxy-reported data at baseline
Type of respondent
Treatment arm, n (%)
Total (N= 494),
n (%)
Usual care
(N= 165)
Exercise programme
(N= 329)
EQ-5D-3L score
No self-reported data or proxy-reported data 3 (1.8) 0 3 (0.6)
Self-reported data onlya 10 (6.1) 25 (7.6) 35 (7.1)
Proxy-reported data only 3 (1.8) 2 (0.6) 5 (1.0)
Both self-reported data and proxy-reported data 149 (90.3) 302 (91.8) 451 (91.3)
EQ-5D-3L VAS score
No self-reported data or proxy-reported data 1 (0.6) 0 1 (0.2)
Self-reported data onlya 10 (6.1) 25 (7.6) 35 (7.1)
Proxy-reported data only 3 (1.8) 6 (1.8) 9 (1.8)
Both self-reported data and proxy-reported data 151 (91.5) 298 (90.6) 449 (90.9)
QoL-AD score
No self-reported data or proxy-reported data 10 (6.1) 23 (7.0) 33 (6.7)
Self-reported data onlya 31 (18.8) 44 (13.4) 75 (15.2)
Proxy-reported data only 15 (9.1) 22 (6.7) 37 (7.5)
Both self-reported data and proxy-reported data 109 (66.1) 240 (73.9) 349 (70.6)
a The only reason that most participants with self-reported outcomes did not have proxy data was if their carer did not
give consent to participate and provide data.
TABLE 10 Comparison of self-reported data and proxy-reported data at baseline when both sets of data
are available
Outcome
Data
Unadjusted estimate (95% CI) p-valueSelf reported Proxy reported
EQ-5D-3L score
n 451 451 0.14 (0.12 to 0.16) < 0001a
Mean (SD) 0.83 (0.19) 0.69 (0.24)
Range –0.07 to 1 –0.35 to 1
EQ-5D-3L VAS score
n 449 449 11.1 (9.1 to 13.0) < 0.001
Mean (SD) 79.0 (18.0) 68.0 (18.9)
Range 20 to 100 5 to 100
QoL-AD score
n 349 349 5.9 (5.2 to 6.6) < 0.001
Mean (SD) 38.9 (5.4) 32.9 (6.0)
Range 21 to 52 14 to 51
a p-value obtained using Wilcoxon signed-rank test as the data are non-normal.
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Falls and fracture
In total, 31.8% (146/459) of the participants had a fall in the last 6 months at baseline. There was no
evidence of a difference in the mean number of falls between the two treatment groups with an overall
mean of 2.7 falls (SD 4.0 falls) in the last 6 months. About 3% (14/459) of all participants had broken
bones as a result of falling in the last 6 months. There was no evidence of a difference in the mean
number of broken bones between the two groups with an overall mean of 1.3 (SD 0.6) broken bones in
the last 6 months (see Table 8).
Carer baseline data
Carer baseline characteristics
Of the 494 participants attending the baseline assessment, 96.2% (475/494) had a carer. Of those with a
carer, 96.6% (459/475) of the carers consented to participate in the study. The carer baseline characteristics
and outcome measures have been summarised, by treatment group, in Table 11. There is a higher number
of female carers in the usual-care arm (81.2%) than in the exercise arm (71.5%). Apart from this, the carer
demographic characteristics and outcome measures are well matched across treatment groups, with the
majority of carers being white females with an average age of 69.5 years (SD 11.1 years) who are providing
care on a daily basis. Most of the carers (99.1%) knew the participant before they had dementia and the
reason for this was that they were either their spouse (77.6%) or their son/daughter (in-law) (18.9%).
Around 91% of the carers had knowledge of the participant’s night-time behaviour.
Carer role and relationship
For most participants in both arms their spouse was the only caregiver: 66.2% (102/154) in the usual-care
arm and 69.8% (213/305) in the exercise arm. Many of the remaining participants had either their spouse
or son or daughter (in-law) as their main carer.
TABLE 11 Baseline demographic characteristics and outcome measures of all carers by treatment group
Characteristic/outcome
Treatment arm, n (%)
Total
(N= 459),
n (%)
Usual care
(N= 154)
Exercise programme
(N= 305)
Age (years)
Mean (SD) 70.2 (10.5) 69.1 (11.4) 69.5 (11.1)
Range 36.5 to 91.3 33.1 to 95.3 33.1 to 95.3
Gender (male) 29 (18.8) 87 (28.5) 116 (25.3)
Knew participant before they had dementia (yes) 152 (98.7) 303 (99.3) 455 (99.1)
Carer role
Only caregiver 112 (72.7) 236 (77.4) 348 (75.8)
Main carer but share caring responsibilities 26 (16.9) 56 (18.3) 82 (17.9)
Share caring responsibilities with others 9 (5.8) 9 (2.9) 18 (3.9)
Share caring responsibilities but someone else is the main carer 4 (2.6) 2 (0.7) 6 (1.3)
Other 1 (0.7) 0 1 (0.2)
Missing 2 (1.3) 2 (0.7) 4 (0.9)
continued
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TABLE 11 Baseline demographic characteristics and outcome measures of all carers by treatment group (continued )
Characteristic/outcome
Treatment arm, n (%)
Total
(N= 459),
n (%)
Usual care
(N= 154)
Exercise programme
(N= 305)
Relationship to participant
Spouse 117 (76.0) 239 (78.4) 356 (77.6)
Son/daughter (in-law) 32 (20.8) 55 (18.0) 87 (18.9)
Other relative 1 (0.6) 5 (1.6) 6 (1.3)
Friend, neighbour, acquaintance 0 3 (1.0) 3 (0.7)
Paid carer 1 (0.6) 0 1 (0.2)
Other 2 (1.4) 3 (1.0) 5 (1.1)
Missing 1 (0.6) 0 1 (0.2)
How often you provide care to the participant
Daily 120 (77.9) 254 (83.3) 374 (81.5)
4–6 times a week 7 (4.6) 14 (4.6) 21 (4.6)
1–3 times a week 16 (10.4) 24 (7.9) 40 (8.7)
Less than once a month 9 (5.8) 8 (2.6) 17 (3.7)
Missing 2 (1.3) 5 (1.6) 7 (1.5)
Do you have knowledge of the participant’s night-time behaviour
Yes 140 (90.9) 279 (91.5) 419 (91.3)
Missing 0 1 (0.3) 1 (0.2)
Ethnicity
White 147 (95.5) 301 (98.7) 448 (97.6)
Other 6 (3.9) 4 (1.3) 10 (2.2)
Missing 1 (0.6) 0 1 (0.2)
EQ-5D-3L utility score
Mean (SD) 0.82 (0.23) 0.79 (0.21) 0.80 (0.22)
Range –0.18 to 1 –0.02 to 1 –0.18 to 1
Missing 1 1 2
EQ-5D-3L VAS score
Mean (SD) 77.7 (18.4) 77.3 (17.7) 77.5 (17.9)
Range 3 to 100 20 to 100 3 to 100
Missing 1 1 2
ZBI score
Mean (SD) 29.0 (15.7) 30.6 (15.4) 30.1 (15.5)
Range 0 to 76 2 to 77 0 to 77
Missing 8 5 13
Missing data are presented only when data are missing.
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Carer baseline outcome measures
A summary of the carer baseline outcomes measures is given in Table 11. All outcome measures were
similar across treatment groups at baseline. Carers had an overall mean EQ-5D-3L utility score of 0.8
(SD 0.22) and mean EQ-5D-3L VAS score of 77.5 (SD 17.9) with mild to moderate carer burden reflected
by a mean Zarit Burden Interview (ZBI) score of 30.1 (SD 15.5).
Participant follow-up
During the study 90% (445/494) and 85% (418/494) of the participants were followed up at 6 months
and 12 months (see Figure 4), respectively. In both arms, all follow-up was completed within the intended
time frames. The mean time from randomisation to the 6-month follow-up time point was 6.2 months
(SD 0.50 months) and to the 12-month follow-up time point was 12.3 months (SD 0.56 months).
Withdrawals and loss to follow-up
At 12 months, the combined withdrawal and loss to follow-up rate was 12 out of 165 (13.9%) for the
usual-care arm, and 35 out of 329 (10.6%) for the exercise arm (see Table 9), which was not statistically
significantly different. The number of losses between these two categories was different, as shown in
Table 12. In total, 9.1% (45/494) of the participants withdrew from the trial completely during follow-up,
with 12.7% (21/165) of these requests being in the usual-care arm compared to 7.3% (24/329) in the
exercise arm, which was significantly different (p < 0.001). A complete withdrawal request from the
participant also meant that their carer also completely withdrew. Loss to follow-up at 12 months was 2 out
of 165 patients in usual care (1.2%) and 11 out of 329 patients (3.3%) in the exercise arm.
Table 13 presents the time from randomisation to complete withdrawal by treatment arm. There was no
evidence of a significant difference between the two arms in the time from randomisation to complete
withdrawal from the trial (p = 0.724).
In the exercise arm, 13.1% (43/329) of the participants had ceased only the trial treatment procedure
(i.e. still remained on follow-up), of which 11.6% (38/329) were by request of the participant and 1.5%
(5/329) were recommended by the physiotherapist (see Table 12). Of these, 10 participants later withdrew
completely from the trial.
TABLE 12 Overall summary of withdrawal requests and deaths reported by treatment arm at 12 months
Type of withdrawal
Treatment arm, n (%)
Total (N= 494),
n (%)
Usual care
(N= 165)
Exercise programme
(N= 329)
Has ceased trial treatment or procedure but remains on follow-up 0 38 (11.6)a 38 (7.7)
Has withdrawn from the trial completely and will not be
followed up
21 (12.7) 24 (7.3) 45 (9.1)
Participant has died 5 (3.0) 13 (4.0) 18 (3.6)
Physiotherapist has recommended withdrawal from treatment 0 5 (1.5)b 5 (1.0)
Lost to follow-up 2 (1.2) 11 (3.3) 13 (2.6)
a Of the 38 participants that withdrew from trial treatment but remained on follow-up, 10 participants went on to request
complete withdrawal from the trial and one participant died.
b Of the five participants who were withdrawn from treatment on recommendation of the physiotherapist, one participant
went on to request complete withdrawal from the trial.
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Deaths
The number of participants who died by the end of the study was similar in both arms with 3.6% (18/494)
deaths in total, as shown in Table 12.
Table 13 presents the time from randomisation to death by treatment arm. There was no evidence of a
significant difference between the two trial arms in the time from randomisation to death (p = 0.423).
Comparison of retained participants to those lost to follow-up
Tables 56 and 57, Appendix 6, present the baseline characteristics of participants not completing (died,
withdrew and lost to follow-up) and completing follow-up at 6 months and 12 months, respectively.
At both time points, people who completed follow-up were, on average, younger than those who died
but were similar in age to those who withdrew or were lost to follow-up. There is evidence of a significant
association between marital status and whether or not a participant completed follow-up, with those
who are separated or divorced being less likely to complete follow-up. Moreover, participants completing
follow-up had significantly better HRQoL at 6 months (measured by the EQ-5D-3L) and at 12 months
(measured by the EQ-5D-3L and QoL-AD) than those not completing follow-up. At 12 months, participants
completing follow-up had significantly better cognition, as measured by the sMMSE score, than the
non-completers. In addition, both the ADAS-Cog (imputed) and the ADAS-Cog (raw) scores suggest that,
on average, participants who died had poorer cognition than those who completed follow-up at both
time points.
Protocol violations
Research protocol violations
A summary of the protocol violations has been presented by treatment arm in Table 14. There were no
participants who were found to be ineligible once randomised.
Clinical protocol violations
Of the 329 participants who were allocated to the exercise arm, 12.5% (41/329) withdrew from the
intervention alone, having completed only ≤ 75% of their scheduled sessions. In the exercise arm,
35% (115/329) of the participants were non-compliers, that is, they attended ≤ 75% of their scheduled
sessions. In total, 9.1% (45/494) of the participants did not complete follow-up at any of the time points.
TABLE 13 Time from randomisation to complete withdrawal from trial and death summarised by treatment arm
Characteristic/outcome
Treatment arm
Unadjusted estimate
(95% CI) p-value
Usual care
(N= 165)
Exercise programme
(N= 329)
Time (days) from randomisation to withdrawal from trial
n 21 24 –12.6 (–84.4 to 59.1) 0.724
Mean (SD) 183.9 (103.4) 196.5 (131.3)
Range 1–363 2–517
Time (days) from randomisation to death
n 5 13 37.5 (–59.1 to 134.1) 0.423
Mean (SD) 288.4 (76.5) 250.9 (89.7)
Range 167–346 89–372
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Outcomes and analyses
Numbers analysed
All 494 randomised participants completed their baseline assessments (usual-care arm, n = 165; exercise
arm, n = 329). A reduced number of 445 participants provided 6-month follow-up data (usual-care arm,
n = 145; exercise arm, n = 300) and a total of 418 participants provided 12-month follow-up data
(usual-care arm, n = 137; exercise arm, n = 281).
Table 15 summarises the completeness of the ADAS-Cog, both overall and at the item level, at each time
point. The ADAS-Cog had missing items for 5.7% (28/494) of the participants at baseline, 6.7% (30/445)
at 6 months and 12.9% (54/418) at 12 months. The two items that were mostly missing were the word
recognition and remember test items.
Primary outcome: Alzheimer’s Disease Assessment Scale – Cognitive Subscale (imputed
at the item level)
On average, cognition declined over time (Tables 16 and 17 and Figures 5 and 6). There was evidence of a
statistically significant difference at 12 months, which suggests that participants in the usual-care arm have
a lower ADAS-Cog score (better cognition) of 1.4 (95% CI –2.62 to –0.17) than participants in the exercise
arm (Table 17 and Figure 6).
Secondary outcomes
Secondary outcomes collected at 6 months and 12 months have been presented in Tables 18 and 19,
respectively.
Alzheimer’s Disease Assessment Scale – Cognitive Subscale (imputed) subscale scores
The ADAS-Cog subscale scores of language, memory and praxis at 6 months and 12 months have been
presented in Tables 18 and 19, respectively. No statistical differences were found in the subscale scores
between the two treatment groups at any of the time points.
Health-related quality of life (EuroQol-5 Dimensions, three-level version and Quality of
Life in Alzheimer’s Disease)
There was no evidence of a difference between the two treatment groups for the HRQoL measures,
that is, the EQ-5D-3L (utility) score, EQ-5D-3L VAS score and QoL-AD score at 6 months and 12 months
(see Tables 18 and 19).
TABLE 14 Number of protocol violations summarised by treatment arm
Category
Treatment arm, n (%)
Total (N= 494),
n (%)
Usual care
(N= 165)
Exercise programme
(N= 329)
Randomised but ineligible 0 0 0
Withdrawals (received opposite treatment to allocation)a 0 41 (12.5) 41 (8.3)
Non-adherence to treatment (≤ 75% compliance) 0 106 (32.2) 106 (21.5)
Incomplete follow-upb 19 (11.5) 26 (7.9) 45 (9.1)
a These participants withdrew from the intervention only (either requested by themselves or by the physiotherapist) and
had attended ≤ 75% of their scheduled sessions.
b These participants have no follow-up at any of the time points.
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TABLE 15 Item-level missingness patterns for the ADAS-Cog at each time point
Time
point,
pattern
number
ADAS-Cog item
Number
of items
Missing
Frequency
of patients
with pattern
Word
recall Commands
Constructional
praxis Naming
Ideational
praxis Orientation
Word
recognition
Remember
test
Comprehension
of spoken
language
Word
finding Language
Baseline
1 + + + + + + + + + + + 0 466
2 + + + + + + + + + 2 17
3 + + + + + + + + + + 1 7
4 + + + + + + + + + + 1 1
5 + + + + + + + + + + 1 1
6 + + + + + + + + 3 1
7 + + + + + + + + 3 1
6 months
1 + + + + + + + + + + + 0 415
2 + + + + + + + + + 2 11
3 11 8
4 + + + + + + + + + + 1 2
5 + + + + + + + + 3 2
6 + + + + + + + + + + 1 1
7 + + + + + + + + + + 1 1
8 + + + + + + + + + 2 1
9 + + + + + + + + + 2 1
10 + + + + + + + + 3 1
11 + + + + + + + + 3 1
12 + + + + + + + 4 1
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Time
point,
pattern
number
ADAS-Cog item
Number
of items
Missing
Frequency
of patients
with pattern
Word
recall Commands
Constructional
praxis Naming
Ideational
praxis Orientation
Word
recognition
Remember
test
Comprehension
of spoken
language
Word
finding Language
12 months
1 + + + + + + + + + + + 0 364
2 + + + + + + + + + 2 20
3 11 10
4 + + + + + + + + + 3 5
5 + + + + + + + + + + 1 4
6 + + + + + + + + + + 1 2
7 + + + + + + + + 3 2
8 + + + + + + + + + + 1 1
9 + + + + + + + + + + 1 1
10 + + + + + + + + 3 1
11 + + + + + + + + 3 1
12 + + + + + + + 4 1
13 + + + + + + + 4 1
14 + + + + + + 5 1
15 + + + + + + 5 1
16 + + + + + + 5 1
17 + + + + 7 1
18 + + + + 7 1
+ in the table indicates that the item was completed. A blank space indicates that the item was not completed.
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TABLE 16 Summary of the primary outcome with estimated treatment effect at 6 months’ follow-up
Outcome
Treatment arm
Adjusted estimate (95% CI)a p-valueUsual care Exercise programme
ADAS-Cog (imputed)
n 145 298
Mean (SD) 22.4 (9.4) 22.9 (11.6) –0.6 (–1.58 to 0.39) 0.237
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
TABLE 17 Summary of the primary outcome with estimated treatment effect at 12 months’ follow-up (primary
time point)
Outcome
Treatment arm
Adjusted estimate (95% CI)a p-valueUsual care Exercise programme
ADAS-Cog (imputed)
n 137 278
Mean (SD) 23.8 (10.4) 25.2 (12.3) –1.4 (–2.62 to –0.17) 0.026
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
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FIGURE 5 Plot of the unadjusted ADAS-Cog score (imputed) over time by treatment arm.
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– 1.40 (– 2.62 to – 0.17)
– 0.60 (– 1.58 to 0.39)
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FIGURE 6 Plot of adjusted treatment estimates (mean difference and 95% CI) for the ADAS-Cog score at 6 and
12 months.
TABLE 18 Summary of the primary and secondary outcomes with estimated treatment effect at 6 months’ follow-up
Outcome
Treatment arm
Adjusted estimate
(95% CI)a p-valueUsual care Exercise programme
Language subscale score (imputed)
n 145 299
Mean (SD) 3.2 (3.7) 3.5 (4.4) 0.01 (–0.42 to 0.45) 0.959
Memory subscale score (imputed)
n 145 298
Mean (SD) 17.3 (5.6) 17.3 (6.9) –0.5 (–1.18 to 0.27) 0.218
Praxis subscale score (imputed)
n 145 299
Mean (SD) 1.9 (1.8) 2.1 (2.0) –0.03 (–0.27 to 0.21) 0.811
EQ-5D-3L score (self-reported)
n 139 292
Mean (SD) 0.83 (0.21) 0.80 (0.21) 0.02 (–0.01 to 0.06) 0.240
EQ-5D-3L VAS score (self-reported)
n 138 288
Mean (SD) 78.7 (18.8) 75.4 (20.6) –0.1 (–3.62 to 3.36) 0.942
QoL-AD score (self-reported)
n 124 263
Mean (SD) 39.0 (5.9) 38.9 (6.1) –0.1 (–0.98 to 0.84) 0.879
continued
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TABLE 18 Summary of the primary and secondary outcomes with estimated treatment effect at 6 months’
follow-up (continued )
Outcome
Treatment arm
Adjusted estimate
(95% CI)a p-valueUsual care Exercise programme
NPI score (proxy-reported)
n 110 234
Mean (SD) 14.8 (15.6) 15.2 (16.1) –0.5 (–3.08 to 2.05) 0.695
BADLS score (proxy-reported)
n 129 271
Mean (SD) 14.6 (10.4) 14.6 (9.5) 0.8 (–0.31 to 1.96) 0.153
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
TABLE 19 Summary of the primary and secondary outcomes with estimated treatment effect at 12 months’ follow-up
Outcome
Treatment arm
Adjusted estimate
(95% CI)a p-valueUsual care Exercise programme
Language subscale (imputed)
n 137 280
Mean (SD) 3.8 (4.7) 4.4 (5.2) –0.2 (–0.75 to 0.44) 0.611
Memory subscale (imputed)
n 137 279
Mean (SD) 18.1 (5.6) 18.5 (6.7) –0.8 (–1.56 to 0.02) 0.056
Praxis subscale (imputed)
n 137 281
Median (range) 1 (0–9) 2 (0–9) – 0.084b
EQ-5D-3L score (self-reported)
n 131 261
Mean (SD) 0.82 (0.25) 0.81 (0.22) –0.002 (–0.04 to 0.04) 0.928
EQ-5D-3L VAS score (self-reported)
n 124 261
Mean (SD) 78.3 (19.4) 75.5 (19.3) 1.4 (–2.38 to 5.23) 0.464
QoL-AD score (self-reported)
n 119 237
Mean (SD) 39.1 (5.7) 38.4 (5.8) 0.7 (–0.21 to 1.65) 0.127
NPI score (proxy-reported)
n 105 215
Mean (SD) 13.5 (13.1) 16.2 (15.9) –2.1 (–4.83 to 0.65) 0.135
BADLS score (proxy-reported)
n 124 251
Mean (SD) 15.9 (9.7) 17.0 (10.2) –0.6 (–2.05 to 0.78) 0.380
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
b Data were non-normal; non-parametric p-value was obtained using the Wilcoxon rank-sum test.
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Behavioural symptoms (Neuropsychiatric Inventory)
There was no evidence of a difference between the two treatment groups at 6 months’ follow-up and at
12 months’ follow-up (see Tables 18 and 19).
Function (Bristol Activities of Daily Living Scale)
There was no evidence of a difference between the two treatment groups at 6 months’ follow-up and at
12 months’ follow-up (see Tables 18 and 19).
Carer outcomes
A summary of the carer-reported outcomes collected at 6 months and 12 months has been presented in
Table 20.
Carer health-related quality of life (EuroQol-5 Dimensions, three-level version)
There was no evidence of a difference between the two treatment groups for the carer’s HRQoL measures,
namely the EQ-5D-3L (utility) score and EQ-5D-3L VAS score, at 6 months and 12 months (see Table 20).
Carer burden (Zarit Burden Interview)
Carer burden was assessed using the ZBI, which was completed by the carer. No evidence of a difference in
the carer’s mean ZBI score was observed between the two treatment groups at 6 months’ and 12 months’
follow-up (see Table 20).
Carer benefit from the study
Carer benefit was measured using a five-level Likert scale, that is, substantial benefit to substantial harm.
At 6 months, most carers (around 73%) in the exercise group felt that they had gained moderate or
substantial benefit, whereas the majority of carers in the usual-care arm (58.1%) felt that they had gained
no benefit (see Table 20). Similarly, at 12 months, most carers (around 71%) in the exercise group felt that
they had gained moderate or substantial benefit, whereas the majority of carers in the usual-care arm felt
that they had gained no benefit (46.1%) or gained moderate benefit (43.1%).
Participant dementia change
Participant dementia change was reported by their carer at 6 and 12 months’ follow-up and was measured
using a five-level Likert scale, that is, much improved to much worsened. There was no evidence of a difference
between the two treatment groups at both time points. At 6 months, around 23% of carers reported no
change in the participant and 52% felt that the participant had slightly worsened. At 12 months, 18% of
carers reported no change in the participant, 55% felt that the participant had slightly worsened and 17%
felt that the participant had much worsened.
Participant falls and fractures
Table 21 summarises the falls and fractures of the person being cared for, as reported by the carer, at 6
and 12 months. There was no evidence of a significant difference in the reported number of falls and the
number of broken bones at 6 and 12 months’ follow-up sustained by the participant. Moreover, there was
no evidence of a significant difference in the number of falls over the entire follow-up period.
Secondary analyses
Sensitivity analyses
Three sensitivity analyses were conducted to see how the treatment effect estimate differs to the primary
analysis if the ADAS-Cog (primary outcome) was computed or analysed differently. The first sensitivity
analysis estimated the treatment effect using the ADAS-Cog score that was computed using the observed
data, that is, only the data provided by those participants who were well enough to complete. Table 22
presents the results of this sensitivity analysis. There was evidence of a statistically significant difference at
12 months, with an estimated between-group difference of –1.7 (95% CI –2.97 to –0.39) in favour of the
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TABLE 20 Carer study outcomes at 6 and 12 months’ follow-up
Time point, outcome
Treatment arm
Adjusted estimate (95% CI)a p-valueUsual care Exercise programme
6 months
EQ-5D-3L score
n 132 277
Mean (SD) 0.77 (0.24) 0.76 (0.23) –0.004 (–0.04 to 0.03) 0.839
EQ-5D-3L VAS score
n 136 277
Mean (SD) 72.4 (20.7) 73.4 (19.7) –1.4 (–4.65 to 1.76) 0.376
ZBI score
n 122 273
Mean (SD) 32.9 (17.1) 33.9 (16.0) 0.06 (–1.96 to 2.08) 0.955
How much benefit have you gained from being involved in the DAPA trial?
Substantial benefit, n (%) 10 (7.3) 79 (28.1) < 0.001b
Moderate benefit, n (%) 44 (32.4) 126 (44.8)
No benefit, n (%) 79 (58.1) 69 (24.5)
Moderate harm, n (%) 0 1 (0.4)
Substantial harm, n (%) 0 1 (0.4)
Missing, n (%) 3 (2.2) 5 (1.8)
12 months
EQ-5D-3L score
n 129 261
Mean (SD) 0.78 (0.23) 0.76 (0.24) –0.002 (–0.04 to 0.04) 0.936
EQ-5D-3L VAS score
n 129 261
Mean (SD) 75.1 (18.7) 74.5 (18.6) 0.2 (–2.87 to 3.27) 0.897
ZBI score
n 125 256
Mean (SD) 32.7 (16.6) 34.5 (16.1) –0.5 (–2.78 to 1.72) 0.644
How much benefit have you gained from being involved in the DAPA trial?
Substantial benefit, n (%) 13 (10.0) 54 (20.5) 0.001b
Moderate benefit, n (%) 56 (43.1) 133 (50.6)
No benefit, n (%) 60 (46.1) 72 (27.4)
Moderate harm, n (%) 0 0
Substantial harm, n (%) 0 1 (0.4)
Missing, n (%) 1 (0.8) 3 (1.1)
a Adjusted for the carer’s age, gender, baseline score and region (random effect).
b p-value from chi-squared or Fisher’s exact test.
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TABLE 21 Summary of the falls and fractures of the person you care for at 6 and 12 months’ follow-up
Time point, mobility outcome
Treatment arm
Adjusted estimate (95% CI) p-valueUsual care Exercise programme
6 months
In the last 6 months, have they had any falls including a slip or trip, following which they have come to rest on the ground,
floor, or lower level?
Yes, n (%) 45 (33.1) 93 (33.1)
Missing, n (%) 0 3 (1.1) OR 0.9 (0.61 to 1.48) 0.817
If yes, how many times have they fallen within the last 6 months?
n 44 93
Mean (SD) 4.1 (7.4) 3.6 (6.2) IRRa 1.2 (0.81 to 1.74) 0.383
Median (range) 2 (1–48) 2 (1–50)
Missing 1 0
Have they had any broken bones in the last 6 months as a result of falling?
Yes, n (%) 1 (0.7) 4 (1.4)
Missing, n (%) 0 4 (1.4) OR 0.5 (0.05 to 4.61) 0.533
If yes, how many broken bones have they had within the last 6 months as a result of falling?
n 1 4
Mean (SD) 1 1 (0) IRRa 1 (0.11 to 8.95) 1.00
Median (range) 1 (1–1) 1 (1–1)
12 months
In the last 6 months, have they had any falls including a slip or trip, following which they have come to rest on the ground,
floor, or lower level?
Yes, n (%) 38 (29.2) 89 (33.8)
Missing, n (%) 2 (1.5) 2 (0.8) OR 0.8 (0.49 to 1.24) 0.285
If yes, how many times have they fallen within the last 6 months?
n 37 88
Mean (SD) 6.4 (13.5) 3.7 (6.2) IRRa 1.1 (0.75 to 1.56) 0.690
Median (range) 2 (1–70) 2 (1–50)
Missing 1 1
Have they had any broken bones in the last 6 months as a result of falling?
Yes, n (%) 4 (3.1) 7 (2.7)
Missing, n (%) 2 (1.5) 3 (1.1) OR 1.2 (0.33 to 4.33) 0.779
If yes, how many broken bones have they had within the last 6 months as a result of falling?
n 4 7
Mean (SD) 1 (0) 1.3 (0.5) IRRa 0.8 (0.24 to 2.53) 0.676
Median (range) 1 (1–1) 1 (1–2)
continued
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usual-care arm. These results are similar to the primary analysis results, with the between-group difference
here being slightly larger at 12 months (Figure 7).
The second sensitivity analysis estimated the treatment effect using the ADAS-Cog score that was
computed using the observed data, for which the worst score was assigned at the item level if the
participant was too distressed or cognitively unable to answer the item. Table 23 presents the results of
this sensitivity analysis. There was no evidence of a difference between the two groups at 6 months
(estimated between-group difference 0.4, 95% CI –0.83 to 1.66) and 12 months (estimated between-
group difference –0.9, 95% CI –2.60 to 0.73) at 12 months. Here, the estimated between-group
difference at 12 months was smaller than that estimated by the primary analysis (see Figure 7).
The third sensitivity analysis used IRT to analyse the ADAS-Cog computed using the observed data.
Moreover, the analysis looked at three particular traits measured by the ADAS-Cog: language, memory
and praxis. The baseline model converged within 0.001 tolerance after 305 Metropolis–Hastings
Robbins–Monro iterations. The model fit was adequate, with a root-mean-square error of approximation
TABLE 21 Summary of the falls and fractures of the person you care for at 6 and 12 months’ follow-up (continued )
Time point, mobility outcome
Treatment arm
Adjusted estimate (95% CI) p-valueUsual care Exercise programme
Entire follow-up period (6 and 12 months)
If yes, how many times have they fallen within the last 6 months?
n 139 284
Mean (SD) 3.0 (11.1) 2.3 (6.1) IRRa 1.1 (0.84 to 1.33) 0.655
Median (range) 0 (0–96) 0 (0–53)
IRR, incident rate ratio.
a Data were analysed using negative binomial regression when the estimate provided is the IRR (unadjusted).
TABLE 22 Sensitivity analysis results using the observed data set to compute the ADAS-Cog score
Outcome
Treatment arm
Adjusted estimate (95% CI)a p-valueUsual care Exercise programme
ADAS-Cog at baseline
n 152 314
Mean (SD) 21.4 (7.4) 20.6 (8.9)
Missing 13 15
ADAS-Cog at 6 months
n 135 280
Mean (SD) 21.4 (8.5) 21.7 (10.3) –0.7 (–1.72 to 0.35) 0.196
Missing 10 20
ADAS-Cog at 12 months
n 119 245
Mean (SD) 22.4 (9.7) 22.9 (10.6) –1.7 (–2.97 to –0.39) 0.011
Missing 18 36
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
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of 0.047 (95% CI 0.043 to 0.051). Furthermore, individual items fit the model well, with all chi-squared
statistics being insignificant. The memory and language traits had a correlation of 0.78, the memory and
praxis traits 0.76 and the language and praxis traits 0.72. A summary of the abilities at each time point is
presented in Table 58, Appendix 6. Tables 60–62, Appendix 6, present univariate analyses of the between-
group differences for each of the traits at baseline and at 6 months and 12 months, respectively. The
respondent ability scores at each time point for each latent trait have also been presented as a box plot in
TABLE 23 Sensitivity analysis results using the observed data set with worst score assignment at the item level to
compute the ADAS-Cog score
Outcome
Treatment arm
Adjusted estimate (95% CI)a p-valueUsual care Exercise programme
ADAS-Cog at baseline
n 163 329 – –
Mean (SD) 22.0 (8.1) 21.7 (10.1)
Missing 2 0
ADAS-Cog at 6 months
n 145 298
Mean (SD) 23.8 (12.8) 23.3 (12.5) 0.4 (–0.83 to 1.66) 0.515
Missing 0 2
ADAS-Cog at 12 months
n 137 278
Mean (SD) 25.5 (13.7) 26.6 (14.8) –0.9 (–2.60 to 0.73) 0.271
Missing 0 3
a Analyses were adjusted for age, gender, sMMSE score, baseline of the outcome measure and region (random effect).
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FIGURE 7 Plot of adjusted ADAS-Cog score (imputed) estimates at 12 months for the primary analysis and
sensitivity analyses.
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
Figure 22, Appendix 6. No significant between-group differences were observed in the univariate analyses.
The adjusted analyses results for the language, memory and praxis scores at 12 months are presented in
Tables 61–63, Appendix 6, respectively. There was no evidence of a significant difference between the two
groups for any of the three traits at 12 months.
Complier-average causal effect
A CACE analysis was conducted to estimate the treatment effect at each time point, having adjusted for
non-compliance. Participants in the exercise arm who attended > 75% of their scheduled sessions were
defined as compliers of treatment. The baseline outcome measures for the usual-care arm and for
compliers and non-compliers in the treatment arm have been summarised in Table 24.
Statistically significant differences in the baseline characteristics were found when comparing compliers and
non-compliers. The compliers were mostly male, lived with their wife or partner and had better quality of
life, as measured by the EQ-5D-3L. The ITT and CACE analysis estimates have been presented in Table 25.
Similar to the ITT results, the CACE results found no difference in treatment effect at 6 months but found
a statistically significant treatment effect of –2.0 (95% CI –3.87 to –0.22) at 12 months in the primary
outcome (imputed ADAS-Cog), having adjusted for non-compliance. The CACE analysis estimates of
treatment effect at 6 months and 12 months were larger than the ITT estimates.
TABLE 24 Baseline characteristics and outcome measures of randomised participants summarised by compliance
status (compliers and non-compliers) and usual-care arm
Outcome Usual care
Compliance status
Mean difference
(95% CI)a p-valuebComplier Non-complier
Age (years)
n 165 214 115
Mean (SD) 78.4 (7.6) 76.4 (7.8) 77.7 (8.1) 1.2 (–0.57 to 3.03) 0.178
Gender (male), n (%) 106 (64.2) 144 (67.3) 51 (44.4) – < 0.001
Living arrangements
Live alone, n (%) 35 (21.2) 32 (14.9) 30 (26.1) – 0.030
Live with relatives, n (%) 5 (3.0) 13 (6.1) 5 (4.3)
Live with wife/husband/
partner, n (%)
125 (75.8) 169 (79.0) 79 (68.7)
Living with friends, n (%) 0 0 1 (0.9)
ADAS-Cog (imputed)
n 163 214 115
Mean (SD) 21.8 (7.7) 21.9 (9.7) 20.5 (9.4) –1.4 (–3.55 to 0.81) 0.217
ADAS-Cog (raw score)
n 152 201 113
Mean (SD) 21.4 (7.4) 20.9 (8.8) 20.2 (9.2) –0.6 (–2.70 to 1.44) 0.550
Language subscale (imputed)
n 165 214 115
Mean (SD) 2.7 (3.0) 3.2 (3.6) 2.7 (3.6) –0.5 (–1.29 to 0.33) 0.241
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TABLE 24 Baseline characteristics and outcome measures of randomised participants summarised by compliance
status (compliers and non-compliers) and usual-care arm (continued )
Outcome Usual care
Compliance status
Mean difference
(95% CI)a p-valuebComplier Non-complier
Memory subscale (imputed)
n 163 214 115
Mean (SD) 17.4 (4.8) 17.0 (6.3) 16.1 (5.9) –0.8 (–2.26 to 0.56) 0.239
Praxis subscale (imputed)
n 165 214 115
Mean (SD) 1.7 (1.5) 1.8 (1.7) 1.7 (1.6) –0.04 (–0.42 to 0.33) 0.823
Language subscale (raw score)
n 161 211 114
Mean (SD) 2.7 (3.0) 3.1 (3.4) 2.6 (3.6) –0.4 (–1.24 to 0.35) 0.275
Memory subscale (raw score)
n 156 205 113
Mean (SD) 17.1 (4.7) 16.7 (6.3) 16.0 (5.9) –0.7 (–2.08 to 0.75) 0.356
Praxis subscale (raw score)
n 165 213 115
Mean (SD) 1.7 (1.5) 1.8 (1.7) 1.7 (1.6) –0.04 (–0.42 to 0.34) 0.840
sMMSE score
n 165 214 115
Mean (SD) 21.6 (4.6) 22.0 (4.8) 21.9 (4.5) –0.1 (–1.15 to 0.98) 0.874
EQ-5D-3L score (self-reported)
n 159 212 115
Mean (SD) 0.85 (0.18) 0.83 (0.19) 0.79 (0.22) –0.05 (–0.10 to –0.004) 0.033
EQ-5D-3L VAS score (self-reported)
n 161 210 113
Mean (SD) 81.8 (17.7) 77.7 (18.2) 74.9 (19.0) –2.9 (–7.13 to 1.35) 0.181
QoL-AD score (self-reported)
n 140 186 98
Mean (SD) 39.3 (5.2) 38.9 (5.7) 38.2 (5.5) –0.7 (–2.12 to 0.63) 0.287
NPI score (proxy-reported)
n 119 164 76
Mean (SD) 13.3 (13.2) 12.5 (14.3) 13.7 (16.6) 1.3 (–2.82 to 5.38) 0.540
BADLS score (proxy-reported)
n 143 188 99
Mean (SD) 11.4 (8.5) 11.7 (8.2) 12.8 (8.6) 1.1 (–0.91 to 3.18) 0.276
a Mean difference between compliers and non-compliers in exercise arm.
b Reported p-values are from a t-test in which mean differences are reported and from a chi-squared or Fisher’s exact
test elsewhere.
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Subgroup analyses
Subgroup analyses were conducted on gender, sMMSE score, EQ-5D-3L mobility score and type of
dementia using the 12-month ADAS-Cog (imputed) score as the outcome measure. No statistically
significant subgroup effects were found (Table 26).
Longitudinal analysis
A longitudinal analysis was conducted (n = 494). The analysis adjusted for age, gender, sMMSE score and
region. No statistically significant between group difference was found [–0.3 (95% CI –1.69 to 1.05)].
TABLE 25 The ITT and CACE model estimates of treatment difference at 6 and 12 months
Time point
ITT covariate model
Standardised
effect at
12 monthsb
CACE covariate model
Standardised
effect at
12 monthsb
Mean compliance
difference (95% CI)a p-value
Mean compliance
difference (95% CI)c p-value
ADAS-Cog (imputed) score
6 months –0.6 (–1.58 to 0.39) 0.237 – –0.8 (–2.22 to 0.65) 0.282 –
12 months –1.4 (–2.62 to –0.17) 0.026 –0.16 –2.0 (–3.87 to –0.22) 0.028 –0.23
a Based on a multilevel model adjusted for age, sex, sMMSE score and baseline measure of the outcome. Region was also
included in the model as a random effect.
b The standardised effect size is the adjusted mean difference between the groups divided by the pooled SD at baseline.
c Based on a single equation instrumental variable regression model with outcome adjusted for age, sex, sMMSE score,
region and baseline measure of the outcome.
TABLE 26 Subgroup analyses of the 12-month ADAS-Cog (imputed) outcome
Subgroups
Treatment arm
Effect estimate
(95% CI)
Interaction effect
(95% CI)
Interaction
p-value
Usual care
Exercise
programme
n Mean (SD) n Mean (SD)
Gender
Male 86 23.9 (11.4) 166 23.9 (11.8) –1.2 (–2.78 to 0.46) –0.6 (–3.17 to 1.88) 0.616
Female 51 23.7 (8.5) 112 27.3 (12.9) –1.8 (–3.60 to 0.08)
sMMSE score
< 20 36 34.3 (10.9) 84 37.7 (10.8) –2.8 (–5.32 to –0.27) 1.8 (–0.98 to 4.50) 0.207
≥ 20 101 20.1 (7.2) 194 19.8 (8.4) –0.9 (–2.32 to 0.46)
EQ-5D-3L mobility score
No problems walking 103 24.5 (10.5) 204 26.6 (12.8) –1.3 (–2.65 to 0.10) 0.00005 (–2.86 to 2.86) 1.000
Some problems/
confined to bed
33 21.7 (10.0) 74 21.4 (10.0) –1.6 (–4.21 to 1.00)
Type of dementia
Alzheimer’s 108 23.7 (10.0) 227 25.6 (12.4) –1.1 (–2.41 to 0.29) 1.3 (–1.81 to 4.35) 0.417
Other (mixed,
vascular, other types)
29 24.5 (11.8) 51 23.5 (11.9) –2.7 (–5.58 to 0.16)
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Adverse events and serious adverse events
During the entire study period, 31 AEs were reported and four SAEs were reported, all of which were from
the exercise programme arm (Table 27). Around 74% of the AEs and 50% of the SAEs occurred during the
session or within 2 hours of the session. The remaining AEs and SAEs occurred during follow-on physical
activities. An assessment of all AEs and SAEs has been summarised in Table 28. All SAEs were assessed by
the chief investigator. Of the four reported SAEs, none was expected and unrelated, two were expected
and related, one was unexpected and unrelated, and one was unexpected and related (see Appendix 7 for
SAE details).
Process evaluation
Process measurements
The time to pre-assessment and first session remained within the protocol-defined boundaries (Table 29).
TABLE 27 Adverse events and SAEs summarised by treatment group
AE and SAE summaries
Treatment arm, n (%)
Total, n (%)Usual care Exercise programme
AEs
Number of AEs reported 0 31 (100.0) 31 (100.0)
When did AE occur
Occurred during session 0 15 (48.4) 15 (48.4)
Within 2 hours of session 0 8 (25.8) 8 (25.8)
During follow-on physical activities 0 8 (25.8) 8 (25.8)
SAEs
Number of SAEs reported 0 4 (100.0) 4 (100.0)
When did SAE occur
Occurred during session 0 1 (25.0) 1 (25.0)
Within 2 hours of session 0 1 (25.0) 1 (25.0)
During follow-on physical activities 0 2 (50.0) 2 (50.0)
Reason AE deemed serious
Participant died 0 0 0
Participant is in life-threatening condition 0 0 0
Participant required hospitalisation or prolongation
of existing hospitalisation
0 2 (50.0) 2 (50.0)
Participant left with persistent or significant
disability or incapacity
0 0 0
Participant required medical intervention to prevent
one of the above
0 2 (50.0) 2 (50.0)
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The delivery of the exercise intervention has been summarised in Table 30. The average number of sessions
attended by each participant was 21 (SD 8.7).
Table 31 details the compliance rates of participants in the intervention group. In total, 65% of the
participants in the intervention group demonstrated > 75% compliance with the exercises and 79.9%
achieved > 50% compliance.
TABLE 28 Assessment of AEs and SAEs summarised by treatment group
Assessment of AEs and SAEs
Treatment arm, n (%)
Total, n (%)Usual care Exercise programme
AE related to trial procedure (clinician/researcher)
Definitely 0 8 (25.8) 8 (25.8)
Probably 0 9 (29.0) 9 (29.0)
Possibly 0 8 (25.8) 8 (25.8)
Unlikely 0 5 (16.2) 5 (16.2)
Unrelated 0 1 (3.2) 1 (3.2)
SAE related to trial procedure (clinician/researcher)
Definitely 0 0 0
Probably 0 0 0
Possibly 0 3 (75.0) 3 (75.0)
Unlikely 0 1 (25.0) 1 (25.0)
Unrelated 0 0 0
SAE related to trial procedure (clinician/researcher)
Expected 0 2 (50.0) 2 (50.0)
Unexpected 0 2 (50.0) 2 (50.0)
Chief investigator assessment of SAE
Expected and unrelated 0 0 0
Expected and related 0 2 (50.0) 2 (50.0)
Unexpected and unrelated 0 1 (25.0) 1 (25.0)
Unexpected and related 0 1 (25.0) 1 (25.0)
TABLE 29 Time to pre-assessment and first session in the trial treatment group
Summary statistic
Time (days)
From randomisation
to pre-assessment
From randomisation
to session 1
From pre-assessment
to session 1
n 317 319 315
Mean (SD) 18.3 (12.2) 24.3 (13.4) 5.9 (4.1)
Range 1–90 1–101 0–27
Missing 12 10 14
Days from randomisation to session 1 and days from pre-assessment to session 1 have been computed regardless of
whether or not the participant attended the first session.
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Participant’s individual fitness was measured with the 6MWT. The reasons for non-completion and the
pre- and post-intervention data for the 6MWT are presented in Table 32.
The demographics, dose received and physical activity of the participants in the intervention arm have
been summarised in Table 33 by compliance status. By taking part in the intervention, participants were
able to lift more weight for the sit-to-stand exercise, indicating an improvement in strength (see Table 33
and Figure 8). On average, across all sessions, participants fully achieved their target number of repetitions
and sets for the sit-to-stand exercise as shown in Figure 9. Regarding the aerobic component (cycling) of
the intervention, participants were able to achieve a large proportion of their set target at each session
both at moderate and hard intensity, as shown in Figure 10. We modelled the association between the
dose achieved and cognition for both the aerobic and resistance components of the intervention; however,
no evidence of an association was found.
TABLE 30 Summary of delivery of the exercise intervention by region
Region
Number of
physiotherapists
involved in delivery
Number of exercise
instructors involved
in delivery
Number (%) of
participants attending
pre-assessment
Mean (SD) number
of sessions attended
Berkshire 5 3 27 (96.4) 18.4 (10.0)
Black Country 7 3 26 (86.7) 17.2 (11.4)
Coventry 12 5 35 (97.2) 21.1 (8.2)
Devon and Exeter 3 2 6 (100.0) 24.2 (5.0)
Gloucestershire and
Herefordshire
5 3 12 (100.0) 25.1 (2.7)
Greater Manchester
West
2 1 12 (100.0) 18.7 (8.9)
Leicester 7 0 10 (83.3) 20.2 (11.3)
North East London 5 2 11 (91.7) 17 (10.1)
Northampton 6 3 40 (97.6) 23.2 (7.6)
Nuneaton 12 5 15 (100.0) 23.1 (8.0)
Oxford 9 7 50 (100.0) 22.6 (7.1)
Rugby 12 5 15 (93.8) 17.3 (10.0)
Solent 2 2 6 (100.0) 17.2 (10.6)
South Warwickshire 12 5 24 (100.0) 24.4 (5.0)
Worcester 7 6 28 (96.6) 20.8 (8.8)
Total 106 52 317 (96.4) 21.0 (8.7)
The number of physiotherapists and exercise assistants are summarised for each region separately, with many of them
delivering the intervention across multiple regions.
TABLE 31 Number (%) of participants in the intervention arm within the different categories of compliance
Compliance range (%) Number (%) of participants (n= 329)
≤ 25 44 (13.4)
> 25 and ≤ 50 22 (6.7)
> 50 and ≤ 75 49 (14.9)
> 75 and ≤ 100 214 (65.0)
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TABLE 32 Summary of 6MWT during the pre-exercise assessment and post-exercise assessment
Test components
Time point of assessment
Pre exercise (n= 317)a Post exercise (n= 233)b
Walking aid used, n (%)
Yes 58 (18.3) 30 (12.9)
Missing 4 (1.3) 2 (0.8)
Was test completed, n (%)
Yes 310 (97.8) 229 (98.3)
Missing 2 (0.6) 1 (0.4)
If test completed, was it completed in the standardised manner, n (%)
Yes 262 (82.7) 193 (82.8)
Missing 10 (3.1) 14 (6.0)
Test not completed because participant became anxious, n (%)
Yes 0 1 (0.4)
Missing 0 0
Test not completed because of signs of overexertion, n (%)
Yes 1 (0.3) 1 (0.4)
Missing 0 0
Test not completed because participant became unsteady, n (%)
Yes 0 0
Missing 0 0
Test not completed because participant declined to continue, n (%)
Yes 1 (0.3) 1 (0.4)
Missing 0 0
Test not completed because of pain, n (%)
Yes 2 (0.6) 0
Missing 0 0
Test not completed because test disrupted, n (%)
Yes 0 1 (0.4)
Missing 0 0
Metabolic equivalents
Mean (SD) 2.6 (0.6) 2.7 (0.6)
Range 1.1 to 5.6 1.2 to 5.5
Missing 3 2
% heart rate reserve
Mean (SD) 32.4 (21.2) 36.7 (24.0)
Range –82 to 158 4 to 94
Missing 16 204
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TABLE 32 Summary of 6MWT during the pre-exercise assessment and post-exercise assessment (continued )
Test components
Time point of assessment
Pre exercise (n= 317)a Post exercise (n= 233)b
Heart rate walking speed index
Mean (SD) 21.0 (18.5) 18.5 (12.5)
Range 0 to 222.9 1.1 to 115.9
Missing 15 24
a Of the 329 participants randomised to the exercise programme arm, 317 attended their pre-exercise assessment.
b Of the 329 participants randomised to the exercise programme arm, 233 attended their 6MWT review.
TABLE 33 Intervention data by compliance status
Participants
Compliance status
All (n= 329)
Compliers
(n= 214)
Non-compliers
(n= 115)
Demographics
Age (years), mean (SD) 76.4 (7.8) 77.7 (8.1) 76.9 (7.9)
Gender (male), n (%) 144 (67.3) 51 (44.4) 195 (59.3)
ADAS-Cog (imputed) score, mean (SD) 21.9 (9.7) 20.5 (9.4) 21.4 (9.6)
ADAS-Cog (raw score), mean (SD) 20.9 (8.8) 20.2 (9.2) 20.6 (8.9)
Language subscale (imputed), mean (SD) 3.2 (3.6) 2.7 (3.6) 3.0 (3.6)
Memory subscale (imputed), mean (SD) 17.0 (6.3) 16.1 (5.9) 16.7 (6.2)
Praxis subscale (imputed), mean (SD) 1.8 (1.7) 1.7 (1.6) 1.7 (1.7)
sMMSE score, mean (SD) 22.0 (4.8) 21.9 (4.5) 22.0 (4.7)
EQ-5D-3L score (self-reported), mean (SD) 0.83 (0.19) 0.79 (0.22) 0.82 (0.20)
QoL-AD score (self-reported), mean (SD) 38.9 (5.7) 38.2 (5.5) 38.7 (5.6)
NPI score (proxy-reported), mean (SD) 12.5 (14.3) 13.7 (16.6) 12.8 (15.0)
BADLS score (proxy-reported), mean (SD) 11.7 (8.2) 12.8 (8.6) 12.0 (8.4)
Medical conditions,a n (%)
Heart or circulatory 102 (47.7) 52 (50.5) 154 (48.6)
GTN spray 18 (8.4) 13 (12.6) 31 (9.8)
Lung disease 22 (10.3) 18 (17.5) 40 (12.6)
Inhaler 22 (10.3) 14 (13.6) 36 (11.4)
Diabetes 38 (17.8) 21 (20.4) 59 (18.6)
Neurological condition 42 (19.6) 15 (14.6) 57 (18.0)
Limiting joint or muscle pain 117 (54.7) 60 (58.3) 177 (55.8)
Broken bone in last 6 months 14 (6.5) 8 (7.8) 22 (6.9)
Mental illness 65 (30.4) 45 (43.7) 110 (34.7)
continued
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TABLE 33 Intervention data by compliance status (continued )
Participants
Compliance status
All (n= 329)
Compliers
(n= 214)
Non-compliers
(n= 115)
Number of medical conditions
No conditions 27 (12.6) 12 (11.7) 39 (12.3)
One condition 56 (26.2) 21 (20.4) 77 (24.3)
Two conditions 57 (26.6) 23 (22.3) 80 (25.2)
≥ Three conditions 74 (34.6) 47 (45.6) 121 (38.2)
Dose receivedb
Number of sessions attended
Mean (SD) 26.2 (2.1) 11.2 (8.0) 21.0 (8.7)
Range 22–30 0–22 0–30
Sit to stand
Repetitions,c mean (SD) 432.8 (115.5) 229.2 (117.8) 370.7 (149.3)
Start weight (kg), mean (SD) 4.3 (4.1) 3.8 (3.4) 4.2 (3.9)
Finish weight (kg), mean (SD) 8.7 (9.1) 6.4 (5.4) 8.0 (8.2)
Difference between start and finish weight (kg),
mean difference (95% CI)
4.4 (3.2 to 5.6) 2.6 (1.7 to 3.5) 3.9 (3.0 to 4.8)
Total weight lifted (kg),d median (IQR) 3460.8
(1857.3–5537.1)
1307.5
(276–2284)
2569.8
(1231.4– 4672)
Arm exercises
Repetitions,c mean (SD) 1031.4 (225.5) 556.1 (277.3) 886.5 (326.5)
Total weight lifted,d median (IQR) 2469.4
(1626.3– 3444.2)
1001.9
(463–1574)
1933.5
(1105–2905)
Cycling (total number of minutes)
Low intensity, mean (SD) 210.5 (70.7) 131.5 (72.6) 186.6 (79.9)
Medium intensity, mean (SD) 287.9 (90.8) 121.5 (94.7) 237.5 (119.6)
High intensity, mean (SD) 66.2 (58.3) 14.6 (27.7) 50.6 (56.2)
First session (total number of minutes)
Target, mean (SD) 14.5 (2.1) 14.2 (2.8) 14.4 (2.3)
Actual, mean (SD) 13.8 (3.3) 13.1 (4.3) 13.6 (3.7)
Target, moderate or high intensity, mean (SD) 0 0.4 (2.1) 0.1 (1.2)
Actual, moderate or high intensity, mean (SD) 0.4 (1.7) 0.7 (2.2) 0.5 (1.8)
Last session (total number of minutes)
Target, mean (SD) 21.3 (7.1) 20.8 (5.5) 21.1 (6.7)
Actual, mean (SD) 19.9 (8.0) 19.4 (7.0) 19.8 (7.7)
Target, moderate or high, mean (SD) 16.0 (6.8) 12.9 (8.2) 15.0 (7.3)
Actual, moderate or high, mean (SD) 14.7 (7.5) 10.6 (8.5) 13.5 (8.0)
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TABLE 33 Intervention data by compliance status (continued )
Participants
Compliance status
All (n= 329)
Compliers
(n= 214)
Non-compliers
(n= 115)
Fitness tests
6MWT
Baseline 6MWT distance (m), mean (SD) 340.0 (114.0) 315.4 (108.7) 332.1 (112.7)
6-week 6MWT walk distance (m), mean (SD) 363.0 (118.1) 355.8 (101.6) 361.8 (115.3)
Difference in 6MWT distance, mean difference
from 0 to 6 weeks (95% CI)
19.6 (12.5 to 26.7) 10.7 (–6.3 to 27.8) 18.1 (11.6 to 24.6)
Self-reported physical activitye
First telephone call, n (%)
No physical activity 19 (9.0) 7 (11.9) 26 (9.6)
Some physical activity 186 (88.2) 47 (79.7) 233 (86.3)
Second telephone call, n (%)
No physical activity 12 (5.9) 8 (14.8) 20 (7.8)
Some physical activity 179 (88.6) 42 (77.8) 221 (86.3)
Third telephone call, n (%)
No physical activity 20 (9.9) 8 (15.1) 28 (10.9)
Some physical activity 177 (87.2) 40 (75.5) 217 (84.8)
First telephone call (minutes per week)
n 205 54 259
Median (IQR) 150 (60–250) 115 (60–230) 140 (60–250)
Second telephone call (minutes per week)
n 191 50 241
Median (IQR) 150 (80–270) 97.5 (35–150) 150 (70–250)
Third telephone call (minutes per week)
n 197 48 245
Median (IQR) 145 (70–275) 117.5 (30–220) 140 (60–270)
GTN, glyceryl trinitrate; IQR, interquartile range.
a Of the 329 participants randomised to the exercise programme arm, 317 attended their pre-exercise assessment.
b Of the 329 participants randomised to the exercise programme arm, 306 had resistance session data.
c The number of repetitions (total) is calculated by taking the sum of the number of repetitions multiplied by the number
of sets across each session for each participant.
d The total weight lifted is calculated by taking the sum of the weight lifted multiplied by the number of repetitions
multiplied by the number of sets across each session for each participant.
e The first telephone call was made 2–3 weeks after classes had finished, the second telephone call made 14–16 weeks
after classes had finished and the third telephone call was made 22–23 weeks after classes had finished. Calls were
made at the same time for compliers and non-compliers.
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FIGURE 8 Plot of the median (interquartile range) weight lifted (kg) over time by compliance status for the sit-to-stand
exercise. (a) Complier and (b) non-complier. The total number of participants attending each session is presented
above each interquartile range bar. IQR, interquartile range.
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The intervention was intended to increase participants’ fitness levels through increasing exercise intensity
over the intervention period. From all of the outcomes generated by the 6MWT, the distance travelled has
been proven as a reliable estimate of fitness.60 There is evidence of a statistically significant increase in the
distance walked post assessment compared with pre-assessment (paired t-test, p < 0.001), suggesting that
the intervention was successful in increasing participants’ fitness levels.
Discussion
The clinical effectiveness evaluation of the exercise on global cognition demonstrated some statistical
evidence of a difference in favour of usual care. Moreover, the intervention had no impact on behavioural
symptoms, HRQoL, daily functioning, falls or carer burden.
The results of this clinical effectiveness analysis differs to results from many smaller single-centre studies.19
However, the quality of this study is a key discerning factor, which is a major strength. Compared with
other studies, this study has a larger representative sample size with high intervention compliance and
follow-up rates. Moreover, we used prospective registration, robust allocation concealment, independent
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FIGURE 9 Mean % target repetitions and sets achieved by the intervention group for the sit-to-stand exercise.
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
computer-based randomisation and masked outcome assessment. Hence, we are confident that the clinical
effectiveness analysis results provide a reliable estimate of the effects of moderate- to high-intensity
exercise in this population and setting. Although there was some difference in how participants withdrew
from the trial, with more participants from the usual-care arm providing notification of formal withdrawal
as opposed to not responding to a request for follow-up, the overall levels of participant retention were
the same. The comparability of the baseline characteristics of people who were analysed at 12 months
was good.
There are some limitations to this study. First, we were faced with the challenge of finding an appropriate
way of dealing with the item-level missingness in the primary outcome measure (ADAS-Cog). After much
discussion with the DMEC and Trial Steering Committee, it was agreed that MI at the item level was the
most sensible approach to take, for which items were only imputed if it was known that the participant
was too unwell to complete it. The sensitivity analyses demonstrated that, regardless of the method used
for handling missingness, the conclusions drawn were still the same, hence giving us confidence in the
findings from the primary analysis. A second limitation was that the prespecified subgroup analyses were
underpowered, although these were still substantially larger than any other previous studies. However, the
direction of the effect estimates supported our conclusions. Finally, as we collected physical parameters
from the intervention arm only, we cannot definitively conclude that the strength and fitness improvements
of participants is caused by intervention, although it seems unlikely that there are other explanations.
In conclusion, moderate- to high-intensity exercise training does not reduce cognitive decline in people
with MMD in a community-dwelling setting and may result in worsening of cognition.
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Chapter 4 Qualitative study
Objectives
To conduct a qualitative study in parallel to the supervised component of the exercise intervention, the aim
of which was to provide insight into participants’ and carers’ attitudes and experiences of taking part in
the experimental intervention and physiotherapists’ experiences of, and attitudes to, delivering it.
Research questions
l For participants and their carers, what are the experiences of, and attitudes to, taking part in the
experimental intervention?
l For physiotherapists, what are the experiences of, and attitudes to, delivering the experimental
intervention?
Methods
Sampling and recruitment
Sampling of participants and their carers was consecutive and participants were drawn from five intervention
delivery sites. Sites were selected to reflect a range of settings and reflexive observations were carried out at
each site. Once observations of the sites were completed, we invited participants and carers to take part in
an interview. Participants had already consented to be approached to take part in the qualitative study as
part of the consent process for the RCT. Ten participants and 10 carers were approached in person, asked if
they would like to learn more about taking part in an interview and given a participant information leaflet.
At the next observation, they were approached again and asked if, having read the information, they would
like to agree to an interview. Once an interview date was agreed, participants were asked to sign an
interview consent form. Participants were advised that they could terminate the interview at any time and
that it would not affect their participation in the intervention.
As we began to reach data saturation, we checked that the sample broadly reflected the population of the
intervention arm of the trial in relation to gender, ethnicity and social class. All of the physiotherapists
delivering the intervention at the included sites were approached for interview and offered a participant
information leaflet and an informed consent form.
Data collection
Observations
A qualified and experienced qualitative researcher (Samantha Lyle) observed classes at three time points
across the duration of the 4-month-long supervised aspect of the intervention. At the start of the observations,
the researcher was introduced to participants by the physiotherapist who was delivering the class. Observations
consisted of watching participants and carers and the interactions of the physiotherapists with them as they
arrived to the classes, and watching and taking handwritten notes of the delivery and end of the classes. The
researcher took notes while visible to those present. She also took time to engage briefly with participants in
order to hear about their particular experience on that day. Observations notes were typed up and formed
part of the data set. No one made any objections to being observed.
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Interviews
A semistructured interview guide was developed by the research team to gather data from the participants,
carers and physiotherapists to answer the research questions (see Appendix 8). This was tested and refined
during the second pilot study. The interviews were carried out by a researcher who was trained and
experienced in qualitative research methodologies (Samantha Lyle).
Participants and carers were offered the opportunity to be interviewed separately or together. When both
expressed indifference, the researcher suggested that the interviews be conducted separately starting with
the participant, thereby allowing participants to engage in the research as autonomous research subjects89,90
and allowing carers the opportunity to speak freely.
Physiotherapists were offered the choice of being interviewed at their workplace or at home via telephone.
The interviews were audio-recorded and transcribed verbatim.
Interviewing participants with cognitive impairment
There are a number of obstacles to interviewing people with cognitive impairment: short-term memory
problems, difficulties in abstract thinking and expressive language, a lack of insight and awareness of their
diagnosis, and damage to their sense of self related to their experiences of diagnosis and symptoms of
dementia.89,91–97 We sought to overcome these obstacles by having the interviewer adopt an attitude that
assumes that the person with dementia has something valuable to say, listen carefully and accept the
interviewee as they are and with an openness to understanding them. The researcher took time to meet
interviewees before the formal interview in order to build rapport and gauge expressive skills. During the
interviews, the researcher was comfortable with long pauses and the expression of strong emotions,
avoided the use of complex concepts, adjusted language to align with participants’ language and used
direct interview styles when expressive skills were very limited.89,94
Data analysis
Our data comprised:
l notes taken during observations of exercise classes
l interviews with trial participants
l interviews with carers of trial participants
l interviews with physiotherapists delivering the classes.
The data were analysed as a single data set. Identifying information was anonymised to ensure
interviewees’ confidentiality was maintained. Interview transcripts and field notes were uploaded into
NVivo version 10 (QSR International, Warrington, UK), a computer program for qualitative data, to assist
with data management and analysis.
Analysis was thematic and broadly followed the principles of grounded theory.98 A thematic analysis
involves identifying, describing, analysing, interpreting and reporting repeated themes and categories in
the data that relate to the research questions and represents some level of patterned response or meaning
across a data set.99 We compared data relating to an individual participant from the participant themselves,
their carer and their physiotherapist. The data were initially organised into broad descriptive codes such
as ‘experiences of the intervention’. The data within these broad codes were reread and subcodes were
identified such as ‘positive experiences of participants’, negative experiences of participants’ and
‘ambivalent experiences of participants’. During the coding process, we compared data between
participants, between carers and between physiotherapists to sharpen our understanding and refine our
subcodes. Transcripts were analysed by the researcher who carried out the interviews (Samantha Lyle). A
second researcher (Frances Griffiths) independently analysed approximately 20% of the transcripts.99 The
two researchers met to discuss and reflect on the coding and analysis as it proceeded. Discussion of the
analytic process and findings were shared within the wider research team, including the chief investigator
(Sarah E Lamb),
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for their reflections, which further informed subcode refinement. Disagreements regarding the identification,
description, analysis or interpretation of data were resolved through discussion and further analysis.
Results
Data collected and the characteristics of sites and interviewees
In total, five sites were observed four times, for approximately 1.5 hours each, between November 2013
and March 2015. Settings for the delivery of the intervention included pleasant leisure centres with cafes
and soft seating for carers to use, large warehouse-style gyms situated on industrial estates with very loud
heating systems and rather run-down local authority amenities with no facilities for carers to use. They
were located in a range of urban, suburban and rural settings.
Eight participants took part in an interview and two declined to do so. Six carers agreed to take part in an
interview and two declined. Six participants chose to be interviewed on their own and two chose to have
their carer present (one was a spouse who had her interview on her own and the other was a friend). Five
carers chose to be interviewed on their own and one to be interviewed with the participant. All participant
interviews took place in their homes and three carer interviews took place in quiet rooms while classes
were being delivered. Interviews lasted between 30 minutes and 2 hours.
All five physiotherapists delivering the intervention at the included sites agreed to an interview (one via
the telephone).
The participants interviewed were slightly younger than the overall study sample. They were all white
British, with five men and three women. Their cognitive function indicated only mild dementia for all but
one participant who had moderate dementia. Their mean cognitive function score is slightly better than
that of the main study sample. The sample of carers interviewed (n = 6) comprised two men and four
women, all were white British and their current level of burden ranged from 8 (low burden) to 64 (high
burden). Table 34 describes the interviewees.
Participant and carer experiences of taking part in the intervention
In this section, we first describe positive experiences that the participants and carers had of the
intervention and then the more burdensome aspects of their experiences.
Participants enjoy being with other people
All participants had something positive to say about their experiences. Reasons they gave for enjoying the
classes were the company, that it was fun and that there was humour and dialogue:
I think the company of everybody you know. I mean we all had a sit down afterwards and we had a
good laugh while we’re doing it.
Patient 12 (male, sMMSE score of 24)
The intervention protocol states that ‘fun, pleasure and enjoyment are recognised as possible motivators
to exercise participation for older people’. Those delivering the intervention were observed in all but one
class to encourage chit-chat, teasing, joking and laughing within the group, particularly when trying to
motivate participants:
[Exercise assistant] chats to all the participants, mentions the World Cup, asks how people’s grandchildren
are while they are getting ready, makes small jokes, generally ‘joshing’ with participants. There is a fun
mood in the room, people are chatting and joking, during and in-between the resistance work.
Observation field notes, 10 July 2014
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TABLE 34 Characteristics of participants and carers interviewed and whether the interview was joint or solo
Participant
ID number Interview
Characteristic
Age
(years) Gender Ethnicity
sMMSE score
out of 30a
Carer ID
number Interview
Relationship
to participant Gender Ethnicity
ZBI score
out of 80b
P4 Solo 67 Female White British 21 N/A Not interviewed Husband Male White British 30
P5 Solo 71 Male White British 19 N/A Not interviewed Wife Female White British 38
P6 Solo 81 Female White British 24 C1 Solo Son Male White British 16
P7 Solo 76 Male White British 28 C3 Solo Wife Female White British 20
P8 Joint 71 Male White British 24 C9 Solo Wife Female White British 64
P10 Solo 87 Male White British 26 C11 Solo Wife Female White British 19
P12 Joint 77 Male White British 24 C13 Joint Friend Female White British 8
P16 Solo 73 Female White British 21 C17 Solo Wife Male White British 24
N/A, not applicable.
a The sMMSE is a ‘standardized approach to scoring and interpreting older people’s cognitive function provides a global score of a cognitive ability that correlates with daily function’.65
‘Total scores of 30 indicate no impairment, scores between 26 and 30 are considered normal’.65 Those with scores between 25 and 20 have MCI but can usually live on their own with
support. Those with scores between 20 and 10 have moderate cognitive impairment; scores below 9 indicate severe cognitive impairment. People with a sMMSE score of < 10 were not
eligible for the trial.
b ZBI100 score is widely used to measure the level of burden experienced by carers and was developed specifically for those caring for people with dementia.75 A higher score indicates
greater carer burden.
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In some classes, this type of banter was initiated by participants. When discussing a class in which there
was a lot of banter, one participant who was asked what they enjoyed about the class said:
It’s just . . . it’s actually um, being with other people and like-minded people.
Patient 16 (female, sMMSE score of 21)
One group did not engage in banter but participants 6 and 7 expressed enjoyment in attending the class:
I like going to the classes, I’m always [laughs] ready to go . . . I enjoy doing it all.
Patient 6 (female, sMMSE score of 24)
I like . . . well I like it all actually, I very much appreciate having it.
Patient 7 (male, sMMSE score of 28)
For one participant, sharing the experience with other people with dementia was an important part of
the enjoyment:
I think it’s just been a lovely time, and you see like-minded people around you and it’s lovely to see
them, you know, how they’re enjoying it . . . with Alzheimer’s. Yeah, with Alzheimer’s . . . it’s just nice
to be there for them as well as me, I can understand you know with the Alzheimer’s, you can have a
chat with them.
Patient 16 (female, sMMSE score of 21)
Participant 16 was the only participant to explicitly say that she enjoyed the classes because she was
around other people living with dementia. However, others talked about gaining pleasure from seeing
others do well in the class. Participant 5 had been a competitive road cyclist and was still very active at the
time he attended the classes. He talked about how other class members had progressed:
Two ladies, they didn’t think much about weights and they were sort of ‘mmmm we don’t do
weights’ and the person in charge, she got me started and the ladies said ‘I’ll do it with little weights
then’ and they started with little weights and they weren’t too sure about it but after a few weeks
they were saying I think I could get to a heavier weight and they could see me going up on my
weights so they thought we’ll try it.
Patient 5 (male, sMMSE score of 19)
Participant 7 spoke also gained pleasure in seeing others in class do well:
It’s nice to see the ladies and particularly one or two of the frailer ladies who have picked up.
Patient 7 (male, sMMSE score of 28)
Participants gain pleasure from exercising
One of the ladies who participant 5 described as frail, described enjoying the exercise:
I feel a bit tired but I feel as if I’ve done the exercises, but yes I’m glad I do them.
Patient 6 (female, sMMSE score of 24)
Participant 10 described his enjoyment:
I’m enjoying it. I’m very tired when I come out because I do 25 minutes on the bike, about 2 miles on
the bike.
Patient 10 (male, sMMSE score of 26)
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Although all participants reported some positive experiences, some also found the classes burdensome.
We will return to this after considering carer perspectives on the experiences of participants.
Carers’ perspectives on the experiences of participants of the intervention
All carers spoke positively about the experiences of participants of taking part in the trial and did not
perceive the trial to be burdensome. They were confident that the person they cared for enjoyed the
classes. They talked about the enjoyment of being with other people, of the exercise itself and of having
something to do regularly:
[He] really, really does enjoy it, yes. I think it’s the men all getting together and they just all of them
get on with the exercises. It is really good.
Carer 11 (wife, ZBI score of 19)
Well he’s absolutely loving it. He is really enjoying the programme; he doesn’t want it to end. I think
he’s benefiting from it . . . being with other people . . . the exercise itself but also doing something
specific twice a week.
Carer 3 (wife, ZBI score of 20)
Carer 1 talked about his mother’s sense of achievement:
I think it’s been excellent . . . she’s getting a sense of achievement . . . she tells me how long she’s
ridden on the bike.
Carer 1 (son, ZBI score of 16)
Some carers talked in positive terms about how tired the classes made participants:
He’s enjoyed it and it’s done him good even . . . especially the last month, because they’ve pushed him
and pushed him, he’s been absolutely nearly incoherent he’s been that tired and luckily fallen asleep
straight away . . . I think it’s good.
Carer 9 (wife, ZBI score of 64)
Carers’ own experiences of the intervention
Most carers were very happy to have been randomised to the intervention arm of the trial:
Oh I was over the moon yeah . . . it just sort of gave focus to a couple of days of the week.
Carer 1 (son, ZBI score of 16)
All carers said they appreciated the opportunity to be with other carers in a similar position:
I’ve actually appreciated the opportunity to talk about it [being a carer/dementia] with you know,
outside of just friends, that’s been quite good for me to be able to talk about it and . . . it has been
nice to talk to other carers.
Carer 3 (wife, ZBI score of 20)
When the participants were attending the classes, carers had free time:
Sometimes I will nip up to [town] and do a bit of shopping and come back. He doesn’t mind.
Carer 11 (wife, ZBI score of 19)
I’ve got a couple of hours that I can catch up on a bit of ironing, I can have a quick vac round and
when [participant 8] comes back I can sit with him.
Carer 9 (wife, ZBI score of 64)
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This break from the burden of caring for someone with dementia was very welcome. Even when carers
stayed at the class venue, taking part in the trial was a welcome change.
The intervention as burden for participant and carer
Although all participants and carers talked about positive experiences, some also talked about the intervention
in terms of being a burden. We also know from trial physiotherapists that some carers found it very difficult
to get participants to attend and so they withdrew from the intervention and were not interviewed. Three
participants who were interviewed talked about what they found difficult about the classes.
Participant 4 talked about, and was seen to enjoy her time at, the class, particularly the social interaction,
but she also found some of the exercise ‘painful’ and ‘a bit of a chore’:
I find I’m getting very tired in an afternoon, I don’t like the bikes. They are very, very uncomfortable.
Patient 4 (female, sMMSE score of 21)
However, she saw the classes as beneficial:
I’d do it again, I’ve done it, I’m coming up towards the end of it now and I think there’s got to be
some reason and some benefit for me. The exercise in itself is beneficial.
Patient 4 (female, sMMSE score of 21)
The therapeutic alliance between participant and physiotherapist
Therapeutic alliance is a term used to describe the fit between therapists and patients; a good or positive
alliance potentially contributes to patient well-being and successful rehabilitation,101 although this is
contested.102 A good therapeutic alliance must be continually reproduced between the patient and the
therapist.103 Trying to maintain a good therapeutic alliance with participants who have dementia is challenging.
One physiotherapist seems to have overestimated what participant 5 could achieve, while perhaps
underestimating his understanding of what was possible:
She loaded the whole waistcoat up with lead, the fronts, the middle, the lot, everything and she sat
me on this chair and then she said right stand up so I went to get up and she said no, no put your
feet there, now get up and I said you can’t do that . . . I knew what I was doing and how to do it and
I said I can’t move. She said you’re not going until you do it once so I got up and I put my knee out,
I thought this is it, I’m going to be punished like this.
Patient 5 (male, sMMSE score of 19)
Participant 5 reported his experience to the trial team and was offered a different class in which he
enjoyed the exercise and the company of the other members of the class:
In contrast, participant 8 talked about how too much surveillance contributed to an incident that he found
stigmatising. This participant was observed to have a lot of energy and was described to the researcher as
having a big personality and that he could sometimes be disruptive. He was positive about the physiotherapist
and exercise assistant but he felt that their surveillance of him undermined his sense of autonomy:
They are frightened to death that you’re going to do something and injure yourself . . . if I pick up a
dumb-bell and start doing oh my . . . [they say], ‘just a minute, just a minute’ . . . and I think well I’ve
just had a bit of a [telling off] for doing something on my own and there’s these other people they’re
doing the same. I don’t feel as though I’ve got anything at the moment. My son calls them ‘window
lickers’ and ‘smell of wee tours’ when they all get on the bus . . . it’s only a little thing, it uh . . . when I
say uh, ‘oh I’ll be back in a minute’, ‘no, no hang on a minute, where are you going?’ I said ‘I’m going
to the toilet’ and then I’ve got [exercise assistant] standing outside the lavatory door!
Patient 8 (male, sMMSE score of 24)
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The wife of participant 8 joined the interview saying that those leading the class had behaved reasonably
in the situation and that the participant lacked insight (the gym was in a warehouse with the toilets near
the exit and no one at the exit to see people leave). However, participant 8 had sufficient insight to
express that he felt was being treated like people who his son call ‘gagas’ and ‘window lickers’.
Participants getting to the classes
Of those participants interviewed, three were unaccompanied to the classes at least some of the time.
Participants 5 and 8 arrived by taxi (provided by the trial) and participant 7 drove himself, with his wife not
accompanying him at least some of the time. Of the carers who had to accompany participants to the
class, none of them spoke of the difficulty in doing so. Carer 1 was still in work but he lived locally to his
mother and was able to work his around his job, and his brother was also on hand should he be unable to
take her to the odd class. He attributed the ease of getting her to classes to her willingness to attend:
When I pulled into her drive I could see her figure behind the door waiting, so she was just ready for me.
Carer 1 (son, ZBI score of 16)
Do participants and carers think that the classes ‘worked’?
Some participants spontaneously offered their view on whether or not they thought the classes ‘worked’
and others were asked directly. With the exception of one participant and one carer, no one reported that
they thought the classes had made an impact on their dementia. But, with the exception of one carer,
everyone interviewed thought that there had been a positive impact on participants physically and that the
class had generally done them some good.
Improving physical health and functioning
Having dementia makes the already difficult act of self-assessment even more difficult, as recent past
experiences are lost to memory. Participant 6, in her early 80s and described as frail by other participants,
carers and the physiotherapist leading her class, struggled to follow the question of whether or not the classes
had worked. When asked if she thought the classes had any impact on her physical health, she said it had:
I never thought there was anything wrong with my physical health I must say, but I do feel that I’m
getting along a bit quicker and everything and, I think it could have been my younger son said ‘you’re
moving a lot faster’ or something but I’ve always moved fast.
Patient 6 (female, sMMSE score of 24)
Participant 12 and his friend, carer 13, agreed that his ability to walk unaided had improved and the
participant seemed to feel better about himself:
I think these classes were very, very good, before I went to them I struggled with my walking . . . I had
to have walking sticks and everything. Now I’m walking normally. I don’t like to feel that I’m helpless,
I don’t like to feel like . . . a disabled person. People look at you and say ‘oh look at that poor old
gentleman’ . . . I don’t want to be old.
Patient 12 (male, sMMSE score of 24)
One carer talked about how the classes had enabled her to change what she felt that she could expect of
her husband with dementia and what he could expect of himself. The carer was reassured by his improved
physical functioning, as this lessened her worry about whether or not she would be able to manage to
continue caring for him:
He was walking really slowly and I used to say to him ‘oh come on move, you can walk better than
this’. Well this has made him realise ‘I can do this’, you know and it’s made him much more active
and doing things now and . . . because he was getting up like this . . . [demonstrates slow, painful
stand up] . . . And I said come on, get up, you can do it and of course in class he has to do this you
know. And so when he starts it at home I say you can do it in class you can do it at home. The longer
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he can stay physically fit the better it will be for me because I’m not going to be able to help him,
especially with my neck problem and back problem . . . So it’s a win–win situation as far as I’m concerned.
If it hasn’t helped him with his memory well we both understood that, it’s not a waste of time at all.
Carer 3 (wife, ZBI score of 20)
Little or no change on cognitive function
Almost all carers and participants did not think the intervention had made a difference to the participant’s
cognitive function. When asked directly about this, participant 12 thought that the classes had helped
his memory ‘a little bit’ (participant 12, sMMSE score of 24) but his carer (carer, sMMSE score of 13)
disagreed, shaking her head for the researcher. Carer 17 thought that the exercise may have improved
participant 16’s memory, influenced by the assessment of the psychiatric nurse:
The psychiatric nurse . . . came 5 weeks ago just before the start of DAPA and she came again last
week, and her view is that his memory has definitely improved. Subjective but . . . and I think that it
has improved. I can’t tell how much but he seems brighter and seems to be able to remember things
that probably were going to be difficult, if not impossible, before.
Carer 17 (wife, ZBI score of 24)
He went on to explain that his wife’s mood had changed to being more positive so the effect of the
exercise may have lifted depression symptoms:
One of the effects that the Alzheimer’s was . . . she would clamp on very negative things and to
repeat those quite regularly. She would have difficulty in dropping things that had happened in the
past but she seems more able to do that now and more able to look at the positive side of things and
enjoy things . . . it’s something that is happening, and the only thing that’s different is the exercise class.
Carer 17 (wife, ZBI score of 24)
Those participants who were not sure if there had been any change in their memory were nevertheless
positive about their improved physical functioning:
I don’t know whether it’s done my dementia any good but I know now that yes I can lift those
heavy weights.
Patient 4 (female, sMMSE score of 21)
Participant 7 talked about physical improvement and then said:
I don’t know whether . . . I’ve been surprised with one or two things I have remembered . . . But no
. . . there are other things that still elude you.
Patient 7 (male, sMMSE score of 28)
Of a participant with Parkinson’s disease, carer 9 said about the intervention classes:
It’s good to exercise because his muscles and his tendons will get . . . [tight] . . . I don’t know about
mental ability, from my point of view I don’t think they’ve made an awful lot of difference.
Carer 9 (wife, ZBI score of 64)
No change
One carer and the participant did not think that the classes had made any physical difference, explaining
that he was fairly active before the classes:
Always just pottering about in the garden or doing something, you know he’s not one to be sitting
down all the time.
Carer 11 (wife, ZBI score of 19)
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Physiotherapists’ experiences of delivering the intervention
We now consider the experience of the physiotherapists, how they delivered the intervention while negotiating
the participant’s dementia symptoms and how they negotiated the label of dementia and its associated stigma.
Dementia symptoms and delivering an exercise intervention
Physiotherapists faced the challenge of engaging participants with dyspraxia, ataxia, memory problems and
low mood in exercise. Strategies used by the physiotherapists for dyspraxia included getting the participants
to copy or mirror their actions, giving them assistance or verbal feedback and not expecting the participant
to perform the movement perfectly. Some participants would copy or mirror their actions all the time, not
just for the exercises. Talking about a participant who seemed to be in a world of his own most of the time,
the physiotherapist said:
I always noticed that he followed, so if you went forward he went forward, if you sat down he sat,
if you stood he stood, which was tricky if you were dealing with someone else . . . Sometimes even
though I didn’t want to sit at that moment I’ll sit because I knew that he will sit. And then before he
gets to stand, because he’s not as fast as me, I’ll probably quickly walk up to him and whisper in his
ear, ‘sit down, I just need to pop over there’, then he will sit.
Physiotherapist 21
Participants found it hard to learn to get on the bikes, even though the physiotherapists would break
down a task into its component parts:
I’ve had to physically guide them through the movement. It’s taken them longer to actually get the
feel of what we’re asking them to do, but not to the extent that they haven’t fitted in with the class.
Getting on and off a bike is something that is not as straightforward as you might think, I mean you
can demonstrate it, you can talk them through it and you could actually physically get them to do it,
but then they get off. When they get back on again 2 seconds later they really haven’t got it, they
don’t know physically what they’re doing.
Physiotherapist 1
The physiotherapists learned to allow for the different abilities of participants to process instructions:
Some participants present quite well but then you start to learn actually that perhaps they’re not fully
understanding all that you’re telling them.
Physiotherapist 15
Physiotherapists would give very explicit instructions and avoided talking to participants while exercising so
as not to distract them:
[At the end of an exercise] two of the ladies in my class would . . . sit there and hold their weights so you
explicitly have to tell them to put them down. Now I don’t know whether that’s a dementia thing or it’s just
a politeness thing. It’s interesting to see, and I think the processing thing is a big one . . . it’s not stopping
anybody, you have to be aware because they may be one down in their repetition. You can’t talk to them
while they’re cycling because if they stop for 5 minutes then that’s 5 minutes of their exercising gone.
Physiotherapist 14
Memory problems posed a number of challenges. If participants did not have a carer living with them,
remembering to come to the classes could be an issue. However, one physiotherapist describes this
problem as being no different from other classes:
I will make sure they’ve got things written down and that if you’re worried you’ll call them and remind
them in that sense, but then I think I would do that anyway even if they weren’t classed as dementia.
Physiotherapist 14
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Repetition, talking about the same thing, within the same class or from class to class, was common:
There were some difficulties with their memory, often people will tell me the same thing a lot.
Physiotherapist 21
Although physiotherapists acknowledged that repetition would be difficult for a partner or family member,
all five agreed that it was a symptom that they ignored by pretending that every time was the first time
the participant has said something. This, it was felt, was the kindest way to react to this:
There’s no reason for them to know that they’ve repeated themselves because it’s embarrassing for
someone potentially if they don’t think that their dementia is that bad and, they, people can get quite
upset potentially or agitated from knowing. If somebody says have I asked you that already and I
would be like yes but don’t worry.
Physiotherapist 14
Another physiotherapist took a similar approach:
Every opportunity he got he went back to [the same] conversation and talked about things he had
said before, you just learn to listen and take it in as new information every single time.
Physiotherapist 21
The physiotherapists suggested that ignoring the fact that some participants repeated themselves and,
therefore, shielding them from social embarrassment, was a normal part of their role. Participants dealt
with the repetition of other participants in a similar way:
[Other participant] is a little bit ahead of me [in dementia progression] because she kept saying every
week I made these, these trousers, I made these myself. I just said, every time I said, brilliant that is,
you know . . . I wouldn’t have dared to say to her yes we’ve heard it six times now, no I just kept
saying that’s marvellous, I don’t know how you do it.
Patient 5 (male, sMMSE score of 19)
Some participants were prone to get lost if they went away from the group:
Quite a few participants we’ve had to accompany, even just to the toilet, just so they don’t get lost.
Physiotherapist 15
At one venue, a participant did not make it into the venue:
The second time she was brought there and she didn’t come into the building, [I spent the] entire time
out looking for her and I couldn’t find her. It turns out, she got into a taxi and went home . . . and
then she had no recollection of having left the house.
Physiotherapist 21
Some participants were difficult to engage owing to their low mood:
There was a chap in one of the groups who . . . I think he was probably a very introspective man even
before he got dementia, but he, um, basically he would go through phases of just extreme brooding
on negative events and it was quite difficult to communicate with him at times like that . . . he would
do the exercises but . . . someone who is in that sort of psychological state probably needs a lot
more supervising.
Physiotherapist 1
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When asked if the participant’s low mood interfered with delivery of the intervention, the physiotherapist
said it made no difference to the physical exercises but did make a difference to the atmosphere in the group:
It was like a black cloud over the group . . . the behavioural aspects of the intervention, the self-efficacy
and the positive feelings around exercise the we’re trying to instil . . . that would have been affected.
Physiotherapist 1
The physiotherapists reported that participants mostly tried to do their best, although needed some reassurance:
You have to reassure people that they’re not actually doing themselves any harm but most people are
pretty keen.
Physiotherapist 1
The physiotherapists gave lots of positive feedback to encourage the participants:
I can see them getting fitter and that’s part of how we motivate them, so we’ll say, this week you’re
lifting more weights, you know your technique is much better and you’re on the bike for longer,
you’re working much harder.
Physiotherapist 21
Navigating the stigma of dementia
During observation and interviews, physiotherapists revealed their awareness of the sensitivities and stigma
associated with dementia. The word dementia was not often used, with phrases such as ‘memory problems’
being used instead. The following example is from a physiotherapist describing how she explained to a
participant why they were at the class:
You’re here because we’re hoping that the class will help your, because I never want to say condition
to a patient just in case they don’t understand but like thinking and memory ability . . . it’s difficult,
dementia’s like a stigmatised word without a doubt. Then she said ‘oh yes, I remember, they think I’m
doolally’ and I said ‘well it’s not that, it’s maybe that your memory isn’t as good as it was but, um,
hopefully the class might help but I can’t promise you’.
Physiotherapist 14
It can be argued that the patient used an even more stigmatising word ‘doolally’ about herself. The other
participants seemed to think so, as the following, from the other physiotherapist delivering the same
class, suggests:
I don’t usually raise it [dementia] unless they do . . . but in all the groups that I’ve been with they’ve all
spoken about it in one form or another, amongst themselves and with us, so it’s not like been taboo.
A lady this week said to the group ‘oh, I’m doolally’ and one of the other participants went up to her
and said ‘I’ve been diagnosed with Alzheimer’s’, and we were just . . . we were just all sort of pitching
in you know this doesn’t mean that you’re doolally. They all suddenly came together as a group, it
was really quite nice, and started talking about it.
Physiotherapist 15
Most of the physiotherapists decided whether or not to use the word dementia on a case-by-case basis:
That was a concern for me because I couldn’t really tell where each individual was as far as, you
know, their diagnosis was concerned. So if this is someone who hasn’t accepted it, I don’t want to be
trying to shove it down their throat, and if this is someone who has, how do I know? So I sort of let
them initiate the conversations [until] I had a definite idea of where the individual stood with, you
know, dementia in general.
Physiotherapist 21
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This same physiotherapist was also concerned about not reinforcing other stigmatising terms:
I find it difficult when you have people who say things like ‘oh yeah I’m a bit cuckoo aren’t I?’ or ‘yeah
my memory’s shit’, things like that. Now as much as you get that dementia is a terrible disease I cannot
affirm that statement . . . I think I shied away from such conversations and said something like, well let’s
hope this helps you know, just to put a very positive vague cloak over it.
Physiotherapist 21
Our data suggest that this was tricky social and emotional terrain for the physiotherapists and that they
engaged in emotional work104,105 in order to negotiate it. The physiotherapists talked about how they tried
to remember that the participants are more than their symptoms or diagnosis:
I don’t think you have to have this dementia head on, you’re trying to understand them as an
individual. That’s no different with somebody with dementia. But I suppose being aware you might
need to make some allowances and some adaptations with possibly needing a little bit more time,
but again I think that would be the same working with the very, very old age groups.
Physiotherapist 18
Discussion
Participants and carers were positive about the exercise classes, with only a few having negative things to
say about them. Participants and carers also enjoyed being with other people having similar experiences
and for carers the classes were a welcome change or break from their caring responsibility. Nearly all
participants gained in terms of physical fitness but very few experienced a change in cognitive function.
However, participants and carers remained positive about the classes. Helping participants maintain their
physical function contributed to participants living well with dementia. In lieu of a cure, being able to live
well with dementia is increasingly being advocated as a humane and practical response to the disease106–110
along with the concept of ‘active ageing’.111
Dementia symptoms posed challenges for the physiotherapists trying to enable participants to undertake
the physical exercises. However, they developed strategies for dealing with these. What was trickier was
negotiating the stigma of the label dementia. Despite increasing public awareness, dementia is still a
stigmatised and stigmatising condition.91,93,95,96,112–122 Our analysis suggests that the physiotherapists were
aware of the sensitivities and stigma surrounding the condition and took a cautious approach, allowing
the participants to lead them.
Strengths and limitations of the study
The analysis and interpretation of the interview data were not influenced by the results of the trial, as it
was completed 6 months before the trial outcome was available. We captured perspectives from all three
groups of stakeholders involved in the trial. Although the number of participants who were interviewed,
eight participants and seven carers, is relatively small even for a qualitative study, interviews were long
and participants were engaged with and observed over several hours from five sites. Participants were
able to contribute their views despite their impaired cognitive function. However, these interviews were
challenging because of the idiosyncratic way in which participants responded to questions. Very often
participants would go off on long tangents. Gauging whether or not participants understood the question,
or if their responses were excessively compliant, was sometimes difficult during the interview, especially
when participants’ answers were short. However, some answers were extensive and nuanced. There were
no participants who struggled to recall the classes, but many participants found it difficult to assess
changes to their physical and mental health. Although interviewing participants was not straightforward,
this research enabled participants to give voice to their own experiences.94,116,118,123
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Our sample did not include anyone from an ethnic minority. We had no interviewees who lived without a
carer. Participants and carers for whom the burden of dementia was becoming too much may not have
agreed to interview. We failed to interview participants who did not commence the intervention.
Given that the participants and carers knew the purpose of the exercise class when asked directly whether
or not it had worked, we would expect responses to be influenced by what might be considered socially
desirable – the idea that the intervention had made a difference or at least the desire to tell the trial team
it had. A few participants tried to suggest there had been change but, apart from the participant whose
depression symptoms improved, there was consensus that it had not worked – there was no improvement
in cognitive function.
Conclusion
Told from the perspectives of participants, carers and physiotherapists, we have learned that:
l participants did not experience an improvement in cognitive function, except one who seemed to
experience improvement in depression symptoms accompanied by some improvement in memory
l all participants, with the exception of one, experienced a worthwhile improvement in physical function
l participants enjoyed being with other people at the classes
l carers appreciated the classes as it gave them a break from their caring responsibilities, they met other
people in a similar situation and they saw the person they were caring for enjoying the classes and
improving in physical fitness
l the physiotherapists faced challenges helping participants with dementia symptoms undertake the
exercises but solved them pragmatically; it was difficult for them to negotiate the stigma of the label
dementia and they approached this case by case, being sensitive to how the participant talked about
their condition.
Attending physical exercise classes contributed to the ability of participants and carers to live well with
dementia but they did not experience improvement in cognitive function.
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Chapter 5 Economic evaluation
Overview of economic evaluation
A prospective economic evaluation was conducted alongside the RCT with the objective of estimating the
cost-effectiveness of a 4-month supervised moderate- to high-intensity exercise training regime and ongoing
supported physical activity programme (exercise) compared with usual care. The economic evaluation took
the form of a cost–utility analysis, expressed in terms of incremental cost per quality-adjusted life-year
(QALY) gained. The primary analysis is based on a NHS and personal social services (PSS) perspective, as
recommended by NICE, and excludes broader societal costs (e.g. by families or informal carers) associated
with the exercise programme.124 A sensitivity analysis was conducted to recalculate cost-effectiveness from a
societal perspective.
Measurement of resource use and costs
The incremental costs associated with the exercise programme were determined through a comprehensive
strategy that encompassed two strands of research: the estimation of (1) costs associated with the delivery
of the intervention and (2) broader health and personal social service resource inputs and costs.
Costing of the exercise (intervention) programme
A specific focus of the economic evaluation was the assessment of the cost of delivering the exercise
programme, including the costs of training of accredited health-care professionals and the cost of
delivering group sessions, participant monitoring activities and any follow-up/management. This involved
asking physiotherapists and exercise assistants in each site to prospectively complete, in detail, weekly activity
logs reporting the number of hours spent delivering each exercise session, including preparation time,
programme delivery time, indirect administrative activities, telephone contacts, as well as intervention-related
training and supervision activities costs. The type of travel (e.g. car, taxi), distance travelled and time spent
travelling by each physiotherapist and exercise assistant as a result of intervention-related activities were
reported on a weekly basis. Additional expenditures associated with the exercise equipment, treatment manual
and related paperwork were also recorded. The costs of venue hire were estimated separately for each site.
When venue hire costs were not available or when venues were made available for use free of charge by
providers, the mean venue hire cost from the remaining sites was applied. The total costs of delivering the
exercise programme in terms of the average (mean) cost per session per attending participant for each group
within each site were estimated (at the group level). For the baseline analysis, estimates of average cost per
session per attending participant excluded practitioner travel costs, as it was assumed that delivery of the
exercise programme in routine NHS settings would not result in additional travel costs by physiotherapists
and exercise assistants. However, the effects of this assumption were tested in the sensitivity analyses.
Collection of broader resource-use data
Data were collected on broader health and personal social service and broader societal resource inputs,
between randomisation and 12 months post randomisation, that were deemed relevant. Trial participants
were required to complete resource-use questionnaires via face-to-face interviews (researcher administered)
at baseline and at 6 and 12 months post randomisation using a modified version of the CSRI (version 1.0),125
that was modified based on the experiences of the economic evaluation that was conducted alongside the
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease (DOMINO-AD) trial.126 The data
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collected from participants at each assessment point covered their use of sheltered housing or care home
accommodation, hospital care and day care services, community-based health care, community-based social
care, medicines, aids and equipment. Details of travel costs (borne by trial participants or their family
members or friends) owing to the trial participants’ health status or contacts (visits) with health or social
services over the relevant time horizons were also collected. Medication use was categorised by drug name
(or active constituent), mode of administration, dose frequency and duration.
Valuation of resource use
Resource inputs were valued using a combination of primary research and data collated from secondary
national tariff sets, using standard accounting methods. Staff time (indirect or direct) for the delivery of the
exercise programme was determined from hourly unit costs for each Agenda for Change band.127 Unit cost
estimates for staffing inputs were inclusive of staff salaries, qualification costs, employer’s on-costs and
associated revenue and capital overheads. Costs relating to travel (for each mile) for practitioners delivering the
exercise intervention were determined from the Automobile Association (AA) for travel by car,128 and estimates
published in the Department for Transport’s Public Service Vehicle Survey: Bus Statistics for travel by public
transport.129 Inpatient admissions during the study (overall and by type) were determined from NHS reference
cost trust schedules.130 Other hospital-based care costs were valued by applying unit costs from national
tariffs.131 NHS medication prices (per mg) were obtained from the NHS Digital’s drug costs.132 Participant-level
costs for medication use were estimated based on reported doses and frequencies, when available, or otherwise
based on an assumed daily dose. Gender-specific median earnings data were applied to occupational
classifications derived from self-reported work status information to determine the costs of time taken off
work by trial participants (or by their family members or carers). In addition, data reported by the participants as
part of the follow-up resource-use questionnaires were used to determine other family-borne costs. The NHS
Hospital and Community Health Services Pay and Prices Index was used to inflate or deflate costs when
necessary to 2014–15 prices (GBP).127 No discounting of costs was applied because the cost-effectiveness of
the exercise programme was determined over a 1-year time horizon (Table 35).
TABLE 35 Unit costs (£) for resource items (2014–15 prices)
Resource item Unit cost (£)
Unit of
analysis Source
Intervention arm
Physiotherapist grade
5 36.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
6 44.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
7 52.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
8 62.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
Exercise assistant grade
3 25.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
4 28.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
5 36.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
6 45.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
7 54.00 Per hour Unit Costs of Health and Social Care 2014,134 p. 179
Venue hire Range:
23.00–80.00
Per session From venue list price
Equipmenta Range
0.44–335.70
Fixed NHS Supply Chain. NHS Supply Chain 2015. URL: https://my.
supplychain.nhs.uk/catalogue (accessed 7 June 2016)
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TABLE 35 Unit costs (£) for resource items (2014–15 prices) (continued )
Resource item Unit cost (£)
Unit of
analysis Source
Patient accommodation
Extra care housing 455.00 Per week Unit Costs of Health and Social Care 2015,127 p. 41
Care home with nursing
care
1110.00 Per week Unit Costs of Health and Social Care 2015,127 p. 39
Care home with
personal care
1134.00 Per week Unit Costs of Health and Social Care 2015,127 p. 39
Acute psychiatric ward 252.90 Per day Unit Costs of Health and Social Care 2010,133 p. 70
Rehabilitation ward 636.00 Per bed-day Unit Costs of Health and Social Care 2015,127 p. 1104
Rehabilitation ward 17,358.10 Per year Unit Costs of Health and Social Care 2014,134 p. 119
General medical ward 400.00 Per day Department of Health and Social Care communication,
data set request, 2015. URL: https://data.gov.uk/data-request/
nhs-hospital-stay (accessed 1 October 2016)
Hospital services
Continuing care respite
Inpatient 635.60 Per week Scottish Government. Respite Care, Scotland 2014, page 3.
URL: www.gov.scot/Resource/0046/00461672.pdf
(accessed 7 June 2016)
743.60 Per 4 days NHS Reference Costs 2014–2015,130 p. 6
Other hospital inpatient
ward
403.60 Per day Department of Health and Social Care communication,
data set request, 2014–15. URL: https://data.gov.uk/data-request/
nhs-hospital-stay (accessed 1 October 2016)
Outpatient services 112.00 Per visit Unit Costs of Health and Social Care 2015,127 p. 107
Accident and emergency
department
133.20 Per visit NHS Reference Costs 2014–2015130
Day hospital 113.00 Per visit/day Unit Costs of Health and Social Care 2014,134 p. 115
Day care services
LA social services
Day care 59.50 Per visit Unit Costs of Health and Social Care 2014134
13.10 Per hour Unit Costs of Health and Social Care 2014134
45.40 Per 3.5 hours Unit Costs of Health and Social Care 2014134
Voluntary and private
Day care 41.40 Per visit Unit Costs of Health and Social Care 2014134
10.20 Per hour Unit Costs of Health and Social Care 2014134
35.30 Per 3.5 hours Unit Costs of Health and Social Care 2014134
NHS (not hospital)
Day care† 36.00 Per hour Unit Costs of Health and Social Care 2015,127 section 9, p. 164,
section 1.6; scientific and professional staff, assumed to be band 5
Lunch club† 12.00 Per day Age UK. Milton Keynes Age UK; 2016. URL: www.ageuk.org.uk/
miltonkeynes/activities-and-events1/lunch-clubs/ (accessed
7 June 2016)
continued
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TABLE 35 Unit costs (£) for resource items (2014–15 prices) (continued )
Resource item Unit cost (£)
Unit of
analysis Source
Social clubb,† 12.30 Per year Age UK. Nuneaton 050 Friendship Centre; 2016. URL: www.
ageuk.org.uk/about-us/local-services-search/groups/nuneaton-
050-friendship-centre-england (accessed 7 June 2016)
General health community services
Geriatrician
Office 134.20 Per contact Unit Costs of Health and Social Care 2015,127 p. 199
GP
Office 44.40 Per
11-minute
contact
General practitioner – Unit Costs of Health and Social Care 2015,127
p. 177, 10.8b
Home 90.40 Per home
visit
General practitioner – Unit Costs of Health and Social Care 2015,127
p. 177, 10.8b
Practice nurse
Office 43.40 Per hour Unit Costs of Health and Social Care 2015,127 p. 174, 10.6
Home 56.50 Per contact Unit Costs of Health and Social Care 2015,127 p. 174, 10.6
District nurse
Office 50.40 Per hour Unit Costs of Health and Social Care 2015,127 p. 169, 10.1
Home 67.60 Per hour Unit Costs of Health and Social Care 2015,127 p. 169, 10.1
Health visitor
Office 50.40 Per hour Unit Costs of Health and Social Care 2015,127 p. 171, 10.3
Home 76.70 Per hour Unit Costs of Health and Social Care 2015,127 p. 171, 10.3
Incontinence nurse
Office 50.40 Per hour Unit Costs of Health and Social Care 2015,127 p. 172, 10.4
Home 75.70 Per hour Unit Costs of Health and Social Care 2015,127 p. 172, 10.4
Occupational therapist
Office – hospital 38.30 Per hour Unit Costs of Health and Social Care 2014,134 p. 218, 13.2
Office – community 36.30 Per hour Unit Costs of Health and Social Care 2014,134 p. 180, 9.2
Home† 48.30 Per hour Unit Costs of Health and Social Care 2010,133 p. 152, 9.1
Physiotherapist
Office – hospital 38.30 Per hour Unit Costs of Health and Social Care (2014–2015), p. 217, 13.1
Office – community 36.30 Per hour Unit Costs of Health and Social Care 2014,134 p. 179, 9.2
Home† 44.00 Per hour Unit Costs of Health and Social Care 2010,133 p. 151, 9.1
Alternative medicine therapist
Office† 31.50 Per contact The Role of Complementary and Alternative Medicine in the NHS.
An Investigation into the Potential Contribution of Mainstream
Complementary Therapies to Healthcare in the UK,135 figure 7.
URL: www.getwelluk.com/uploadedFiles/Publications/
SmallwoodReport.pdf (accessed 7 June 2016)
Home† 31.50 Per contact The Role of Complementary and Alternative Medicine in the NHS.
An Investigation into the Potential Contribution of Mainstream
Complementary Therapies to Healthcare in the UK,135 figure 7
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TABLE 35 Unit costs (£) for resource items (2014–15 prices) (continued )
Resource item Unit cost (£)
Unit of
analysis Source
Mental health service
CPN/CMHN
Office 42.40 Per hour Unit Costs of Health and Social Care 2015,127 p. 199, 12.1
Home 74.70 Per contact Unit Costs of Health and Social Care 2015,127 p. 188
Community psychiatrist
Office 77.80 Per hour Unit Costs of Health and Social Care 2015,127 p. 18
Psychologist
Office 61.50 Per hour Unit Costs of Health and Social Care 2015,127 p. 183, 9–5
Home 139.20 Per contact Unit Costs of Health and Social Care 2015,127 p. 183, 9–5
Social care services
Care manager
Office 39.30 Per hour Unit Costs of Health and Social Care 2015,127 p. 211
Home 39.30 Per hour Unit Costs of Health and Social Care 2015,127 p. 211
Social worker
Office 68.60 Per hour Unit Costs of Health and Social Care 2015,127 p. 205
Home 93.80 Per hour Unit Costs of Health and Social Care 2015,127 p. 205
Home care worker
Office 19.20 Per hour Unit Costs of Health and Social Care 2015,127 p. 192, 11.6
Home 24.20 Per hour Unit Costs of Health and Social Care 2015,127 p. 192, 11.6
Care support worker
Office 24.20 Per hour Unit Costs of Health and Social Care 2015,127 p. 223, 13.7
Home 24.20 Per hour Unit Costs of Health and Social Care 2015,127 p. 223, 13.7
Chiropodist
Office 32.30 Per contact Unit Costs of Health and Social Care 2015,127 p. 182, 9.4
Home 42.40 Per contact Unit Costs of Health and Social Care 2015,127 p. 182, 9.4
Sitting scheme
Home† 10.10 Per hour Northallerton & District Voluntary Service Association,136 2016.
URL: www.ndvsa.co.uk/index.php/carers-respite-sitting-scheme
(accessed 7 June 2016)
Meals on wheels
Home 46.40 Per week Unit Costs of Health and Social Care 2015,127 p. 118
Laundry service
Home† 9.00 Per hour Laing.137 URL: www.laingbuisson.co.uk/portals/1/media_packs/
Fact_Sheets/Fair_Price_ThrdEd_2008.pdf (accessed 7 June 2016)
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TABLE 35 Unit costs (£) for resource items (2014–15 prices) (continued )
Resource item Unit cost (£)
Unit of
analysis Source
Self-help group
Office – health service 36.30 Per contact Unit Costs of Health and Social Care 2015,127 p. 118
Office – local
authority†
5.00 Per week Shropshire Community Directory, 2016. URL: http://search3.
openobjects.com/kb5/shropshire/cd/view.page?record%20=%
20796AeasoHso (accessed 7 June 2016)
Office – voluntary† 5.00 Per week Assumed to be the same as local authority
Office – private† 5.00 Per week Not identifiable – assumed to be same as local authority
Office – health
service†
5.00 Per contact Assumed to be the same as for local authority support self-help
group
Private health services
GP
Office –private 70.00 15-minute
contact
Bupa,138 2015. URL: www.bupa.co.uk/health/bupa-on-demand/
gp-services (accessed 1 October 2016)
Nurse 65.10 Per contact Assume 50% above NHS unit cost Unit Costs of Health and Social
Care 2015,127 p. 174
Physiotherapist
Office 55.00 Per contact/
session
Nuffield Health,139 2016. URL: www.nuffieldhealth.com/
physiotherapy/faqs (accessed 1 October 2016)
Home† 65.00 Per contact/
session
London Home Visit Physiotherapy,140 2015. URL: www.
londonhomevisitphysiotherapy.com/about-us/fees/ (accessed
1 October 2016)
Community psychiatrist 150.00 Per hour Psychiatry UK, 2016.141 URL: www.psychiatry-uk.com/fees/
(accessed 1 October 2016)
Equipment and adaptations
Various aidsc Range:
4.80–930.00
Per item NHS Supply Chain. NHS Supply Chain 2015. URL: https://my.
supplychain.nhs.uk/catalogue/ (accessed 7 June 2016)
Medications
Various medications Range:
0.02–207.00
Per dose NHS Digital,132 2015
Other
Various itemsd Range:
13.10–134.20
Per visit/
contact
Provider sources (e.g. website)
Time taken off work
National average 530.00 Per
37.5-hour
week
Office for National Statistics,142 2015. URL: www.ons.gov.uk/
employmentandlabourmarket/peopleinwork/
earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/
2015provisionalresults (accessed 1 October 2016)
Parking Range:
1.00–3.00
Per hour Participant reported
Other 34.00–88.00 Per contact Participant reported
CPN, community psychiatric nurse; LA, local authority.
a Equipment includes items such as telephones, DAPA intervention manual, belts, vest, weights, bikes, cones, compact disc,
lap counter and stationery.
b Most centres were free; the unit cost was based on the average of three payment-requiring clubs.
c Equipment aids included support rails, bathroom aids and accessories, ramps, beds, wheelchairs and bed supports.
d Including resource use such as dentist or optometrist.
† Inflated/deflated to 2014–15 prices using the NHS Hospital and Community Health Services Pay and Prices Index.
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Calculation of utilities and quality-adjusted life-years
The economic evaluation estimated QALY profiles for trial participants, based on participant and carer reports
of preference-based HRQoL outcomes. The HRQoL of trial participants was assessed using the EQ-5D-3L,143
measured at baseline and at 6 and 12 months post randomisation, as a secondary outcome of the trial. The
EQ-5D-3L consists of two principal measurement components. The first is a descriptive system, which defines
HRQoL across five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Responses in each dimension are categorised into three ordinal levels, namely (1) no problems, (2) some or
moderate problems and (3) severe or extreme problems. For the purposes of the economic evaluation, the UK
time trade-off tariff was applied to each set of responses to generate an EQ-5D-3L utility score (preference
weight) for each trial participant.143 Resulting utility scores range from –0.59 to 1.0, with 0 representing
death and 1.0 representing full health; values below 0 are indicative of health states worse than death.
The second measurement component of the EQ-5D-3L consists of a 20-cm vertical VAS ranging from 100
(best imaginable health state) to 0 (worst imaginable health state), which provided an indication of the
respondent’s assessment of the trial participant’s health status on the day of the survey. QALYs were calculated
as the area under the baseline-adjusted utility curve, and were calculated using linear interpolation between
baseline and between 6 and 12 months post-randomisation utility scores. No discounting of QALYs was
applied because cost-effectiveness was determined over a 1-year time horizon.
Missing data
Multiple imputation (MI) using the method of chained equations was used for the base-case analysis to
impute missing data. This avoids potential biases associated with complete-case analysis and is consistent
with good practice guidance. MI was used at the aggregate level (i.e. on missing total costs or QALYs).
When data are missing at random, MI provides unbiased estimates of treatment effect. The missing at
random assumption was explored in the data, using logistic regression for missingness of total costs and
QALYs for each time point (separately) as a function of baseline variables. A model was used to generate
multiple imputed data sets for treatment groups, in which missing values were estimated conditional on
available covariates, which included baseline costs, baseline utilities, age, gender and baseline sMMSE score
(< 20; ≥ 20). With MI, a complete data set is generated, reflecting the distributions and correlations between
variables in the observed data. Mean matching, using predictive methods, was used to improve estimates of
imputed values as normality could not be assumed. Each imputed data set was analysed independently using
model-based approaches; the estimates obtained were pooled to generate mean and variance estimates of
costs and QALYs using Rubin’s rule in order to capture within and between variances for imputed samples.
Information loss from finite imputation sampling was minimised using 20 data sets, resulting in minimal loss
of efficiency (< 0.5%) when compared with infinite sampling. As the fraction of information missing was
reasonably low, n = 20 imputation sets were considered adequate.144 Imputed and observed values were
compared to establish that imputation did not introduce bias into subsequent estimation.
Analyses of resource use, costs and outcome data
Resource-use items were summarised by treatment group and assessment point; differences between
groups were analysed using two-sample t-tests for continuous variables. Mean [standard error (SE)] values
of each resource use and cost type were estimated by trial allocation group for each time period. Costs
were estimated from a NHS and PSS perspective for the baseline analysis. This was also repeated from a
broader societal perspective for a separate sensitivity analysis. Differences between trial groups in terms of
costs, along with their respective CIs, were estimated and reported. Non-parametric bootstrap estimates
using 10,000 replications124 were also calculated for differences along with their respective CIs. For the
EQ-5D-3L dimension, the proportion of participants with suboptimal levels of function (moderate problems
or severe or extreme problems) at each assessment point were compared between trial groups using the
chi-squared (χ2) test. EQ-5D-3L utility score differences at each follow-up point between the trial groups
were tested using two-sample t-tests for unequal variance.
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Regression-based methods, namely, seemingly unrelated regression, were used to estimate mean incremental
changes in costs and QALYs and these accounted for the correlation between costs and outcomes within the
data while adjusting for covariates, including baseline costs and utility scores to adjust for potential baseline
imbalances. Non-parametric bootstrap methods were used to generate the joint distributions of costs and
outcomes to populate the cost-effectiveness plane. Bootstrapping (specifically bias-corrected non-parametric
bootstrapping) is a resampling method which jointly resamples costs and outcomes from the observed data
while maintaining the sample correlation structure. From each bootstrap sample (10,000 samples in our
analyses), differences in costs and QALYs were estimated. Mean estimates are reported with their 95% CIs.
Cost-effectiveness analyses
The incremental cost-effectiveness ratio (ICER) was estimated as the difference between the trial comparators
in mean total costs divided by the difference in mean total QALYs. Value for money was determined by
comparing the ICER with a cost-effectiveness threshold value; typically, the NICE cost-effectiveness threshold
for British studies ranges between £20,000 and £30,000 per QALY. In addition, a £15,000 cost-effectiveness
threshold was used to reflect recent evidence around the declining value of the cost-effectiveness threshold.145
This represents society’s willingness to pay for an additional QALY; lower ICER values than the threshold could
be considered cost-effective for use in the NHS. Base-case assumptions were explored using a range of
supportive sensitivity analyses.
The incremental net monetary benefit (INMB) of switching to the exercise programme was also reported
as a recalculation of the ICER at a range of cost-effectiveness thresholds. The INMB succinctly describes
the resource gain (or loss) when investing in a new intervention when resources can be used elsewhere
at the same threshold. INMB estimates were used to generate cost-effectiveness acceptability curves. The
cost-effectiveness acceptability curve illustrates the likelihood that interventions are cost-effective as the
cost-effectiveness threshold varies.
All statistical analyses and cost-effectiveness modelling were conducted in SAS® software version 9.4 on a
Windows platform. SAS and all other SAS Institute Inc., product or service names are registered trademarks
or trademarks of SAS Institute Inc., in the USA and other countries. The symbol ® indicates USA registration.
Sensitivity and subgroup analyses
Several sensitivity analyses were undertaken to assess the impact on the base-case economic evaluation.
The following sensitivity analyses were undertaken in line with the trial’s prespecified health economics
analysis plan (version 4, 5 May 2015):
1. restricting the analyses to complete cases (i.e. those with complete cost and outcome data throughout
the trial time horizon)
2. adopting a wider societal perspective that included costs incurred by all sectors of the economy and by
families and informal carers
3. recalculating the trial participants’ QALY profiles using the carer-reported EQ-5D-3L scores
4. recalculating the average cost per exercise session per attending participant by taking into account
practitioner travel costs
5. varying the cohort size for the exercise programme to the lowest number of participants attending
across all groups (n = 3)
6. varying the cohort size for the exercise programme to the highest number of participants attending
across all groups (n = 10)
7. setting the venue hire costs to zero on the assumption that delivery of the exercise programme in
routine NHS settings rather than community venues may be associated with zero opportunity costs.
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Prespecified subgroup analyses were also conducted for the main cost-effectiveness results to explore
heterogeneity in the trial population. These were conducted by:
1. gender (male, female)
2. baseline sMMSE score (< 20, ≥ 20).
Results
Study population
A total of 494 participants were randomised into the trial: 329 to the exercise programme (experimental
arm) and to usual care (control arm). Complete baseline information was available for 488 participants
(exercise arm, n = 326; control arm, n = 162). Consequently, the baseline study population for the bulk of
the health economic analyses is 488 participants. Between 91% and 99% of all health resource-use data
were complete at baseline for the exercise group; for the usual-care group, this ranged between 91% and
98% (Table 36). Similarly, these values ranged between 84% and 91% and 78% to 86% at 6 months;
and between 77% and 85% and 78% and 82% at 12 months, for exercise and usual care, respectively.
A complete QALY profile was available for 435 (88%) participants based on the patient-reported EQ-5D-3L
(84% for the carer-reported EQ-5D-3L).
TABLE 36 Summary of data completeness of economic measures
Time point
Treatment arm, n (%)
Exercise programme (N= 329) Usual care (N= 165)
Completeda Missingb Unavailablec Completed Missing Unavailable
Q2 patient accommodation
Baseline 326 (99.09) 0 (0.00) 3 (0.91) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 142 (86.06) 1 (0.61) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 136 (82.42) 0 (0.00) 29 (17.58)
Q5a hospital services
Baseline 327 (99.09) 1 (0.30) 2 (0.61) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q5c day services
Baseline 325 (98.78) 2 (0.61) 2 (0.61) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q5e general community health services
Baseline 326 (99.09) 1 (0.30) 2 (0.61) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 297 (90.27) 2 (0.61) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q5g community mental health services
Baseline 326 (99.09) 1 (0.30) 2 (0.61) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
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TABLE 36 Summary of data completeness of economic measures (continued )
Time point
Treatment arm, n (%)
Exercise programme (N= 329) Usual care (N= 165)
Completeda Missingb Unavailablec Completed Missing Unavailable
Q5i social care services
Baseline 326 (99.09) 1 (0.30) 2 (0.61) 161 (97.58) 1 (0.61) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q6a equipment, adaptations
Baseline 325 (98.78) 1 (0.30) 3 (0.91) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 298 (90.58) 1 (0.30) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 136 (82.42) 0 (0.00) 29 (17.58)
Q7a medications
Baseline 326 (99.09) 0 (0.00) 3 (0.91) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 297 (90.27) 2 (0.61) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q8 patient/carer travel
Baseline 326 (99.09) 0 (0.00) 3 (0.91) 162 (98.18) 0 (0.00) 3 (1.82)
6 months 297 (90.27) 2 (0.61) 30 (9.12) 141 (85.45) 2 (1.21) 22 (13.33)
12 months 280 (85.11) 2 (0.61) 47 (14.29) 135 (81.82) 1 (0.61) 29 (17.58)
Q9d given up or cut down on work
Baseline 303 (92.10) 23 (6.99) 3 (0.91) 153 (92.73) 9 (5.45) 3 (1.82)
6 months 278 (84.50) 21 (6.38) 30 (9.12) 131 (79.39) 12 (7.27) 22 (13.33)
12 months 256 (77.81) 26 (7.90) 47 (14.29) 128 (77.58) 8 (4.85) 29 (17.58)
Q10c time off work
Baseline 299 (90.88) 27 (8.21) 3 (0.91) 150 (90.91) 12 (7.27) 3 (1.82)
6 months 277 (84.19) 22 (6.69) 30 (9.12) 129 (78.18) 14 (8.48) 22 (13.33)
12 months 255 (77.51) 27 (8.21) 47 (14.29) 128 (77.58) 8 (4.85) 29 (17.58)
EQ-5D-3L index (patient)
Baseline 321 (97.56) 6 (1.82) 2 (0.61) 159 (96.34) 2 (1.21) 4 (2.42)
6 months 288 (87.54) 11 (3.34) 30 (9.12) 137 (83.03) 7 (4.24) 21 (12.73)
12 months 255 (77.51) 26 (7.90) 48 (14.59) 124 (75.15) 12 (7.27) 29 (17.58)
EQ-5D-3L index (carer)
Baseline 302 (91.79) 2 (0.61) 25 (7.59) 153 (92.73) 1 (0.61) 11 (6.67)
6 months 276 (83.89) 4 (1.22) 49 (14.89) 132 (80.00) 4 (2.42) 29 (17.58)
12 months 261 (79.33) 2 (0.61) 66 (20.06) 129 (78.18) 0 (0.00) 36 (21.82)
a Assessments were made and data were available.
b Assessments were made, but data collection forms were returned with incomplete data.
c Assessments were not made, but there were data collection forms missing (as a result of deaths, withdrawals from the
study or losses to follow-up).
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Resource use and costs
Cost of intervention
Estimates of the total costs of delivering the exercise programme are provided in Tables 37 and 38 for
each group within each study site. The cost components are aggregated into four headings, namely
(1) staff costs, inclusive of training activities, planning, direct delivery, administrative activities, meetings
with professionals, telephone calls and supervision activities associated with group delivery, (2) travel costs,
based on distances travelled by practitioners by mode of transport, (3) venue hire costs and (4) equipment
and other costs for each site, including cost of belts, stopwatches, timers, cones, lap counters, compact
discs, stationery (e.g. pens, erasers) and trial manuals, associated with group delivery. Total intervention
costs are also presented within each group within each site. These varied between £4443.90 (Worcester,
cohort 53) and £11,342 (Wolverhampton, cohort 50).
Group- and site-specific estimates of average cost per exercise session per attending participant were
estimated using the total cost data in Table 37 and data on group size and mean session attendance
reported in Table 38. These average costs varied from £28.60 (Amersham, cohort 4) to £107.50
TABLE 37 Cost of delivery of intervention by site and cohort
Site Cohorta
Costs (£)
Staff Travelb Venue Equipmentc Totald
Total
(including travel)
Gloucestershire &
Herefordshire
1 5640.00 2915.20 1194.80 109.60 6944.40 9859.60
Gloucestershire &
Herefordshire
2 5640.00 1027.90 1194.80 96.10 6930.90 7958.80
Abingdon 3 4702.40 2152.90 2400.00 112.30 7214.70 9367.60
Amersham 4 5085.00 3657.60 713.00 142.20 5940.20 9597.80
Amersham 5 5997.80 3476.60 782.00 124.20 6904.00 10,380.60
Amersham 6 7971.60 5559.50 667.00 121.60 8760.20 14,319.70
Atrium 7 6144.60 621.20 1450.00 84.10 7678.70 8299.90
Atrium 8 7403.80 970.10 2500.00 195.50 10,099.30 11,069.40
Atrium 9 6273.60 938.80 1500.00 72.30 7845.90 8784.70
Atrium 10 6656.80 2030.40 1600.00 132.20 8389.00 10,419.40
Atrium 11 6947.80 907.60 1450.00 96.10 8493.90 9401.50
Atrium 12 6087.60 907.60 1600.00 118.10 7805.70 8713.30
Aylesbury 13 4523.30 1927.10 775.00 114.90 5413.20 7340.30
Banbury 14 6473.50 3547.40 1710.00 133.40 8316.90 11,864.30
Bromsgrove 15 5594.80 2937.50 1740.00 84.10 7418.90 10,356.40
Bromsgrove 16 7223.80 2462.60 1740.00 83.30 9047.10 11,509.70
Daventry 17 8358.30 3231.80 1929.70 133.40 10,421.40 13,653.20
Exeter 18 5307.80 5716.20 1194.80 109.60 6612.20 12,328.40
High Wycombe 19 4047.50 1941.80 2320.00 109.60 6477.10 8418.90
Jubilee 20 6111.00 1743.90 1720.00 108.80 7939.80 9683.70
Jubilee 21 5594.30 909.80 1200.00 59.10 6853.40 7763.20
Jubilee 22 5521.00 909.80 1160.00 121.60 6802.60 7712.40
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TABLE 37 Cost of delivery of intervention by site and cohort (continued )
Site Cohorta
Costs (£)
Staff Travelb Venue Equipmentc Totald
Total
(including travel)
Kenilworth 23 6824.30 1546.60 1550.00 114.90 8489.20 10,035.80
Kettering 24 5742.90 3310.90 1359.60 120.20 7222.80 10,533.60
Loughborough 25 6664.60 4238.00 2310.00 134.70 9109.40 13,347.30
Maidenhead 26 4087.80 1428.20 1682.00 96.90 5866.70 7294.90
Maidenhead 27 6207.50 2839.50 1682.00 121.60 8011.10 10,850.60
Melton Mowbray 28 5535.30 3368.40 1162.90 71.40 6769.60 10,138.00
North East London 29 7011.00 7490.00 1277.20 114.90 8403.10 15,893.10
North East London 30 6362.00 892.50 1318.40 75.80 7756.20 8648.70
Newbury 31 5682.10 1982.70 1240.00 101.30 7023.40 9006.10
Northampton 32 6839.00 4002.20 1750.00 171.70 8760.70 12,762.90
Northampton 33 6439.20 2797.20 1450.00 96.10 7985.30 10,782.50
Northampton 34 6244.10 3915.50 1700.00 139.20 8083.30 11,998.80
Oxford Brookes 35 5345.60 4506.90 2030.00 84.10 7459.70 11,966.60
Reading 36 7768.10 3049.40 1740.00 84.10 9592.20 12,641.60
Salford 37 6931.00 3412.30 1194.80 109.60 8235.40 11,647.70
Salford 38 5711.20 2514.60 1194.80 96.10 7002.10 9516.70
Sandwell 39 5474.70 2379.50 1120.00 119.30 6714.00 9093.50
Sandwell 40 6354.80 3020.40 1320.00 106.60 7781.40 10,801.80
Sandwell 41 6823.10 2073.30 1160.00 83.30 8066.40 10,139.70
Solent 42 6138.30 3405.90 1606.80 136.00 7881.10 11,287.00
St Cross 43 6365.20 3733.00 925.00 195.90 7486.10 11,219.10
Wellingborough 44 5374.30 5269.50 1194.80 84.10 6653.20 11,922.70
Wildmoor Spa 45 7492.60 1722.10 1277.20 142.20 8912.00 10,634.10
Wildmoor Spa 46 7912.90 525.50 1277.20 101.40 9291.50 9817.00
Wildmoor Spa 47 4647.90 2548.00 1194.80 83.30 5926.00 8474.00
Wokingham 48 4163.50 3056.30 1194.80 96.90 5455.20 8511.50
Wolston 49 4983.80 1595.50 1194.80 122.40 6301.00 7896.50
Wolverhampton 50 9659.40 3460.50 1565.60 116.70 11341.70 14,802.20
Wolverhampton 51 5852.80 3036.20 1236.00 85.50 7174.30 10,210.50
Worcester 52 5400.00 4211.80 700.00 119.30 6219.30 10,431.10
Worcester 53 3635.60 3784.60 725.00 83.30 4443.90 8228.50
Worcester 54 6331.50 3793.80 850.00 139.20 7320.70 11,114.50
a Cohort sizes ranged from 3 to 10 (depending on site) (see Table 38).
b Based on distances travelled by practitioners by mode of transport.
c Inclusive for each site: cost of belt, stopwatch, timers, cones, lap counter, compact discs, stationery (e.g. pens, erasers),
DAPA intervention manual, associated with group delivery.
d Inclusive: training activities, planning, direct delivery, administrative activities, meetings with professionals, telephone calls
and supervision activities associated with group delivery.
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TABLE 38 Mean cost per session per participant (including sensitivity analyses)
Venue Cohort
Participants
per cohort
Total number
of sessions
delivered
Mean number
of sessions
attended
Mean cost (£) per
session/participanta
Mean cost (£) per
session/participant
including practitioner
travel costs
Sensitivity analyses, mean cost (£) per
session/participant
Participants
per cohort
Participants per cohort,
including practitioner
travel costs
n= 3 n= 10 n= 3 n= 10
Gloucestershire & Hereford 1 6 29 23.50 49.30 69.90 98.50 29.60 139.90 42.00
Gloucestershire & Hereford 2 6 29 26.70 43.30 49.70 86.60 26.00 99.50 29.80
Abingdon 3 6 30 23.80 50.50 65.50 100.90 30.30 131.00 39.30
Amersham 4 8 29 26.00 28.60 46.10 76.20 22.80 123.00 36.90
Amersham 5 7 29 25.60 38.60 58.00 90.00 27.00 135.30 40.60
Amersham 6 8 29 24.10 45.40 74.20 121.00 36.30 197.90 59.40
Atrium 7 4 29 23.80 80.80 87.40 107.80 32.30 116.50 34.90
Atrium 8 8 31 24.80 51.00 55.90 136.00 40.80 149.10 44.70
Atrium 9 4 30 18.30 107.50 120.30 143.30 43.00 160.50 48.10
Atrium 10 8 29 21.30 49.30 61.30 131.60 39.50 163.40 49.00
Atrium 11 6 29 15.30 92.30 102.20 184.60 55.40 204.40 61.30
Atrium 12 7 29 24.30 45.90 51.30 107.10 32.10 119.60 35.90
Aylesbury 13 6 29 25.70 35.20 47.70 70.30 21.10 95.30 28.60
Banbury 14 6 29 21.80 63.50 90.60 127.00 38.10 181.10 54.30
Bromsgrove 15 4 29 27.50 67.40 94.10 89.90 27.00 125.50 37.70
Bromsgrove 16 5 29 26.00 69.60 88.50 116.00 34.80 147.60 44.30
Daventry 17 6 29 26.00 66.80 87.50 133.60 40.10 175.00 52.50
Exeter 18 6 29 24.20 45.60 85.00 91.20 27.40 170.00 51.00
High Wycombe 19 6 29 22.50 48.00 62.40 96.00 28.80 124.70 37.40
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TABLE 38 Mean cost per session per participant (including sensitivity analyses) (continued )
Venue Cohort
Participants
per cohort
Total number
of sessions
delivered
Mean number
of sessions
attended
Mean cost (£) per
session/participanta
Mean cost (£) per
session/participant
including practitioner
travel costs
Sensitivity analyses, mean cost (£) per
session/participant
Participants
per cohort
Participants per cohort,
including practitioner
travel costs
n= 3 n= 10 n= 3 n= 10
Jubilee 20 4 29 23.50 84.50 103.00 112.60 33.80 137.40 41.20
Jubilee 21 3 29 22.70 100.80 114.20 100.80 30.20 114.20 34.20
Jubilee 22 8 29 24.10 35.20 40.00 94.00 28.20 106.60 32.00
Kenilworth 23 6 29 26.20 54.10 63.90 108.10 32.40 127.80 38.40
Kettering 24 6 31 25.30 47.50 69.30 95.00 28.50 138.60 41.60
Loughborough 25 7 29 26.40 49.20 72.10 114.90 34.50 168.30 50.50
Maidenhead 26 5 29 27.00 43.50 54.00 72.40 21.70 90.10 27.00
Maidenhead 27 8 29 21.60 46.30 62.70 123.50 37.00 167.30 50.20
Melton Mowbray 28 3 29 25.70 87.90 131.70 87.90 26.40 131.70 39.50
North East London 29 6 29 20.70 67.80 128.20 135.50 40.70 256.30 76.90
North East London 30 4 28 20.00 97.00 108.10 129.30 38.80 144.10 43.20
Newbury 31 5 29 21.40 65.60 84.20 109.40 32.80 140.30 42.10
Northampton 32 9 29 24.90 39.10 57.00 117.30 35.20 170.90 51.30
Northampton 33 6 29 25.30 52.50 70.90 105.10 31.50 141.90 42.60
Northampton 34 8 29 24.60 41.00 60.90 109.40 32.80 162.40 48.70
Oxford Brookes 35 4 29 18.30 102.20 163.90 136.20 40.90 218.60 65.60
Reading 36 4 29 23.50 102.00 134.50 136.10 40.80 179.30 53.80
Salford 37 6 29 22.70 60.60 85.60 121.10 36.30 171.30 51.40
Salford 38 6 29 15.20 76.90 104.60 153.90 46.20 209.20 62.70
Sandwell 39 7 28 21.70 44.20 59.80 103.10 30.90 139.60 41.90
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Venue Cohort
Participants
per cohort
Total number
of sessions
delivered
Mean number
of sessions
attended
Mean cost (£) per
session/participanta
Mean cost (£) per
session/participant
including practitioner
travel costs
Sensitivity analyses, mean cost (£) per
session/participant
Participants
per cohort
Participants per cohort,
including practitioner
travel costs
n= 3 n= 10 n= 3 n= 10
Sandwell 40 6 31 22.00 59.00 81.80 117.90 35.40 163.70 49.10
Sandwell 41 5 29 24.60 65.60 82.40 109.30 32.80 137.40 41.20
Solent 42 6 29 17.30 75.80 108.50 151.60 45.50 217.10 65.10
St Cross 43 10 31 21.70 34.50 51.70 115.00 34.50 172.30 51.70
Wellingborough 44 4 29 27.30 61.00 109.40 81.40 24.40 145.80 43.80
Wildmoor Spa 45 8 29 25.90 43.10 51.40 114.80 34.40 137.00 41.10
Wildmoor Spa 46 6 29 20.50 75.50 79.80 151.10 45.30 159.60 47.90
Wildmoor Spa 47 5 29 19.80 59.90 85.60 99.80 29.90 142.70 42.80
Wokingham 48 5 29 20.80 52.50 81.80 87.40 26.20 136.40 40.90
Wolston 49 7 29 22.40 40.10 50.30 93.60 28.10 117.40 35.20
Wolverhampton 50 5 32 21.80 104.10 135.80 173.40 52.00 226.30 67.90
Wolverhampton 51 5 29 26.40 54.40 77.40 90.60 27.20 128.90 38.70
Worcester 52 7 28 22.60 39.40 66.00 91.80 27.60 154.00 46.20
Worcester 53 5 29 17.40 51.10 94.60 85.10 25.50 157.60 47.30
Worcester 54 8 29 24.50 37.40 56.70 99.60 29.90 151.20 45.40
a Total cost of delivery for a cohort within a site divided by number of participants per cohort per site × mean number of sessions attended.
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(Atrium, cohort 9). Table 38 also reports group- and site-specific estimates of average cost per exercise
session per attending participant following sensitivity analyses; varying the number of exercise group
participants from three (lowest observed) to 10 (highest observed) per cohort. As expected, increases in
values for both the session attendance variable and the group size variable had the tendency to decrease
the average cost per exercise session per participant.
Broader resource use
Table 39 shows resource-use values for participants with complete data by trial allocation, resource-use
category and study period. The resource-use values are presented for subcategories of resource use,
including accommodation, hospital services, day care services, general community health services,
community mental health services, social care services, equipment (adaptation and repairs), medication
use, participant travel and other resource items. Societal resource items included privately provided
community health and mental health services, and time taken off work.
Notably, among participants with complete resource-use data, the most frequent health resource inputs
were GP visits, hospital stays, practice nurse visits and community psychiatrist contacts (see Table 39).
About 57% versus 58%, 69% versus 66% and 66% versus 64% of participants had at least one visit to
the GP at baseline, 6 months post randomisation and 12 months post randomisation for exercise versus
usual care, respectively. The mean (SE) number of GP contacts per participant over 12 months was 1.8
(0.14) in the exercise arm compared with 1.7 (0.27) in the usual-care arm (see Table 39).
TABLE 39 Health resource use by trial allocation, category and study period for complete cases at baseline
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Patient accommodation (number of nights) N = 326 N = 162
Care home providing nursing care 0.0 (0.02) 1 (0.3) 0.0 (0.00) 0 (0.0)
Care home providing personal care 0.0 (0.00) 0 (0.0) 0.1 (0.13) 1 (0.6)
Dual-registered home (providing both personal and nursing care) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
General medical ward 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Rehabilitation ward 0.0 (0.00) 0 (0.0) 0.3 (0.26) 1 (0.6)
Acute psychiatric ward 0.0 (0.03) 3 (0.9) 0.1 (0.06) 3 (1.9)
Hospital services N = 327 N = 162
General medical ward (days) 0.2 (0.06) 12 (3.7) 0.1 (0.06) 4 (2.5)
Continuing care/respite in-patient ward (days) 0.0 (0.04) 1 (0.3) 0.0 (0.00) 0 (0.0)
Rehabilitation ward (days) 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.6)
Acute psychiatric ward (days) 0.1 (0.03) 5 (1.5) 0.0 (0.02) 3 (1.9)
Other hospital in-patient ward (days) 0.6 (0.06) 103 (31.5) 0.7 (0.13) 54 (33.3)
Out-patient services (appointments) 0.0 (0.01) 15 (4.6) 0.1 (0.02) 8 (4.9)
Accident and emergency (appointments) 0.1 (0.04) 9 (2.8) 0.0 (0.01) 2 (1.2)
Day hospital (days) 0.0 (0.01) 3 (0.9) 0.0 (0.01) 1 (0.6)
Other 0.0 (0.02) 9 (2.8) 0.0 (0.02) 5 (3.1)
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
TABLE 39 Health resource use by trial allocation, category and study period for complete cases at baseline (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Day care services N = 325 N = 162
Local authority social service (half days) 0.1 (0.04) 6 (1.8) 0.1 (0.05) 6 (3.7)
Voluntary/private (half days) 0.1 (0.04) 19 (5.8) 0.5 (0.33) 8 (4.9)
NHS (not hospital) (half days) 0.1 (0.04) 9 (2.8) 0.0 (0.02) 2 (1.2)
Unit (accommodation) (half days) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Lunch club (visits) 0.1 (0.02) 10 (3.1) 0.0 (0.01) 1 (0.6)
Social club (visits) 0.0 (0.01) 9 (2.8) 0.1 (0.08) 6 (3.7)
Other 0.0 (0.01) 12 (3.7) 0.2 (0.15) 6 (3.7)
General community health services (number of visits) N = 326 N = 162
Geriatrician
Office visit 0.0 (0.01) 5 (1.5) 0.0 (0.01) 2 (1.2)
General practitioner
Office visit 1.1 (0.08) 187 (57.4) 1.2 (0.13) 94 (58.0)
Home visit 0.1 (0.03) 8 (2.5) 0.0 (0.02) 6 (3.7)
Practice nurse (GP clinic)
Office visit 0.7 (0.13) 91 (27.9) 0.6 (0.10) 47 (29.0)
Home visit 0.0 (0.00) 2 (0.6) 0.0 (0.01) 2 (1.2)
District nurse
Office visit 0.0 (0.02) 2 (0.6) 0.0 (0.01) 2 (1.2)
Home visit 0.0 (0.02) 6 (1.8) 0.0 (0.01) 2 (1.2)
Health visitor
Home visit 0.0 (0.04) 2 (0.6) 0.0 (0.00) 0 (0.0)
Incontinence nurse
Office visit 0.0 (0.01) 4 (1.2) 0.0 (0.02) 2 (1.2)
Home visit 0.0 (0.00) 1 (0.3) 0.0 (0.01) 1 (0.6)
Occupational therapist
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Home visit 0.0 (0.02) 5 (1.5) 0.0 (0.02) 3 (1.9)
Physiotherapist
Office visit 0.1 (0.03) 8 (2.5) 0.0 (0.04) 2 (1.2)
Home visit 0.0 (0.01) 3 (0.9) 0.1 (0.07) 3 (1.9)
Alternative medicine/therapist
Office visit 0.0 (0.01) 1 (0.3) 0.0 (0.00) 0 (0.0)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
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TABLE 39 Health resource use by trial allocation, category and study period for complete cases at baseline (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Other
Office visit 0.1 (0.03) 20 (6.1) 0.1 (0.05) 11 (6.8)
Home visit 0.0 (0.01) 3 (0.9) 0.0 (0.02) 3 (1.9)
Exercise class/physical activity 0.0 (0.00) 2 (0.6) 0.0 (0.04) 2 (1.2)
Optician 0.1 (0.04) 9 (2.8) 0.1 (0.07) 3 (1.9)
Dentist 0.1 (0.02) 10 (3.1) 0.1 (0.07) 3 (1.9)
Community mental health services (number of visits) N = 326 N = 162
CPN/CMHN
Office visit 0.1 (0.02) 33 (10.1) 0.1 (0.02) 11 (6.8)
Home visit 0.2 (0.10) 34 (10.4) 0.1 (0.07) 12 (7.4)
Community psychiatrist
Office visit 0.3 (0.03) 75 (23.0) 0.3 (0.05) 41 (25.3)
Home visit 0.0 (0.01) 9 (2.8) 0.0 (0.02) 5 (3.1)
Psychologist
Office visit 0.0 (0.01) 7 (2.1) 0.0 (0.00) 0 (0.0)
Home visit 0.0 (0.00) 2 (0.6) 0.0 (0.02) 2 (1.2)
Other
Office visit 0.1 (0.02) 9 (2.8) 0.2 (0.15) 2 (1.2)
Home visit 0.1 (0.10) 5 (1.5) 0.0 (0.04) 2 (1.2)
Social care services (number of visits) N = 326 N = 161
Care manager
Home 0.0 (0.00) 2 (0.6) 0.0 (0.00) 0 (0.0)
Social worker
Office 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Home 0.0 (0.02) 9 (2.8) 0.0 (0.01) 5 (3.1)
Home care worker
Home 0.7 (0.41) 7 (2.1) 2.6 (2.44) 2 (1.2)
Carer worker
Office 0.0 (0.00) 1 (0.3) 0.0 (0.01) 1 (0.6)
Carer worker – home 0.1 (0.06) 5 (1.5) 0.0 (0.01) 1 (0.6)
Chiropodist
Office 0.1 (0.02) 17 (5.2) 0.0 (0.02) 4 (2.5)
Home 0.0 (0.02) 6 (1.8) 0.1 (0.03) 5 (3.1)
Sitting scheme
Home 0.1 (0.08) 2 (0.6) 0.0 (0.00) 0 (0.0)
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TABLE 39 Health resource use by trial allocation, category and study period for complete cases at baseline (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Meals on wheels
Home 0.5 (0.34) 2 (0.6) 0.0 (0.00) 0 (0.0)
Self-help group
Office 0.1 (0.05) 7 (2.1) 0.1 (0.03) 5 (3.1)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Self-help group carer
Office 0.0 (0.01) 3 (0.9) 0.1 (0.05) 3 (1.9)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.6)
Other
Office 0.1 (0.06) 8 (2.5) 0.1 (0.05) 4 (2.5)
Home 0.0 (0.02) 5 (1.5) 0.0 (0.02) 3 (1.9)
Equipment, adaptations/repairs, n (%) N = 325 N = 162
Health service 0.03 (0.01) 11 (3.4) 0.06 (0.02) 10 (6.2)
Local authority 0.0 (0.00) 0 (0.0) 0.01 (0.01) 1 (0.6)
Voluntary organisation 0.0 (0.00) 1 (0.3) 0.01 (0.01) 2 (1.2)
Self-financed 0.04 (0.01) 14 (4.3) 0.04 (0.01) 6 (3.7)
Private organisation 0.05 (0.01) 19 (5.8) 0.11 (0.02) 16 (9.9)
Medications, n (%) N = 325 N = 162
Number (%) of participants with:
One medication 0.0 (0.01) 113 (34.7) 0.31 (0.04) 51 (31.5)
Two medications 0.2 (0.02) 59 (18.1) 0.12 (0.03) 20 (12.3)
Three medications 0.1 (0.02) 39 (12.0) 0.19 (0.03) 31 (19.1)
More than three medications 0.0 (0.01) 113 (34.7) 0.36 (0.04) 58 (35.8)
Participant travel, n (%) N = 326
Hospital service visit
Bus 0.1 (0.01) 16 (4.9) 0.05 (0.02) 8 (4.9)
Car 0.3 (0.02) 92 (28.2) 0.25 (0.03) 40 (24.8)
Taxi 0.01 (0.01) 6 (1.8) 0.03 (0.01) 5 (3.1)
Train 0.0 (0.01) 2 (0.6) 0.0 (0.00) 0 (0.0)
Walk/cycle 0.0 (0.01) 3 (0.9) 0.0 (0.00) 0 (0.0)
Ambulance 0.01 (0.01) 6 (1.8) 0.01 (0.01) 1 (0.6)
Voluntary 0.0 (0.01) 2 (0.6) 0.01 (0.01) 2 (1.2)
continued
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
TABLE 39 Health resource use by trial allocation, category and study period for complete cases at baseline (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Hospital day visit
Bus 0.0 (0.01) 4 (1.2) 0.01 (0.01) 2 (1.2)
Car 0.0 (0.01) 23 (7.1) 0.07 (0.02) 12 (7.4)
Taxi 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Walk/cycle 0.0 (0.01) 3 (0.9) 0.01 (0.01) 2 (1.2)
Voluntary 0.0 (0.01) 4 (1.2) 0.02 (0.01) 3 (1.9)
General health community visit
Bus 0.1 (0.01) 19 (5.8) 0.07 (0.02) 12 (7.4)
Car 0.1 (0.01) 205 (62.9) 0.56 (0.04) 90 (55.9)
Taxi 0.0 (0.00) 8 (2.5) 0.04 (0.01) 6 (3.7)
Walk/cycle 0.2 (0.02) 52 (16.0) 0.2 (0.03) 32 (19.8)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 2 (0.6) 0.0 (0.00) 0 (0.0)
Mental health community visit
Bus 0.0 (0.01) 13 (4.0) 0.05 (0.02) 8 (4.9)
Car 0.0 (0.01) 123 (37.7) 0.35 (0.04) 56 (34.7)
Taxi 0.0 (0.01) 5 (1.5) 0.01 (0.01) 1 (0.6)
Walk/cycle 0.0 (0.00) 3 (0.9) 0.01 (0.01) 2 (1.2)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Social care visit
Bus 0.0 (0.00) 4 (1.2) 0.01 (0.01) 2 (1.2)
Car 0.1 (0.01) 26 (8.0) 0.09 (0.02) 14 (8.6)
Taxi 0.0 (0.00) 2 (0.6) 0.01 (0.01) 2 (1.2)
Walk/cycle 0.0 (0.01) 4 (1.2) 0.01 (0.01) 2 (1.2)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 2 (0.6) 0.01 (0.01) 2 (1.2)
Privately provided general community health servicesb N = 326 N = 162
0.1 (0.03) 10 (3.0) 0.0 (0.03) 2 (1.2)
Privately provided mental health services N = 326 N = 162
0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Time off work N = 303 N = 153
Hours 0.7 (0.20) 15 (4.9) 0.6 (0.29) 5 (3.2)
Days 0.1 (0.04) 4 (1.3) 0.1 (0.03) 6 (3.9)
CMHN, community mental health nurse; CPN, community psychiatric nurse.
a Number of participants who used a health resource at least once at a given assessment.
b Consisting of private health professional visits (GP, alternative health and physiotherapist).
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Community mental health care use, primarily through psychiatric support, fell over time in both groups
relative to baseline, and by 12 months it was 4% lower in the exercise group (10% vs. 14%; p = 0.2269).
No noticeable differences in terms of health-care resource use were observed post baseline for hospital
stays, practice nurse visits and community psychiatrist contacts. Resource-use frequencies in other
categories were low; hence, meaningful comparisons could not be easily made. There were no marked
differences between the trial arms in terms of the proportion of participants who incurred travel costs or
lost earnings as a result of their health state or their contacts with health- and social-care professionals.
Resource-use values at the individual participant level were combined with unit costs for each resource
item (Tables 40 and 41) to estimate economic costs for each resource category.
TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Patient accommodation (number of nights) N = 298 N = 142
Care home providing nursing care 0.0 (0.04) 1 (0.3) 0.1 (0.10) 1 (0.7)
Care home providing personal care 0.0 (0.00) 0 (0.0) 0.0 (0.05) 1 (0.7)
Dual-registered home (providing both personal and nursing care) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
General medical ward 0.0 (0.00) 0 (0.0) 0.1 (0.10) 1 (0.7)
Rehabilitation ward 0.0 (0.03) 1 (0.3) 0.0 (0.00) 0 (0.0)
Acute psychiatric ward 0.2 (0.08) 10 (3.4) 0.2 (0.15) 2 (1.4)
Hospital services N = 298 N = 141
General medical ward (days) 0.5 (0.14) 22 (7.4) 0.3 (0.16) 6 (4.3)
Continuing care/respite inpatient ward (days) 0.1 (0.10) 2 (0.7) 0.0 (0.00) 0 (0.0)
Rehabilitation ward (days) 0.7 (0.66) 1 (0.3) 0.0 (0.00) 0 (0.0)
Acute psychiatric ward (days) 0.3 (0.14) 11 (3.7) 0.2 (0.14) 6 (4.3)
Other hospital in-patient ward (days) 1.2 (0.18) 120 (40.3) 1.2 (0.20) 59 (41.8)
Outpatient services (appointments) 0.1 (0.02) 30 (10.1) 0.1 (0.02) 10 (7.1)
Accident and emergency (appointments) 0.1 (0.03) 19 (6.4) 0.1 (0.03) 8 (5.7)
Day hospital (days) 0.0 (0.01) 6 (2.0) 0.0 (0.01) 2 (1.4)
Other 0.2 (0.06) 13 (4.4) 0.1 (0.03) 6 (4.3)
Day care services N = 298 N = 141
Local authority social service (half-days) 0.0 (0.02) 6 (2.0) 0.2 (0.07) 8 (5.7)
Voluntary/private (half-days) 0.2 (0.04) 27 (9.1) 0.1 (0.04) 6 (4.3)
NHS (not hospital) (half-days) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Unit (accommodation) (half-days) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Lunch club (visits) 0.0 (0.02) 8 (2.7) 0.0 (0.02) 5 (3.5)
Social club (visits) 0.0 (0.01) 11 (3.7) 0.2 (0.17) 5 (3.5)
Other 0.1 (0.02) 10 (3.4) 0.1 (0.06) 10 (7.1)
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TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
General community health services (number of visits) N = 297 N = 141
Geriatrician
Office visit 0.0 (0.00) 1 (0.3) 0.0 (0.01) 1 (0.7)
General practitioner
Office visit 2.0 (0.15) 205 (69.0) 1.9 (0.24) 93 (66.0)
Home visit 0.1 (0.02) 16 (5.4) 0.0 (0.02) 4 (2.8)
Practice nurse (GP clinic)
Office visit 1.3 (0.25) 130 (43.8) 1.2 (0.27) 61 (43.3)
Home visit 0.0 (0.01) 3 (1.0) 0.0 (0.04) 2 (1.4)
District nurse
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.7)
Home visit 0.2 (0.17) 9 (3.0) 0.0 (0.01) 2 (1.4)
Health visitor
Home visit 0.0 (0.00) 2 (0.7) 0.0 (0.00) 0 (0.0)
Incontinence nurse
Office visit 0.0 (0.01) 5 (1.7) 0.0 (0.02) 2 (1.4)
Home visit 0.0 (0.01) 3 (1.0) 0.0 (0.01) 1 (0.7)
Occupational therapist
Office visit 0.0 (0.01) 2 (0.7) 0.1 (0.07) 1 (0.7)
Home visit 0.0 (0.01) 6 (2.0) 0.1 (0.04) 8 (5.7)
Physiotherapist
Office visit 0.1 (0.06) 12 (4.0) 0.0 (0.02) 4 (2.8)
Home visit 0.1 (0.04) 6 (2.0) 0.0 (0.02) 2 (1.4)
Alternative medicine/therapist
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Home visit 0.1 (0.05) 2 (0.7) 0.0 (0.00) 0 (0.0)
Other
Office visit 0.1 (0.04) 21 (7.1) 0.3 (0.12) 13 (9.2)
Exercise class/physical activity 0.0 (0.01) 2 (0.7) 0.0 (0.01) 1 (0.7)
Optician 0.2 (0.17) 9 (3.0) 0.0 (0.02) 3 (2.1)
Dentist 0.1 (0.06) 12 (4.0) 0.0 (0.02) 4 (2.8)
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TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Community mental health services (number of visits) N = 298 N = 141
CPN/CMHN
Office visit 0.1 (0.02) 29 (9.7) 0.1 (0.03) 15 (10.6)
Home visit 0.3 (0.17) 30 (10.1) 0.3 (0.11) 11 (7.8)
Community psychiatrist
Office visit 0.2 (0.03) 56 (18.8) 0.2 (0.04) 29 (20.6)
Home visit 0.0 (0.01) 6 (2.0) 0.0 (0.01) 4 (2.8)
Psychologist
Office visit 0.0 (0.02) 3 (1.0) 0.2 (0.11) 2 (1.4)
Home visit 0.0 (0.01) 2 (0.7) 0.1 (0.06) 2 (1.4)
Other
Office visit 0.1 (0.05) 12 (4.0) 0.5 (0.35) 5 (3.5)
Home visit 0.3 (0.25) 9 (3.0) 0.0 (0.03) 4 (2.8)
Social care services (number of visits) N = 298 N = 141
Care manager
Home 0.0 (0.01) 3 (1.0) 0.0 (0.01) 1 (0.7)
Social worker
Office 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.7)
Home 0.1 (0.02) 16 (5.4) 0.1 (0.05) 7 (5.0)
Home care worker
Home 1.9 (1.32) 3 (1.0) 0.3 (0.34) 1 (0.7)
Carer worker
Office 0.0 (0.01) 1 (0.3) 0.0 (0.00) 0 (0.0)
Home 1.5 (0.72) 11 (3.7) 0.7 (0.74) 2 (1.4)
Chiropodist
Office 0.1 (0.03) 13 (4.4) 0.2 (0.07) 12 (8.5)
Home 0.0 (0.02) 7 (2.3) 0.0 (0.03) 2 (1.4)
Sitting scheme
Home 0.2 (0.18) 2 (0.7) 0.0 (0.02) 1 (0.7)
Meals on Wheels
Home 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Self-help group
Office 0.1 (0.06) 6 (2.0) 0.5 (0.26) 5 (3.5)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.04) 2 (1.4)
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TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Self-help group carer
Office 0.0 (0.02) 2 (0.7) 0.0 (0.00) 0 (0.0)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Other
Office 0.2 (0.11) 6 (2.0) 0.0 (0.02) 3 (2.1)
Home 0.0 (0.02) 4 (1.3) 0.0 (0.01) 2 (1.4)
Equipment, adaptations/repairs, n (%) N = 298 N = 141
Health service 0.04 (0.01) 13 (4.4) 0.06 (0.02) 9 (6.3)
Local authority 0.01 (0.01) 3 (1.0) 0.01 (0.01) 1 (0.7)
Voluntary organisation 0.0 (0.00) 1 (0.3) 0.01 (0.01) 1 (0.7)
Self-financed 0.04 (0.01) 13 (4.4) 0.06 (0.02) 9 (6.3)
Private organisation 0.13 (0.02) 38 (12.8) 0.13 (0.03) 18 (12.7)
Medications, n (%) N = 297 N = 141
Number (%) of participants with
One medication 0.14 (0.02) 41 (13.8) 0.17 (0.03) 24 (17.0)
Two medications 0.21 (0.02) 62 (20.9) 0.15 (0.03) 21 (14.9)
Three medications 0.13 (0.02) 39 (13.1) 0.11 (0.03) 16 (11.3)
More than three medications 0.05 (0.01) 157 (52.8) 0.57 (0.04) 81 (57.4)
Participant travel (societal), n (%) N = 298 N = 141
Hospital service visit
Bus 0.07 (0.02) 22 (7.4) 0.07 (0.02) 10 (7.0)
Car 0.03 (0.01) 105 (35.2) 0.39 (0.04) 55 (39.0)
Taxi 0.02 (0.01) 7 (2.3) 0.06 (0.02) 8 (5.6)
Train 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Walk/cycle 0.01 (0.00) 2 (0.7) 0.0 (0.00) 0 (0.0)
Ambulance 0.05 (0.01) 16 (5.4) 0.02 (0.01) 3 (2.1)
Voluntary 0.01 (0.01) 3 (1.0) 0.01 (0.01) 1 (0.7)
Hospital day visit
Bus 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Car 0.03 (0.01) 8 (2.7) 0.03 (0.01) 4 (2.8)
Taxi 0.0 (0.00) 1 (0.3) 0.01 (0.01) 1 (0.7)
Walk/cycle 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Voluntary 0.01 (0.00) 2 (0.7) 0.01 (0.01) 2 (1.4)
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TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
General health community visit
Bus 0.07 (0.02) 22 (7.4) 0.04 (0.02) 6 (4.2)
Car 0.06 (0.01) 177 (59.4) 0.58 (0.04) 82 (58.1)
Taxi 0.02 (0.01) 7 (2.3) 0.05 (0.02) 7 (4.9)
Walk/cycle 0.17 (0.02) 50 (16.8) 0.18 (0.03) 25 (17.8)
Ambulance 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
Mental health community visit
Bus 0.04 (0.01) 13 (4.4) 0.04 (0.02) 6 (4.2)
Car 0.03 (0.01) 106 (35.6) 0.37 (0.04) 52 (36.9)
Taxi 0.02 (0.01) 5 (1.7) 0.01 (0.01) 1 (0.7)
Walk/cycle 0.01 (0.01) 4 (1.3) 0.01 (0.01) 2 (1.4)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Social care visit
Bus 0.02 (0.01) 5 (1.7) 0.01 (0.01) 2 (1.4)
Car 0.07 (0.01) 20 (6.7) 0.12 (0.03) 17 (12.0)
Taxi 0.01 (0.01) 3 (1.0) 0.02 (0.01) 3 (2.1)
Walk/cycle 0.01 (0.01) 3 (1.0) 0.01 (0.01) 1 (0.7)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.01 (0.00) 2 (0.7) 0.01 (0.01) 1 (0.7)
Privately provided general community health servicesb N = 297 N = 141
General practitioner
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Practice nurse (GP clinic)
Office visit 0.0 (0.00) 1 (0.3) 0.0 (0.00) 0 (0.0)
District nurse
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Physiotherapist
Office visit 0.0 (0.01) 1 (0.3) 0.0 (0.01) 1 (0.7)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Alternative medicine/therapist
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Other
Office visit 0.0 (0.01) 4 (1.3) 0.4 (0.21) 5 (3.5)
Home visit 0.0 (0.02) 2 (0.7) 0.0 (0.00) 0 (0.0)
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TABLE 40 Health resource use by trial allocation, category and study period for complete cases: baseline to
6 months (continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Privately provided mental health services N = 298 N = 141
Community psychiatrist
Office visit 0.0 (0.00) 1 (0.3) 0.0 (0.01) 1 (0.7)
Other
Home visit 0.1 (0.14) 1 (0.3) 0.0 (0.00) 0 (0.0)
Time off work (societal) N = 278 N = 131
Hours 0.6 (0.16) 17 (5.7) 0.3 (0.17) 3 (2.1)
Days 0.4 (0.15) 14 (4.7) 0.3 (0.11) 9 (6.3)
CMHN, community mental health nurse; CPN, community psychiatric nurse.
a Number of participants who used a health resource at least once at a given assessment.
b Consisting of private health professional visits (GP, alternative health and physiotherapist).
TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Patient accommodation (number of nights) N = 280 N = 136
Care home providing nursing care 0.3 (0.22) 2 (0.7) 0.2 (0.22) 1 (0.7)
Care home providing personal care 0.5 (0.24) 4 (1.4) 0.1 (0.05) 2 (1.5)
Dual-registered home (providing both personal and nursing care) 0.2 (0.13) 3 (1.1) 0.0 (0.00) 0 (0.0)
General medical ward 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Rehabilitation ward 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Acute psychiatric ward 1.0 (0.39) 15 (5.4) 0.9 (0.70) 2 (1.5)
Hospital services N = 280 N = 135
General medical ward (days) 1.1 (0.40) 28 (10.0) 1.4 (0.74) 13 (9.6)
Continuing care/respite inpatient ward (days) 0.0 (0.03) 1 (0.4) 0.0 (0.01) 1 (0.7)
Rehabilitation ward (days) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Acute psychiatric ward (days) 0.1 (0.11) 3 (1.1) 0.0 (0.00) 0 (0.0)
Other hospital inpatient ward (days) 1.0 (0.13) 102 (36.4) 1.1 (0.18) 53 (39.3)
Outpatient services (appointments) 0.1 (0.03) 29 (10.4) 0.1 (0.02) 9 (6.7)
Accident and emergency (appointments) 0.1 (0.05) 13 (4.6) 0.1 (0.02) 8 (5.9)
Day hospital (days) 0.0 (0.01) 3 (1.1) 0.0 (0.01) 3 (2.2)
Other 0.3 (0.17) 8 (2.9) 0.0 (0.01) 2 (1.5)
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TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
(continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Day care service N = 280 N = 135
Local authority social service (half-days) 0.0 (0.02) 8 (2.9) 0.1 (0.05) 8 (5.9)
Voluntary/private (half-days) 0.2 (0.04) 35 (12.5) 0.2 (0.13) 10 (7.4)
NHS (not hospital) (half-days) 0.0 (0.00) 0 (0.0) 0.1 (0.04) 3 (2.2)
Unit (accommodation) (half-days) 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Lunch club (visits) 0.1 (0.02) 9 (3.2) 0.0 (0.01) 4 (3.0)
Social club (visits) 0.1 (0.06) 9 (3.2) 0.1 (0.06) 3 (2.2)
Other 0.2 (0.08) 24 (8.6) 0.1 (0.06) 7 (5.2)
General community health services (number of visits) N = 280 N = 135
Geriatrician
Office visit 0.0 (0.00) 1 (0.4) 0.0 (0.01) 1 (0.7)
General practitioner
Office visit 1.8 (0.14) 184 (65.7) 1.7 (0.27) 86 (63.7)
Home visit 0.1 (0.03) 19 (6.8) 0.2 (0.10) 13 (9.6)
Practice nurse (GP clinic)
Office visit 1.0 (0.24) 109 (38.9) 0.8 (0.13) 53 (39.3)
Home visit 0.1 (0.05) 5 (1.8) 0.2 (0.19) 2 (1.5)
District nurse
Office visit 0.1 (0.04) 5 (1.8) 0.0 (0.00) 0 (0.0)
Home visit 0.3 (0.18) 10 (3.6) 0.1 (0.09) 2 (1.5)
Health visitor
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Incontinence nurse
Office visit 0.0 (0.01) 7 (2.5) 0.0 (0.01) 2 (1.5)
Home visit 0.0 (0.01) 7 (2.5) 0.1 (0.03) 5 (3.7)
Occupational therapist
Office visit 0.0 (0.01) 1 (0.4) 0.0 (0.00) 0 (0.0)
Home visit 0.1 (0.02) 11 (3.9) 0.1 (0.04) 2 (1.5)
Physiotherapist
Office visit 0.1 (0.04) 8 (2.9) 0.2 (0.09) 7 (5.2)
Home visit 0.1 (0.04) 7 (2.5) 0.1 (0.06) 3 (2.2)
Alternative medicine/therapist
Office visit 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.0)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
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TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
(continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Other
Exercise class/physical activity 0.3 (0.22) 2 (0.7) 0.0 (0.01) 1 (0.7)
Optician 0.1 (0.05) 12 (4.3) 0.0 (0.01) 4 (3.0)
Dentist 0.2 (0.04) 14 (5.0) 0.1 (0.03) 5 (3.7)
Office visit 0.2 (0.04) 26 (9.3) 0.1 (0.05) 6 (4.4)
Home visit 0.5 (0.40) 12 (4.3) 0.5 (0.44) 2 (1.5)
Community mental health services (number of visits) N = 280 N = 136
CPN/CMHN
Office visit 0.1 (0.02) 27 (9.6) 0.1 (0.03) 18 (13.3)
Home visit 0.5 (0.29) 29 (10.4) 0.1 (0.06) 7 (5.2)
Community psychiatrist
Office visit 0.1 (0.02) 28 (10.0) 0.2 (0.04) 19 (14.1)
Home visit 0.1 (0.02) 9 (3.2) 0.0 (0.01) 2 (1.5)
Psychologist
Office visit 0.0 (0.00) 0 (0.0) 0.1 (0.10) 2 (1.5)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Other
Office visit 0.1 (0.06) 6 (2.1) 0.2 (0.15) 2 (1.5)
Home visit 0.0 (0.01) 3 (1.1) 0.1 (0.11) 3 (2.2)
Social care services (number of visits) N = 280 N = 135
Care manager
Home 0.0 (0.01) 4 (1.4) 0.0 (0.01) 2 (1.5)
Social worker
Office 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.7)
Home 0.1 (0.04) 19 (6.8) 0.2 (0.05) 14 (10.4)
Home care worker
Home 3.0 (1.69) 9 (3.2) 8.7 (4.91) 7 (5.2)
Carer worker
Office 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Home 2.4 (1.29) 8 (2.9) 1.3 (1.24) 2 (1.5)
Chiropodist
Office 0.1 (0.04) 14 (5.0) 0.2 (0.06) 13 (9.6)
Home 0.0 (0.02) 2 (0.7) 0.3 (0.22) 2 (1.5)
Sitting scheme
Home 0.1 (0.11) 3 (1.1) 0.4 (0.36) 1 (0.7)
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TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
(continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Meals on wheels
Home 0.1 (0.09) 1 (0.4) 1.2 (1.24) 1 (0.7)
Self-help group
Office 0.1 (0.07) 1 (0.4) 0.0 (0.04) 1 (0.7)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Self-help group carer
Office 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Home 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Other
Office 0.1 (0.04) 5 (1.8) 0.3 (0.23) 2 (1.5)
Home 0.8 (0.67) 3 (1.1) 0.2 (0.19) 2 (1.5)
Equipment, adaptations/repairs, n (%) N = 280 N = 136
Self-financed 0.08 (0.02) 21 (7.5) 0.11 (0.03) 15 (11.0)
Health service 0.08 (0.02) 22 (7.9) 0.22 (0.04) 30 (22.1)
Local authority 0.02 (0.01) 6 (2.1) 0.07 (0.02) 9 (6.6)
Voluntary organisation 0.0 (0.00) 0 (0.00) 0.03 (0.01) 4 (2.9)
Private organisation 0.17 (0.02) 48 (17.1) 0.2 (0.03) 27 (19.9)
Medications, n (%) N = 280 N = 135
Number (%) of participants with
One medication 0.12 (0.02) 33 (11.8) 0.13 (0.03) 17 (12.6)
Two medications 0.35 (0.03) 98 (35.0) 0.4 (0.04) 54 (40.0)
Three medications 0.15 (0.02) 41 (14.6) 0.13 (0.03) 17 (12.6)
More than three medications 0.04 (0.01) 108 (38.6) 0.35 (0.04) 47 (34.8)
Participant travel (societal), n (%) N = 280 N = 135
Hospital service visit
Bus 0.05 (0.01) 13 (4.6) 0.07 (0.02) 9 (6.7)
Car 0.04 (0.01) 104 (37.1) 0.4 (0.04) 54 (40.0)
Taxi 0.01 (0.01) 4 (1.4) 0.04 (0.02) 6 (4.4)
Train 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.00)
Walk/cycle 0.01 (0.01) 2 (0.7) 0.02 (0.01) 3 (2.2)
Ambulance 0.09 (0.02) 24 (8.6) 0.04 (0.02) 6 (4.4)
Voluntary 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.00)
Hospital day visit
Bus 0.03 (0.01) 9 (3.2) 0.01 (0.01) 2 (1.5)
Car 0.08 (0.02) 23 (8.2) 0.1 (0.03) 13 (9.6)
Taxi 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.00)
Walk/cycle 0.0 (0.00) 0.0 (0.00) 0.0 (0.00) 0 (0.00)
Voluntary 0.01 (0.01) 2 (0.7) 0.0 (0.00) 0 (0.00)
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TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
(continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
General health community visit
Bus 0.06 (0.01) 17 (6.1) 0.05 (0.02) 7 (5.1)
Car 0.06 (0.01) 164 (58.6) 0.6 (0.04) 81 (59.6)
Taxi 0.02 (0.01) 5 (1.8) 0.03 (0.01) 4 (2.9)
Walk/cycle 0.16 (0.02) 44 (15.7) 0.16 (0.03) 22 (16.2)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Voluntary 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.00)
Mental health community visit
Bus 0.04 (0.01) 12 (4.3) 0.04 (0.02) 6 (4.4)
Car 0.34 (0.03) 94 (33.6) 0.35 (0.04) 48 (35.3)
Taxi 0.01 (0.01) 4 (1.4) 0.01 (0.01) 1 (0.7)
Walk/cycle 0.01 (0.01) 4 (1.4) 0.01 (0.01) 2 (1.5)
Ambulance 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.00)
Voluntary 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.00)
Social care visit
Bus 0.01 (0.01) 3 (1.1) 0.01 (0.01) 1 (0.7)
Car 0.08 (0.02) 21 (7.5) 0.1 (0.03) 13 (9.6)
Taxi 0.01 (0.01) 2 (0.7) 0.02 (0.01) 3 (2.2)
Walk/cycle 0.01 (0.01) 4 (1.4) 0.01 (0.01) 1 (0.7)
Ambulance 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.00)
Voluntary 0.0 (0.00) 1 (0.4) 0.01 (0.01) 1 (0.7)
Privately provided general community health servicesb N = 280 N = 135
General practitioner
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.7)
Practice nurse (GP clinic)
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
District nurse
Home visit 0.0 (0.02) 1 (0.4) 0.0 (0.00) 0 (0.0)
Physiotherapist
Office visit 0.0 (0.02) 1 (0.4) 0.0 (0.04) 1 (0.7)
Home visit 0.0 (0.02) 1 (0.4) 0.0 (0.01) 1 (0.7)
Alternative medicine/therapist
Office visit 0.0 (0.00) 0 (0.0) 0.0 (0.01) 1 (0.7)
Other
Office visit 0.1 (0.09) 5 (1.8) 0.0 (0.02) 3 (2.2)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.04) 1 (0.7)
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
Economic costs
Economic costs for participants with complete data are presented in Tables 42–45 by trial group, study period
and cost category. With the exception of the cost of the exercise intervention, there were no statistically
significant differences between the trial groups in any cost category, at any time point. The mean cost of the
exercise programme in participants with complete resource-use data over the entire follow-up period was
£1269 (SE £30) (see Table 45). Over the entire follow-up period, and for participants with complete data,
the mean total NHS and personal social service costs, inclusive of the cost of the intervention, were £5945
(SE £492) in the intervention arm compared with £4597 (SE £444) in the control arm, generating a mean cost
difference of £1347 (bootstrap 95% CI £8 to £2136; p = 0.00426). Over the entire follow-up period, and for
participants with complete data, the mean total societal costs, inclusive of the cost of the intervention, were
£6063 (SE £494) in the intervention arm compared with £4761 (SE £447) in the control arm, generating a
mean cost difference of £1301 (bootstrap 95% CI £3 to £2096; p = 0.00479) (see Table 45).
Health-related quality-of-life outcomes
There were no statistically significant differences in suboptimal levels of function in HRQoL for either
participant- or carer-reported dimensions of the EQ-5D-3L, between the exercise and usual-care groups, at
each of the 6- and 12-month follow-up time points (Tables 46 and 47). For complete cases, the mean (SE)
patient-reported QALY estimate was 0.787 (SE 0.012) versus 0.826 (SE 0.019) for exercise versus control
(Table 48); this was 0.758 (SE 0.014) versus 0.782 (SE 0.020) based on the carer-reported EQ-5D-3L,
respectively. There were no statistically significant differences in the overall EQ-5D-3L utility scores or
EQ-5D-3L VAS scores between the exercise and usual-care groups at each of the follow-up time points.
There were no statistically significant differences in either participant- or carer-reported QALY estimates
(see Table 48).
TABLE 41 Health resource use by trial allocation, category and study period for complete cases: 6–12 months
(continued )
Resource category (unit)
Treatment arm
Exercise programme Usual care
Mean (SE) na (%) Mean (SE) na (%)
Privately provided mental health (community) N = 280 N = 136
Community psychiatrist
Office visit 0.0 (0.00) 1 (0.4) 0.0 (0.00) 0 (0.0)
Home visit 0.0 (0.00) 0 (0.0) 0.0 (0.00) 0 (0.0)
Time off work (societal) N = 255 N = 128
Hours 0.4 (0.14) 8 (3.1) 0.4 (0.20) 4 (3.1)
Days 0.3 (0.11) 9 (3.5) 0.1 (0.03) 5 (3.9)
CMHN, community mental health nurse; CPN, community psychiatric nurse.
a Number of participants who used a health resource at least once at a given assessment.
b Consisting of private health professional visits (GP, alternative health and physiotherapist).
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TABLE 42 Economic costs (£) for complete cases by trial allocation, study period and cost category (2014–15 prices):
baseline (N= 488)
Cost category by period
Treatment arm, mean cost (£) (SE)
Mean cost
(£) difference p-valuea Bootstrap 95% CIb
Exercise
programme
(n= 326)
Usual care
(n= 162)
NHS/PSS costs
Patient accommodation 2.90 (2.89) 201.90 (179.92) –199.00 0.2704 –597.00 to 3.30
Hospital services 315.50 (33.96) 303.30 (52.94) 12.20 0.8459 –131.00 to 107.30
Day care services 8.60 (2.63) 15.90 (5.44) –7.30 0.2302 –19.90 to 3.60
General community health
services
101.40 (7.53) 93.10 (9.86) 8.30 0.5048 –17.60 to 33.30
Community mental health
services
60.90 (7.53) 53.30 (6.28) 7.60 0.4365 –6.70 to 28.90
Social care services 105.90 (26.67) 163.50 (69.20) –57.60 0.4381 –196.80 to 59.00
Equipment, adaptations/
repairs
1.00 (0.74) 0.80 (0.43) 0.23 0.7811 –0.80 to 2.20
Patient travelc 2.00 (0.21) 2.10 (0.34) –0.10 0.7861 –0.90 to 0.76
Concomitant/prescription
medications
57.3 (8.83) 38.30 (7.39) 18.90 0.1000 –1.30 to 41.60
Other 25.1 (10.93) 41.00 (30.18) –15.90 0.6312 –83.00 to 38.90
Total (NHS/PSS) 680.62 (48.23) 913.10 (201.56) –232.50 0.2748 –648.10 to 26.10
Broader societal costs
Privately provided general
community health services
2.90 (1.61) 2.40 (1.80) 0.55 0.8175 –5.20 to 5.00
Privately provided mental
health services
10.30 (7.29) 6.00 (3.07) 4.30 0.5856 –8.40 to 17.00
Patient equipment 2.20 (1.35) 1.20 (0.94) 1.00 0.5116 –2.50 to 3.90
Patient traveld 0.70 (0.20) 0.90 (0.33) –0.20 0.5920 –1.00 to 0.48
Time off work
Hours 9.30 (2.87) 8.20 (4.06) 1.000 0.8320 –10.30 to 9.50
Days 5.50 (4.01) 7.10 (3.17) –1.50 0.7559 –10.30 to 9.80
Total broader societal 30.90 (5.37) 25.80 (5.52) –5.10 0.9956 –17.40 to 8.30
Total (societal) 711.50 (48.90) 938.90 (202.05) –227.40 0.2374 –670.90 to 6.70
a The p-value was calculated using the Student’s t-test, two-tail unequal variance.
b Non-parametric bootstrap estimation using 10,000 replications, bias corrected.
c Patient travel consisted of ambulance or NHS-supported travel.
d Patient travel consisted of private transport costs (e.g. private taxi).
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TABLE 43 Economic costs (£) for complete cases by trial allocation, study period and cost category (2014–15 prices):
randomisation to 6 months (N = 440)
Cost category by period
Treatment arm, mean cost (£) (SE)
Mean cost (£)
difference p-valuea Bootstrap 95% CIb
Exercise
programme
(n= 298)
Usual care
(n= 142)
NHS/PSS costs
Patient accommodation 37.60 (24.11) 43.00 (27.59) –5.39 0.8831 –69.10 to 50.70
Hospital services 590.10 (75.69) 676.70 (103.80) –86.6 0.5006 –299.40 to 140.60
Day care services 9.80 (1.96) 12.20 (3.18) –2.40 0.5111 –8.50 to 4.80
General community health
services
138.60 (15.60) 136.00 (13.07) 2.60 0.8945 –28.10 to 32.00
Community mental health
services
60.30 (4.48) 69.80 (11.66) –9.50 0.4421 –34.10 to 13.40
Social care services 224.50 (68.74) 246.90 (80.22) –22.40 0.8332 –249.40 to 162.50
Equipment, adaptations/
repairs
0.80 (0.30) 2.60 (2.13) –1.80 0.4067 –6.20 to 0.920
Patient travelc 2.70 (0.32) 2.80 (0.35) –0.10 0.8264 –0.88 to 0.79
Concomitant/prescription
medications
331.80 (33.73) 343.90 (69.95) –12.10 0.8778 –157.60 to 122.10
Other 36.70 (14.13) 40.00 (21.58) –3.30 0.9096 –59.00 to 41.40
Total (NHS/PSS) 1432.90 (119.87) 1573.00 (150.01) –140.10 0.4890 –569.70 to 71.10
Broader societal costs
Privately provided general
community health services
4.50 (2.18) 1.90 (1.31) 2.50 0.3079 –2.10 to 7.20
Privately provided mental
health services
8.00 (2.68) 19.10 (15.39) –11.00 0.4877 –53.40 to 9.60
Patient equipment 2.00 (1.24) 1.30 (1.06) 0.69 0.6712 –2.50 to 3.70
Patient traveld 1.10 (0.31) 1.20 (0.32) –0.0097 0.8278 –1.40 to 0.98
Time off work
Hours 8.80 (2.68) 4.10 (2.34) 4.70 0.1820 –1.30 to 12.10
Days 39.60 (15.98) 27.60 (11.48) 12.00 0.5412 –33.20 to 49.70
Total broader societal 64.00 (16.91) 55.10 (12.55) 8.90 0.7463 –39.20 to 33.40
Total (societal) 1496.90 (123.61) 1628.10 (151.16) –131.20 0.5198 –566.80 to 85.10
a The p-value was calculated using the Student’s t-test, two-tail unequal variance.
b Non-parametric bootstrap estimation using 10,000 replications, bias corrected.
c Patient travel consisted of ambulance or NHS-supported travel.
d Patient travel consisted of private transport costs (e.g. private taxi).
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TABLE 44 Economic costs (£) for complete cases by trial allocation, study period and cost category (2014–15 prices):
between 6 and 12 months (N= 422)
Cost category by
period
Treatment arm, mean cost (£) (SE)
Mean cost (£)
difference p-valuea Bootstrap 95% CIb
Exercise
programme
(n= 280)
Usual care
(n= 142)
NHS/PSS costs
Patient accommodation 150.00 (55.71) 11.40 (8.20) 138.60 0.0143 37.80 to 257.90
Hospital services 1429.20 (454.93) 1150.30 (290.21) 278.90 0.6043 –636.30 to 1392.50
Day care services 24.10 (4.28) 37.00 (8.56) –12.80 0.1827 –32.00 to 7.24
General community
health services
227.70 (28.008) 211.60 (23.14) 16.20 0.6576 –58.30 to 80.40
Community mental health
services
103.30 (26.32) 80.40 (14.87) 22.90 0.4411 –31.80 to 75.00
Social care services 422.50 (92.75) 513.00 (152.95) –90.50 0.6128 –373.30 to 230.00
Equipment, adaptations/
repairs
1.10 (0.45) 11.90 (10.24) –10.80 0.2939 –31.40 to 0.87
Patient travelc 3.00 (0.33) 4.20 (0.92) –1.20 0.2328 –3.40 to 0.16
Concomitant/prescription
medications
714.40 (66.48) 723.50 (118.67) –9.10 0.9428 –307.00 to 255.70
Other 167.80 (30.85) 281.00 (211.91) –113.30 0.6197 –493.30 to 152.00
Total (NHS/PSS) 3243.10 (479.93) 3024.30 (389.91) 219.30 0.7644 –1170.20 to 919.70
Broader societal costs
Privately provided general
community health services
4.60 (2.26) 1.50 (1.09) 3.20 0.2031 –1.62 to 7.40
Privately provided mental
health services
11.60 (4.16) 84.40 (72.15) –72.85 0.3238 –187.05 to 7.80
Patient equipment 6.50 (3.70) 6.10 (4.59) 0.420 0.9489 –15.10 to 13.40
Patient traveld 1.00 (0.31) 2.20 (0.90) –1.20 0.2066 –3.50 to 0.10
Time off work
Hours 5.00 (1.94) 6.20 (3.05) –1.20 0.7345 –9.60 to 4.80
Days 25.60 (11.21) 8.20 (4.11) 17.40 0.1443 –3.70 to 38.40
Total broader societal 54.30 (13.85) 108.60 (19.94) –54.30 0.0256e –108.20 to –27.10
Total (societal) 3297.40 (481.22) 3132.90 (398.75) 165.30 0.8222 –1240.10 to 871.90
a The p-value was calculated using the Student’s t-test, two-tail unequal variance.
b Non-parametric bootstrap estimation using 10,000 replications, bias corrected.
c Patient travel consisted of ambulance or NHS-supported travel.
d Patient travel consisted of private transport costs (e.g. private taxi).
e Statistically significant at the two-sided 5% level.
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TABLE 45 Economic costs (£) for complete cases by trial allocation, study period and cost category (2014–15 prices):
randomisation to 12 months (N = 416)
Cost category by
period
Treatment arm, mean cost (£) (SE)
Mean cost (£)
difference p-valuea Bootstrap 95% CIb
Exercise
programme
(n= 280)
Usual care
(n= 136)
NHS/PSS costs
Patient accommodation 187.60 (58.02) 54.40 (30.16) 133.20 0.0513 –6.90 to 210.80
Hospital services 2019.30 (466.80) 1827.00 (320.04) 192.30 0.7342 –1001.90 to 858.10
Day care services 33.90 (4.82) 49.20 (10.25) –15.30 0.1685 –36.90 to 1.12
General community
health services
366.30 (38.25) 347.60 (27.88) 18.70 0.6438 –62.30 to 64.90
Community mental
health services
163.60 (27.08) 150.20 (23.81) 13.40 0.7108 –62.20 to 56.30
Social care services 647.00 (123.90) 759.90 (190.09) –112.90 0.6190 –565.30 to 169.30
Equipment, adaptations/
repairs
1.90 (0.62) 14.50 (10.23) –12.60 0.2092 –30.60 to 1.74
Patient travelc 5.70 (0.58) 7.00 (1.01) –1.30 0.2651 –3.60 to 0.16
Concomitant/prescription
medications
1046.20 (78.66) 1067.40 (161.72) –21.20 0.9081 –372.30 to 209.40
Other 204.50 (37.86) 32.00 (184.50) –116.50 0.5366 –466.40 to 140.40
Total (NHS/PSS) 4676.20 (507.66) 4597.30 (444.35) 78.70 0.9066 –1336.70 to 880.30
Broader societal costs
Privately provided
general community
health services
9.10 (4.32) 3.4 (2.33) 5.70 0.2431 –4.80 to 11.40
Privately provided
mental health services
19.60 (5.35) 103.5 (73.61) –83.90 0.2562 –216.50 to 21.10
Patient equipment 8.50 (4.12) 7.4 (4.77) 1.10 0.8617 –11.80 to 8.80
Patient traveld 2.10 (0.57) 3.4 (0.97) –1.30 0.2656 –3.60 to 0.16
Time off work
Hours 13.80 (3.92) 10.3 (4.24) 3.50 0.5417 –8.30 to 10.40
Days 65.20 (19.19) 35.8 (12.46) 29.40 0.2001 –19.10 to 56.30
Total broader societal 118.30 (20.55) 163.7 (20.01) –45.40 0.0594 –104.10 to 1.40
Total (societal) 4794.30 (510.66) 4761.00 (447.24) 33.30 0.9609 –1390.50 to 838.80
Intervention costs 1268.70 (29.56)
Total PSS/NHS including
intervention costs
5944.90 (491.75) 4597.30 (444.35) 1347.40 0.0426 8.20 to 2135.70
Total societal including
intervention costs
6063.00 (494.08) 4761.10 (447.24) 1301.90 0.0479 2.80 to 2095.50
a The p-value was calculated using the Student’s t-test, two-tail unequal variance.
b Non-parametric bootstrap estimation using 10,000 replications, bias corrected.
c Patient travel consisted of ambulance or NHS-supported travel.
d Patient travel consisted of private transport costs (e.g. private taxi).
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TABLE 46 Participant-reported EQ-5D-3L scores by trial allocation, study period and dimension
Time point
EQ-5D-3L item (level), n (%)
EQ-5D-3L VAS,
mean (SE)
EQ-5D-3L
utility,
mean (SE)
Mobility Self care Usual activities Pain/discomfort Anxiety/depression
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Baseline (N= 494)
Exercise
(n= 329)
234 (71) 95 (29) 0 283 (86) 44 (13) 1 (0) 240 (73) 82 (25) 6 (2) 209 (64) 110 (33) 8 (2) 230 (70) 96 (29) 2 (1) 76.74 (1.03) 0.819 (0.011)
Control
(n= 165)
121 (73) 42 (25) 0 142 (86) 21 (13) 0 123 (75) 35 (21) 3 (2) 110 (67) 51 (31) 2 (1) 120 (73) 41 (25) 0 81.83 (1.39) 0.849 (0.014)
p-valuea 0.0035 0.1043
6 months (N= 445)
Exercise
(n= 300)
202 (67) 93 (31) 0 251 (84) 39 (13) 3 (1) 202 (67) 79 (26) 12 (4) 183 (61) 106 (35) 5 (2) 201 (67) 88 (29) 5 (2) 75.42 (1.21) 0.800 (0.013)
Control
(n= 145)
101 (70) 39 (27) 0 116 (80) 23 (16) 1 (1) 108 (74) 31 (21) 1 (1) 99 (68) 37 (26) 4 (3) 103 (71) 34 (23) 2 (1) 78.67 (1.60) 0.833 (0.018)
p-valuea 0.1067 0.1480
12 months (N= 418)
Exercise
(n= 281)
184 (65) 86 (31) 0 223 (79) 39 (14) 7 (2) 184 (65) 72 (26) 9 (3) 171 (61) 93 (33) 5 (2) 183 (65) 79 (28) 3 (1) 75.46 (1.19) 0.805 (0.014)
Control
(n= 137)
92 (67) 39 (28) 1 (1) 113 (82) 14 (10) 4 (3) 97 (71) 30 (22) 4 (3) 88 (64) 40 (29) 4 (3) 100 (73) 29 (21) 3 (2) 78.27 (1.74) 0.816 (0.022)
p-valuea 0.1829 0.6815
a Comparisons of EQ-5D-3L VAS score and utility score were made using the Student’s t-test for unequal variances.
Some categories have missing values (not included in percentage computation).
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TABLE 47 Carer-reported EQ-5D-3L score by trial allocation, study period and dimension
Time Point
EQ-5D-3L item (level), n (%)
EQ-5D-3L VAS,
mean (SE)
EQ-5D-3L
utility,
mean (SE)
Mobility Self care Usual activities Pain/discomfort Anxiety/depression
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Baseline (N= 459)
Exercise
(n= 305)
229 (75) 76 (25) 0 292 (96) 13 (4) 0 228 (75) 74 (24) 3 (1) 155 (51) 139 (46) 11 (4) 165 (54) 135 (44) 4 (1) 77.35 (1.02) 0.794 (0.012)
Control
(n= 154)
120 (78) 34 (22) 0 151 (98) 3 (2) 0 121 (79) 32 (21) 1 (1) 96 (62) 50 (32) 8 (5) 93 (60) 57 (37) 3 (2) 77.67 (1.49) 0.819 (0.019)
p-valuea 0.8601 0.2558
6 months (N= 417)
Exercise
(n= 281)
187 (67) 91 (32) 0 269 (96) 9 (3) 0 195 (69) 81 (29) 2 (1) 133 (47) 131 (47) 14 (5) 133 (47) 135 (48) 9 (3) 73.37 (1.18) 0.760 (0.014)
Control
(n= 136)
101 (74) 33 (24) 0 129 (95) 6 (4) 0 96 (71) 35 (26) 3 (2) 70 (51) 56 (41) 9 (7) 66 (49) 66 (49) 2 (1) 72.38 (1.77) 0.774 (0.021)
p-valuea 0.6417 0.5731
12 months (N= 393)
Exercise
(n= 263)
177 (67) 84 (32) 0 250 (95) 11 (4) 0 183 (70) 76 (29) 2 (1) 128 (49) 122 (46) 11 (4) 136 (52) 112 (43) 13 (5) 74.52 (1.15) 0.765 (0.015)
Control
(n= 130)
99 (76) 30 (23) 0 128 (98) 1 (1) 0 88 (68) 39 (30) 2 (2) 67 (52) 54 (42) 8 (6) 68 (52) 58 (45) 3 (2) 75.09 (1.64) 0.779 (0.020)
p-valuea 0.7742 0.5795
a Comparisons of EQ-5D-3L VAS score and utility score were made using the Student’s t-test for unequal variances.
Some categories have missing values (not included in percentage computation).
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Cost-effectiveness results
Baseline analysis
The incremental cost-effectiveness of the exercise programme is shown in Table 49 for the participants
with costs and QALY data subject to MI. When a NHS/PSS perspective was adopted (i.e. that adopted for
the baseline analysis) and health outcomes were measured in terms of QALYs, the mean (SE) total cost
was £5580 (SE £436) in the exercise group, compared with £3917 (SE £620) in the usual-care group,
generating a mean incremental cost of £1663. The mean incremental cost-effectiveness of the exercise
intervention was estimated at –£74,227 per QALY, that is, on average, the intervention was associated
with a higher net cost and a lower net effect and was dominated in health economic terms.
The associated mean INMB at cost-effectiveness thresholds of £15,000, £20,000 and £30,000 per
QALY were –£2158, –£2306 and –£2601, respectively (see Table 49). The base-case mean INMB was
< 0, suggesting that the exercise group would result in an average NHS/PSS loss of about £2158 (INMB
–£2158, 95% CI –£3455 to –£969). The cost-effectiveness plane (Figure 11) shows that the vast majority
of the ICER values lie in the north-west quadrant. These result in a probability of cost-effectiveness
close to zero (Figure 12), that is, if decision-makers are willing to pay between £15,000 and £30,000
for an additional QALY, the probability that the exercise intervention is cost-effective is very low < 1%
(see Table 49).
Sensitivity analyses
Several sensitivity analyses were undertaken to assess the impact of uncertainty surrounding key
parameters or methodological features on the cost-effectiveness results. The probability that the exercise
intervention is cost-effective remained relatively static (< 1%) for the majority of the sensitivity analyses
(complete cases, societal costs, carer-reported EQ-5D-3L score, inclusion of practitioner travel costs and
changes in the number of participants per cohort to the lowest number observed). When venue hire costs
were excluded and when the number of participants per cohort was set at the highest number observed
across all groups, the probability that the exercise intervention is cost-effective increased but remained at
< 5%. All sensitivity analyses show the average INMB is unlikely to be positive, as all upper limits of the
95% CIs remain below zero (see Table 49 and Figures 13–15).
TABLE 48 Participant- and carer-reported EQ-5D-3L QALYs (complete cases)
Treatment arm
QALY (EQ-5D-3L)
Participant Carer
n Mean (SE) n Mean (SE)
Exercise 294 0.787 (0.012) 279 0.758 (0.014)
Usual care 141 0.826 (0.019) 137 0.782 (0.020)
Mean differencea –0.039 –0.024
p-value 0.090 0.330
95% CI –0.083 to 0.0061 –0.073 to 0.0324
a Comparisons of EQ-5D-3L QALYs were made using the Student’s t-test for unequal variances.
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TABLE 49 Cost-effectiveness, cost/QALY (£, 2014–15): exercise programme compared with usual care
Type of analysis
Incremental
cost (95% CI)
Incremental QALYs
(95% CI)
ICERa
(95% CI)
Probability of
cost-effectiveness INMB
pb pc pd INMBa,b INMBa,c INMBa,d
Base case (NHS/PSS perspective)
Imputed attributable costs and
QALYs, covariate- and baseline-
adjusted EQ-5D-3L utility score
1663
(120 to 3207)
–0.0220
(–0.0621 to 0.0181)
Dominated 0.0011 0.0012 0.0014 –2158
(–3455 to –969)
–2306
(–3678 to –1041)
–2601
(–4128 to –1176)
Sensitivity analyses
1. Complete cases attributable
costs and QALYs, and baseline-
adjusted EQ-5D-3L utility score
1549
(458 to 2764)
–0.0254
(–0.0592 to 0.0084)
Dominated 0.0044 0.0044 0.0050 –1943
(–3238 to –756)
–2071
(–3420 to –828)
–2325
(–3823 to –922)
2. Imputed societal attributable
costs and QALYs, covariate- and
baseline-adjusted EQ-5D-3L
utility score
1574
(6 to 3123)
–0.0220
(–0.0621 to 0.0181)
Dominated 0.0079 0.0079 0.0068 –1710
(–2896 to –503)
–2233
(–3789 to –777)
–2412
(–3936 to –972)
3. Imputed attributable costs
and QALYs, covariate- and
baseline-adjusted carer-reported
EQ-5D-3L utility score
1663
(120 to 3207)
–0.00665
(–0.0453 to 0.0320)
Dominated 0.0026 0.0027 0.0044 –1867
(–3094 to –757)
–1917
(–3182 to –757)
–2017
(–3380 to –738)
4. Imputed attributable costs
and QALYs, covariate- and
baseline-adjusted EQ-5D-3L
utility score, including
practitioner travel costs
1971
(959 to 3122)
–0.0220
(–0.0621 to 0.0181)
Dominated 0 0.0010 0.0025 –2264
(–3439 to –1124)
–2379
(–3625 to –1178)
–2610
(–4034 to –1216)
5. Imputed attributable costs
and QALYs, covariate- and
baseline-adjusted EQ-5D-3L
utility score assuming cohort
size (n= 3)
2773
(2458 to 2954)
–0.0220
(–0.0621 to 0.0181)
Dominated 0 0 0.0001 –3055
(–3327 to –2790)
–3172
(–3454 to –2891)
–3406
(–3723 to –3085)
continued
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TABLE 49 Cost-effectiveness, cost/QALY (£, 2014–15): exercise programme compared with usual care (continued )
Type of analysis
Incremental
cost (95% CI)
Incremental QALYs
(95% CI)
ICERa
(95% CI)
Probability of
cost-effectiveness INMB
pb pc pd INMBa,b INMBa,c INMBa,d
6. Imputed attributable costs
and QALYs, covariate- and
baseline-adjusted EQ-5D-3L
utility score assuming cohort
size (n= 10)
983
(669 to 1165)
–0.0220
(–0.0621 to 0.0181)
Dominated 0.0495 0.0486 0.0511 –1265
(–1538 to –1000)
–1382
(–1663 to –1102)
–1616
(–1931 to –1294)
7. Imputed attributable costs
and QALYs, covariate- and
baseline-adjusted EQ-5D-3L
utility score, excluding venue
hire costs
1203
(–61 to 2240)
–0.0220
(–0.0621 to 0.0181)
Dominated 0.0250 0.0260 0.050 –1417
(–2698 to –219)
–1543
(–2892 to –286)
–1796
(–3297 to –364)
Subgroup analyses (gender and sMMSE score)
Imputed attributable costs and QALYs, covariate- and baseline-adjusted EQ-5D-3L utility score
Male 1383
(23 to 3068)
–0.0263
(–0.049 to 0.027)
Dominated 0.0461 0.0486 0.0608 –1631
(–3346 to –33)
–1688
(–3469 to –12)
–1802
(–3784 to –105)
Female 1511
(–74 to 3126)
–0.0215
(–0.087 to 0.0127)
Dominated 0.0012 0.0016 0.0030 –2140
(–3744 to –568)
–2239
(–4028 to –499)
–2440
(–4632 to –322)
Baseline sMMSE score of < 20 1206
(804 to 1385)
–0.00204
(–0.0135 to 0.00935)
Dominated 0.0318 0.0326 0.0375 –1128
(–1470 to –779)
–1139
(–1519 to –753)
–1161
(–1624 to –696)
Baseline sMMSE score of ≥ 20 1951
(1585 to 2331)
–0.0334
(–0.0415 to 0.0253)
Dominated 0.0090 0.0011 0.0021 –2453
(–2856 to –2066)
–2621
(–3042 to –2216)
–2955
(–3415 to –2505)
a CIs based on 10,000 simulations. Each simulation based on model-based mean values adjusted for baseline, gender, age and region unless stated otherwise (12% data missing/imputed
for QALYS and 5% for costs).
b Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £15,000/QALY.
c Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £20,000/QALY.
d Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £30,000/QALY.
Dominated indicates incremental effects were worse and incremental costs were higher for the exercise treatment than for usual care.
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FIGURE 11 Cost-effectiveness plane for exercise programme: incremental cost (£) vs. incremental QALY: base case.
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FIGURE 12 Cost-effectiveness acceptability curve: base case.
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– 5000 – 4000 – 3000 – 2000 – 1000 0 1000 2000 3000 4000 5000
Favours exercise (INMB > 0)
MMSE score of ≥ 20
MMSE score of < 20
Female
Male
Cohort size (n = 10)
Cohort size (n = 3)
Including practitioner travel
Carer EQ-5D
Societal perspective
Complete cases
Excluding venue costs
Base case
– 2955
– 1161
– 2440
– 1802
– 1616
– 3406
– 2610
– 2017
– 2412
– 2325
– 1796
– 2601
INMB
Favours usual care (INMB < 0)
(95% CI)
(– 4128 to – 1176)
(– 3297 to – 364)
(– 3823 to – 922)
(– 3936 to – 972)
(– 3380 to – 738)
(– 4034 to – 1216)
(– 3723 to – 3085)
(– 1931 to – 1294)
(– 3784 to – 105)
(– 4632 to – 322)
(– 1624 to – 696)
(– 3415 to – 2505)      
FIGURE 13 Forest plot of sensitivity and subgroup analyses (impact on INMB): cost-effectiveness threshold of £30,000/QALY.
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MMSE score of < 20
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Cohort size (n = 3)
Including practitioner travel
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Societal perspective
Complete cases
Excluding venue costs
Base case
INMB
– 2621
– 1139
– 2239
– 1688
– 1382
– 3172
– 2379
– 1917
– 2233
– 2071
– 1543
– 2306 (– 3678 to – 1041)
(– 2892 to – 286)
(– 3420 to – 828)
(– 3789 to – 777)
(– 3182 to – 757)
(– 3625 to – 1178)
(– 3454 to – 2891)
(– 1663 to – 1102)
(– 3469 to – 12)
(– 4028 to – 499)
(– 1519 to – 753)
(– 3042 to – 2216)      
(95% CI)
FIGURE 14 Forest plot of sensitivity and subgroup analyses (impact on INMB): cost-effectiveness threshold of £20,000/QALY.
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MMSE score of ≥ 20
MMSE score of < 20
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Cohort size (n = 3)
Including practitioner travel
Carer EQ-5D
Societal perspective
Complete cases
Excluding venue costs
Base case
INMB
– 2453
– 1128
– 2140
– 1631
– 1265
– 3055
– 2264
– 1867
– 1710
– 1943
– 1417
– 2158 (– 3455 to – 969)
(– 2698 to – 219)
(– 3238 to – 756)
(– 2896 to – 503)
(– 3094 to – 757)
(– 3439 to – 1124)
(– 3327 to – 2790)
(– 1538 to – 1000)
(– 3346 to – 33)
(– 3744 to – 568)
(– 1470 to – 779)
(– 2846 to – 2066)      
(95% CI)
FIGURE 15 Forest plot of sensitivity and subgroup analyses (impact on INMB): cost-effectiveness threshold of £15,000/QALY.
ECO
N
O
M
IC
EVA
LU
A
TIO
N
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
116
Subgroup analyses
Four subgroups were subjected to cost-effectiveness analyses to explore the heterogeneity in cost-effectiveness
results: males, females, baseline sMMSE score of < 20 and baseline sMMSE score of ≥ 20 (see Table 49 and
Figures 13–15). Both subgroup analyses were based on the patient-reported EQ-5D-3L score using MI adjusted
for covariates. There was no evidence that gender or the baseline sMMSE score has a significant effect on the
cost-effectiveness of the exercise programme.
Discussion
This trial-based economic evaluation revealed that the exercise programme is not cost-effective compared with
usual care for adults with MMD in a community-dwelling setting. The INMB estimate was negative, a finding
that remained robust to several sensitivity and subgroup analyses. The clear-cut result of the trial-based
economic evaluation precluded the need for extrapolation of cost-effectiveness over a longer-time horizon
than observed within the trial. This would have required the development of a de novo decision-analytic
model according to accepted guidelines for good practice in decision-analytic modelling and the general
principles outlined in the NICE ‘reference case’.124,146
The main reason for lack of cost-effectiveness appears to stem from a combination of higher cost in the
experimental group with no evidence of effectiveness based on EQ-5D-3L-derived QALYs, although, from a
NHS and PSS perspective, a number of costs were, on average, slightly lower (although not statistically
significant) within the exercise group.
There is little evidence for cost-effectiveness of exercise in dementia patients reported in literature. This
cost-effectiveness analysis using patient-level data is based on the largest RCT of its kind reported to date.
The results from these analyses are consistent with a recent cost-effectiveness analysis of exercise as a
therapy for behavioural and psychological symptoms of dementia.147 In that smaller (n = 131) RCT [EVIDEM-E;
(Evidence Based Interventions in Dementia Exercise Therapy)] the exercise therapy was not cost-effective
based on the incremental cost per QALY metric. In the DAPA study, we confirm this conclusion. Results from
other much smaller (n = 40) trials148 suggest that community-based exercise programmes confer cognitive
and physical benefits with the potential to show cost-effectiveness but this has not been substantiated.
The main strengths of this analysis are that the trial was prospectively designed for a cost-effectiveness
analysis using individual-level data. Costs and outcomes were carefully considered in the design of this trial
with the purpose of reaching a robust conclusion with respect to cost-effectiveness in a large sample of
individuals. There were, however, several limitations to this cost-effectiveness analysis. In the absence of
any effect in either the primary clinical outcome or the EQ-5D-3L-based QALYs, usual care was dominant
in health economic terms. Unless the expected costs are lower for the exercise group, usual care would
almost always dominate.
Second, QALYs were based on utility measurement at just two time points post randomisation. Although
the trial did not yield benefits, the assumption of linearity of HRQoL between data collection points is
uncertain and more uncertain when missing data are present. Third, despite the longitudinal nature of
the study, resource use was retrospectively recalled by trial participants, which is likely to result in recall
bias. Fourth, similar pilot or Phase II trials may have been useful in identifying the critical costs that drive
cost-effectiveness. Instead, data for a broad spectrum of cost categories were collected that, on average,
had little impact on the ICER. Many costs items did not occur (see Tables 40 and 41) and a reduced form
of the CSRI in this setting may be advisable, with a focus on the largest and more relevant costs. In addition,
the CSRI could be improved in several places, as it leads to many categories of ‘other’ costs that are very
difficult and time-consuming to cost. Many of these costs had little impact on the results. Sensitivity
analyses, for example, showed the cohort size to be the most influential factor on the INMB and not some
of the cost components that were incorporated into the analysis.
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Finally, the 95% CIs surrounding the incremental QALYs do not exclude the possibility of a small QALY
benefit because the 95% CIs contain the value zero (see Table 49). However, the upper limit of these
intervals from the sensitivity analyses never exceeds 0.03 (carer-reported EQ-5D-3L), in which case for an
observed base-case incremental cost of £1683, the ICER would be very unlikely to be < £55,000 per
QALY – rendering it not cost-effective at NICE thresholds in the most optimistic case.
In conclusion, the data collected in the DAPA trial strongly support a hypothesis that exercise therapy in
addition to usual care, when compared with usual care alone, is more expensive and less effective.
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Chapter 6 Systematic review
Effects of exercise in adults with dementia: a systematic review and
meta-analysis of randomised controlled trials
We initiated the first version of this systematic review at the application stage to NIHR. We have updated
the review at key stages. First it was updated during the intervention development stage (see Chapter 2)
and then again as the results of the trial were finalised.
Aim
The aim was to undertake a systematic, comprehensive and replicable search for RCTs of exercise
interventions in dementia, in which data on cognitive impairment were reported, and to assess the quality
of evidence. We prespecified the reporting of global and specific domains of cognition and subgroup
analyses defined by diagnosis (Alzheimer’s disease or any dementia), the setting from which participants
were recruited (community or residential), intervention duration (< 4 or ≥ 4 months), total weekly exercise
duration (< 150 or ≥ 150 minutes), exercise intensity (moderate or high) and intervention type (aerobic,
resistance or mixed). We also explored length of follow-up as a potential source of heterogeneity in
the review.
Methods
Search methods
Studies were identified using electronic searches of PubMed, Allied and Complementary Medicine
Database (AMED), MEDLINE In-Process & Other Non-Indexed Citations (via OVID SP), EMBASE (via OVID
SP), PsycINFO (via ProQuest), Applied Social Sciences Index and Abstracts (ASSIA), Latin American and
Caribbean Health Sciences Literature (LILACS) and Cumulative Index to Nursing and Allied Health Literature
(CINAHL; via EBSCOhost), as well as ALOIS (Cochrane Dementia and Cognitive Improvement Group), a
specialist register of dementia studies. The original search was from inception to March 2014 and was
updated to 13 September 2016. In addition, to identify any undetected studies, forward and backward
citation tracking of systematic reviews and included studies was conducted and study authors, experts and
research groups were contacted when necessary. An example of the search strategy used for the MEDLINE
search is given in Appendix 9.
Inclusion criteria
Design
Inclusion was restricted to RCTs or studies from which RCT evidence could be extracted.
Participants
We included studies of people with probable dementia, diagnosed by a clinician and/or using recognised
assessment measures. Studies were not restricted based on severity of dementia. Details on dementia
severity, as indicated by either a recognised cognitive impairment scale or author assessment, were
extracted. Studies must have sampled from community settings or residential care and not hospitals or
psychiatric institutions. Two studies with more general populations (thus including participants without
cognitive impairment) were included, as data were made available on the subgroup of eligible participants
consistent with a clinical diagnosis of dementia.149
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Intervention
Included studies delivered interventions that prescribe an exercise programme, for which exercise is defined
as any planned or structured movement of the body performed systematically for the purpose of gaining
physical fitness.150 Studies of interventions that provided general advice about exercise without prescribing
an exercise programme were excluded. We included physical activity within our definition of exercise if the
activity was prescribed and structured for the purpose of gaining fitness, for example prescribed walking
programmes. We defined and categorised exercise types using the Taxonomy of Fall Prevention Interventions,
which includes descriptors for the types and dose parameters for exercise and physical activity interventions
used in older populations.151 This included gait/balance/functional training (D100), strength/resistance training
(D101), flexibility training (D102) and three-dimensional training, such as tai chi (D103), physical activity
(D104) and endurance activity (D105).
Studies of multicomponent interventions were included if exercise was a core component. When studies
had two or more exercise intervention arms, data from the exercise arm delivering the highest exercise
dose (frequency, intensity and/or duration) were used. We defined low- and high-dose exercise using
WHO’s guidance,106 which combines frequency and duration of an exercise session into low frequency
(< 150 minutes per week) and high frequency ≥ 150 minutes per week) and intensity into low (3–6
metabolic equivalents) and high intensity (> 6 metabolic equivalents). We categorised intervention duration
into short (< 4 months) and long duration (≥ 4 months), recognising that it takes a minimum of 6–8 weeks
for physiological conditioning of the muscular and cardiovascular systems to occur, and between 8 and
16 weeks for improvements in physical function to emerge.152
Control
Any study using a control group in which exercise was not a component was eligible for inclusion
(including pharmacological, exercise advice or no active treatment). The control groups were classified as
attention control (non-exercise activity/social contact of the same duration and frequency as the exposure
to exercise in the exercise arm), active control (non-exercise-based activity and/or social contact for a
duration or frequency less than that provided to participants in the exercise arm) or treatment as usual.
When studies had two or more control arms, data from the attention control arm were used.
Outcomes
Studies were only included if they measured global and/or specific cognitive function outcomes. Specific
cognitive functions were attention, memory, language, praxis and executive function, provided these were
tested with recognised methods. If a study used two measurements that tested the same cognitive function,
then we included the outcome measure with stronger psychometric validity based on the literature and
expert opinion. In the case of outcome measures having similar psychometric properties, we used the
measure that was most commonly used across our included studies.
Data collection
Search results were merged, duplicates were removed and studies reviewed for eligibility. Each reviewer’s
decisions were quality checked by another author (Bethan Copsey, Susanne Finnegan and Deborah Brown).
Disagreements were discussed with a fourth author for a final decision (Beth Fordham). All authors are either
experienced in the dementia and exercise research field or experienced systematic reviewers. The eligible studies
were retrieved for full-text review and assessed using the same process used for the original search results.
Data were extracted on study setting, inclusion/exclusion criteria, participant characteristics, intervention
and control treatments and outcomes. If data were not available and could not be calculated from the
reported details, we contacted the primary author for clarification. The quality of studies was assessed
using the Cochrane risk-of-bias assessment.153 All data extraction was performed by two independent
reviewers and disagreements were resolved with Beth Fordham. For papers not published in English,
data extraction and quality assessment (risk of bias) were performed by a native speaker.
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We also include within the meta-analysis the results of the DAPA trial to place the results of the study into
the context of the broader literature. Assessments of DAPA study quality were performed by researchers
independent of the trial team (Beth Fordham and Bethan Copsey).
We defined studies as being rated as having a low risk of bias if they reported the use of random
sequence generation and allocation concealment, if an additional two criteria were assessed as having a
low risk of bias and if no criteria were assessed as having a high risk of bias. Studies were categorised as
having a high risk of bias if they did not report the use of random sequence generation or allocation
concealment or if two other criteria were rated as having a high risk of bias. Studies were rated as having
unclear risk of bias if either random sequence generation, allocation concealment or three other criteria
had not been reported sufficiently well to be able to be assessed or if one criterion, other than random
sequence generation or allocation concealment, was rated as having a high risk of bias.
Data analysis
The primary analysis pooled data from the earliest follow-up time point after completion of the intervention.
When study reporting did not include the required summary data, these were, when possible, calculated
from the reported data. The most common example was calculation of the SD from the reported SE. For
cluster RCTs, when clustering was not taken into account during the analysis, the effective sample size was
calculated using the number of clusters.85,154
Data synthesis
Meta-analyses were conducted using random-effects models and the results were synthesised using the
inverse variance method in RevMan version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark).85
For characteristics of study populations (e.g. age), summary statistics were presented using the median and
range of the population average for each study. For trial characteristics (e.g. follow-up time period), summary
statistics were presented using the median and range across studies. For intervention characteristics (e.g.
intervention duration), summary statistics were presented using the mean and range across studies.
Treatment effects were summarised as the standardised mean differences (as outcome measures differed
between studies).85 Effect sizes were interpreted as follows: small, 0.2; moderate, 0.5; and large, 0.8.155
A positive effect size indicated a treatment effect in favour of exercise.
Heterogeneity was assessed using the chi-squared and I2 statistics.156 The interpretation of I2 values were
as follows: 0–40%, might not be important; 30–60%, moderate heterogeneity; 50–90%, substantial
heterogeneity; and 75–100%, considerable heterogeneity.85 When at least 10 studies were included in a
meta-analysis, publication bias was assessed using visual assessment of funnel plots and Egger’s test.157
Subgroup analysis
When there were at least two studies in each subgroup, subgroup analysis was undertaken on the following
factors: diagnosis [Alzheimer’s disease or any dementia (Alzheimer’s disease and non-Alzheimer’s disease)],
setting (community or residential), length of follow-up (< 20 or ≥ 20 weeks), intervention duration (< 4 or
≥ 4 months), weekly exercise dose (< 150 or ≥ 150 minutes) and intervention type (aerobic, resistance,
three-dimensional or mixed). Pooled effects were calculated within each subgroup and a chi-squared test
was performed to test for interactions.
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Sensitivity analysis
Sensitivity analyses were conducted in order to assess the robustness of the summary effect estimates for
global cognition. First, inclusion was restricted to studies with low overall risk of bias. Second, inclusion
was restricted to studies with an attention control arm only. Third, study results were included from the
follow-up time point furthest from the end of the intervention. Sensitivity analyses were undertaken when
two or more studies met the inclusion criterion.
Results
Database searches identified 2436 articles and additional searching within systematic reviews identified
another two articles. After removing duplicates, 1796 abstracts were screened and, from these, 193
full-text articles were assessed for eligibility. One study was published in Spanish158 and all others were
published in English. The flow of studies is presented in Figure 16.
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Summary of included studies
Characteristics of included studies are shown in Table 50. We included 19 studies, the majority of these
(13/19, 68%) sampled participants who had MMD, as most studies restricted eligibility to participants
with a sMMSE score of 10–26.158–163,165,167,169,170,172,173,DAPA RCT Eleven studies included participants with
Alzheimer’s disease only148,158,159,164–166,168,169,171–173 and eight included various types of dementia, including
Alzheimer’s Disease, or did not report the disease type.149,160–163,167,170,DAPA RCT Participants were either
recruited from community settings (9/19, 58%)148,158,164,165,167–169,173,DAPA RCT or nursing homes. Three studies
(3/19, 16%)164,165,172 had an upper-age restriction within their eligibility criteria, and for these studies the
average age of participants ranged from 70 to 85 years. For studies with no upper age restriction, the
average age of participants within each study sample ranged from 71 to 87 years (median 78 years).
The study with the median proportion of females had a 65% proportion in favour of women (n = 23/35)
and the range in proportions of women was 31–81%. The cognitive outcome measures used in each
study and those that were included in our analysis are presented in Table 51.
The majority of the interventions (10/19, 53%) were aerobic exercise alone.160,163,164,166,167,169–173 Seven studies
used a mixed-resistance and aerobic exercise.148,149,159,161,165,168,DAPA RCT One study used resistance exercise
only158 and one study used three-dimensional exercises (tai chi and yoga only).162 The interventions varied in
the mode of delivery. Some used fixed equipment (mainly in community settings), including treadmills and
static bicycles (n = 7/19, 37%),168,164–167,173,DAPA RCT and others used functional training activities, including
walking (n = 11/19, 58%).148,158,159,161,163,166,168,169,171,172,DAPA RCT The mode of delivery was not associated with
disease type. Across the 19 included studies, the average number of minutes of exercise per week was 142,
ranging from 60 to 300 minutes. Seven of the included studies149,158,160,163,168,172,DAPA RCT equalled or surpassed
the 150 minutes per week recommended by WHO’s guidelines.43 The interventions continued for an
average of 4.5 months, ranging from 1.5 to 12 months, and the majority were supervised. There was a
paucity in reporting of exercise intensity, only 2 out of 20 studies explicitly described the intensity.158,173
Both of these studies used moderate-intensity exercise.
Nine studies used a usual-care control arm158–160,164,166,167,170,171,DAPA RCT and the most common control group
treatment was educational initiatives (4/19).149,168,172,173 Five studies (n = 5/19, 26%)161,162,168,170,172 had three
or more treatment arms. For inclusion in the meta-analysis, it was necessary to select one of two eligible
control treatments for two studies (n = 2/19, 11%)170,172 and to select one of two eligible intervention
treatments for two studies (n = 2/19, 11%).161,168
Study quality
The sample sizes of the included RCTs are presented as a histogram in Figure 17. The sample sizes
ranged from 20 to 494 participants (median 75 participants). All studies assessed the effect of exercise
immediately following the intervention period. The median time from randomisation to first follow-up after
the interventions was 4 months from baseline (range 1.5–6 months). Eight studies reported further time points,
the longest of which was 12 months after randomisation (8 months after completion of the intervention).
The risk-of-bias ratings are given in Figure 18. The overall risk-of-bias scores indicated that the majority of
studies had a rating of unclear risk of bias (n = 15/19, 79%), three had a rating of low risk of bias and two
had a rating of high risk of bias. Most studies were judged as ‘unclear’ overall, as they did not report the
use of adequate random sequence generation or allocation concealment.
Effects on global cognition
The global cognitive outcomes analysis included 16 studies (n = 1420 participants). A pooled analysis
reported a small–medium effect size of 0.36 (95% CI 0.12 to 0.61) in favour of exercise, with evidence of
substantial heterogeneity (I2 = 76%). Additional analyses to explore heterogeneity found that using data
generated from the final follow-up assessments generated similar effects and levels of heterogeneity, as
did restricting studies to those using an attention control comparison. The pooled effect size in the strata
of studies that were assessed as having a low risk of bias was null (standardised mean difference 0.001,
95% CI –0.18 to 0.21, I2 = 13%) (Table 52).
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TABLE 50 Characteristics of included studies
Study Arms n Disease type Baseline cognition Control Intervention Intervention characteristicsa
Aguiar et al.159 2 40 Alzheimer’s
disease
Mild, moderate (sMMSE
score of > 12)
Usual care: rivastigmine
transdermal patch
delivering daily dose
Mixed: rivastigmine patch,
stretching, walking or resistance,
and balance
Type: D100, D101, D102, D105
Frequency: 80 minutes per week
Duration: 6 months
Arcoverde et al.160 2 20 Various Mild, moderate (sMMSE
score of ≥ 15)
Usual care: continuation
of previous medical
management
Aerobic: treadmill-based exercise Type: D102, D105
Frequency: 150 minutes per week
Duration: 6 months
Bossers et al.161 3 123 Various Mild, moderate (sMMSE
score of 9–23)
Attention: social
intervention
Mixed:
l I1: walking and strength
trainingb
l I2: walking and strength
training with social
intervention
Type: D101, D105
Frequency: 70 minutes per week
Duration: 3 months
Cheng et al.162 3 117 Not reported Mild, moderate (sMMSE
score of 10–24)
Attention: C1:
handicraftsb C2: Mahjong
Three-dimensional only:
yang-style tai chi
Type: D103
Frequency: 50–100 minutes per week
Duration: 2.5 months
DAPA RCT 2 494 Various Mild, moderate (sMMSE
score of > 10)
Usual care Mixed: cycling, sit-to-stand,
weighted belted and jackets,
bicep curls, dumb-bells
Type: D101, D105
Frequency: 150 minutes per week
Duration: 4 months supervised,
8 months unsupervised
Eggermont et al.163 2 97 Not reported Mild, moderate (sMMSE
score of 10–24)
Attention: social
intervention
Aerobic: indoor walking at
self-selected speed
Type: D100, D104
Frequency: 280 minutes per week
Duration: 6 months
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Study Arms n Disease type Baseline cognition Control Intervention Intervention characteristicsa
Hoffmann et al.164 2 200 Alzheimer’s
disease
Mild (sMMSE score of
> 19)
Usual care: treatment
within memory clinic
(medical or other)
Aerobic: ergometer static bicycle,
cross-trainer and treadmill
Type: D105
Frequency: 135 minutes per week
Duration: 4 months
Holthoff et al.165 2 30 Alzheimer’s
disease
Mild, moderate (CDR of
1–2)
Active: monthly clinical
visits and counselling to
increase physical activity
Mixed: seated pedalling action
and alternated passive, assisted
and resisted lower limb
movement
Type: D101, D105
Frequency: 120 minutes per week
Duration: 2.25 months
Kemoun et al.166 2 38 Alzheimer’s
disease
Mild, moderate, severe
(sMMSE score of < 23)
Usual care: no additional
input
Aerobic: articular mobilisation
and muscle stimulation then
walking, static cycling, balance/
endurance activity
Type: D100, D103 D105
Frequency: 105 minutes per week
Duration: 3 months
López et al.158 2 60 Alzheimer’s
disease
Mild, moderate (sMMSE
score of 10–24)
Usual care: telephone
follow-up
Resistance: warm up/stretching/
flexibility, walking, balance
exercises and moderate
cardiovascular resistance work
(aerobic) with word recall during
exercise
Type: D100, D101 D102
Frequency: 180 minutes per week
Duration: 3 months
Miu et al.167 2 85 Various Mild, moderate (sMMSE
score of 10–26)
Usual care: usual care
included drug treatment
Aerobic: treadmill, bicycle and
arm ergometer
Type: D102, D105
Frequency: 90 minutes per week
Duration: 3 months
Pitkälä et al.168 3 210 Alzheimer’s
disease
NR (clinical diagnosis) Active: usual care and
oral and written advice
about nutrition and
exercise
l Mixed: I1: group-based
exercise programme of
balance, endurance,
strength training, and
executive function exercisesb
l I2: home-based tailored
physical exercise programme
Type: D100, D101, D105
Frequency: 150 minutes per week
Duration: 1.5 months
Steinberg et al.169 2 27 Alzheimer’s
disease
Mild, moderate (sMMSE
score of ≥ 10)
Active: a home safety
assessment
Aerobic: daily exercise
programme with caregivers
Type: D104
Frequency: 90 minutes per week
Duration: 12 months
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TABLE 50 Characteristics of included studies (continued )
Study Arms n Disease type Baseline cognition Control Intervention Intervention characteristicsa
Stevens and
Killeen170
3 75 Not reported Mild, moderate (sMMSE
score of 10–22)
Attention: social
intervention
Usual care: no intervention
Aerobic: group-based aerobic
exercise programme
Type: D104
Frequency: 90 minutes per week
Duration: 3 months
Underwood et al.149 2 247c Various Mild, moderate, severe Active: usual care plus
depression awareness
training for care home
staff
Mixed: progressive aerobic and
resistance training activities
Type: D101, D105
Frequency: 180 minutes per week
Duration: 3.75 months
Venturelli et al.171 2 24 Alzheimer’s
disease
Moderate, severe
(sMMSE score of 5–15)
Usual care: leisure
activities
Aerobic: walking programme
with caregivers
Type: D105
Frequency: 120 minutes per week
Duration: 6 months
Venturelli et al.172 4 80 Alzheimer’s
disease
Moderate (sMMSE score
of 10–15)
C1 attention: cognitive
training (reality
orientation)
C2 usual care
Aerobic: walking programme
with caregiver
Type: D105
Frequency: 300 minutes per week
Duration: 3 months
Vreugdenhill et al.148 2 40 Alzheimer’s
disease
NR (clinical diagnosis) Active: telephone calls to
check on well-being
Mixed: daily home exercise
programme with carers
Type: D100, D101 D105
Frequency: 60 minutes per week
Duration: 12 months
Yang et al.173 2 50 Alzheimer’s
disease
Mild, moderate (sMMSE
score of 10–24)
Active: health education
intervention
Aerobic: cycling training at
moderate intensity (70% MHR)
Type: D105
Frequency: 120 minutes per week
Duration: 3 months
CDR, clinical dementia rating; NR, not reported.
a D100: gait, balance, co-ordination; D101: strength, resistance; D102: flexibility; D103: three-dimensional (tai chi); D104: general physical activity; and D105: endurance.
b Included in meta-analysis when multiple eligible treatment arms.
c Subgroup of eligible participants – not whole-study sample.
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TABLE 51 Details of cognitive outcome measures reported
Study
Outcome measure
Global cognition Language Memory Attention Executive function Praxis
Aguiar et al.159 sMMSEa
Arcoverde et al.160 sMMSE, CAMCOGa Verbal fluencya WMS-R digit span forward,a RAVLT TMT-Aa Stroop testa Clock drawing testa
Bossers et al.161 sMMSEa Verbal fluencya WMS-R digit span forward,a RBMT TMT-Aa Stroop testa Picture testa
Cheng et al.162 sMMSE, CDR-SOBa WMS-R digit span forward,a RAVLT
DAPA trial sMMSE, ADAS-Coga ADAS-Cog language subscale ADAS-Cog memory subscale ADAS-Cog praxis
subscale
Eggermont et al.163 Category fluency, letter fluency
Hoffmann et al.164 sMMSEa Category fluency,a letter fluency ADAS-Cog VMT delayed,a
ADAS-Cog VMT immediate
Stroop test, symbol
digit modalities testa
Holthoff et al.165 sMMSEa CERAD,a PVF (F-A-S)
Kemoun et al.166 ERFCa
López et al.158 sMMSEa List learning delayed recall,a
Rey complex figure test
TMT-A,a TMT-B
Miu et al.167 sMMSE, ADAS-Coga
Pitkälä et al.168 FIM-Coga Category fluencyb Clock drawing testb
Steinberg et al.169 BNT, Hopkins VLT
Stevens and Killeen170 Clock drawing test
Underwood et al.149 sMMSEa
Venturelli et al.171 sMMSEa
Venturelli et al.172 sMMSEa
Vreugdenhill et al.148 sMMSE, ADAS-Coga
Yang et al.173 sMMSEa
BNT, Boston Naming Test; CAMCOG, Cambridge Cognition Examination; CDR, Clinical Dementia Rating; CDR-SOB, Clinical Dementia Rating – Sum of Boxes; CERAD, Consortium to Establish
a Registry for Alzheimer’s Disease; ERFC, Rapid Evaluation of Cognitive Function; FIM-Cog, Functional Independence Measure – Cognitive subscale; PVF (F-A-S), Phonemic Verbal Fluency;
RAVLT, Rey Auditory Verbal Learning Test; RBMT, Rivermead Behavioural Memory Test; TMT-A, Trail Making Test A; TMT-B, Trail Making Test B; VLT, Verbal Learning Test; VMT, Verbal
Memory Test; WMS-R, Wechsler Memory Scale-Revised.
a Outcome measurement chosen for inclusion in meta-analysis.
b Reported in a separate article.
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Subgroup analysis on cognition: by exercise and disease type
Subgroup analysis found that the effects of exercise on global cognition differed significantly by disease
type (Figure 19). There was a large, statistically significant effect on global cognition in favour of exercise
(standardised mean difference 0.62, 95% CI 0.22 to 1.02) in studies that sampled participants with
Alzheimer’s disease only. However, the level of heterogeneity was substantial (I2 = 80%) and this effect
was not evident when limited to trials with low risk of bias (I2 = 13% in studies rated as having a low risk
of bias). We found no effect on global cognition in undifferentiated dementia populations.
Using data from patients with Alzheimer’s disease only within the DAPA trial, the overall effect size was
reduced but still remained statistically significant (Figure 20).
Subgroup analysis indicated that effects on global cognition were similar for aerobic exercise, resistance or
a combination of both (Figure 21). Similarly, there were no statistically significant differences in the effects
of exercise on cognition by setting, exercise duration or exercise dose. We could not conduct an analysis by
intensity, as few studies reported this information.
Effects on specific cognitive domains
The majority of studies reported global cognition scores only (n = 13/28, 46%). Some studies reported
outcomes in specific cognitive domains only (n = 4/28, 14%) and some reported a global outcome and other
independent measures of specific cognitive domains (n = 11/28, 39%). There was no evidence of clinically
worthwhile benefits or statistically significant effects for attention, memory, language, executive function or
praxis (see Table 53). There was lower heterogeneity in the effects of specific cognitive outcomes (I2 < 50%)
than for the measures of global cognition. For studies that reported both global and specific cognitive
measures there was a lack of concordance in the estimates of effect. Studies that measured both global
cognition and attention or memory found larger heterogeneity in the global measure and substantially less
in the specific measures (Figure 22).
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FIGURE 18 Risk-of-bias table. Low risk of bias is represented by+ (dark green), unclear risk of bias is represented by
? (green) and high risk of bias is represented by – (light green).
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Summary
The literature presents a confusing picture with very few well-conducted trials. When well-conducted trials
are available, these point to a negligible effect of exercise on cognition in people with dementia regardless
of the aetiology of the disease. The DAPA trial has been important in confirming these emerging trends
and is the largest study to date.
Although quite large in number, nearly half of the trials are single centre and extremely small in their
sample size. The quality of these studies is highly questionable, with most failing to report even the most
basic elements of recognised good practice in clinical trials. The inadequacies of simple randomisation,
even when the sample size is large, have been highlighted in a recent simulation study.174 Failure of
investigators to properly understand key concepts in reporting studies has also been reported.175 All of the
studies in the review are open label and protection against a range of biases associated with masked
assessment are inadequately addressed in all but a few trials.
A recent study has found temporal differences in global and specific cognitive decline within older adults and
recommends a focus upon specific rather than global physical and cognitive functioning.176 Our exploration
of a range of specific cognitive functions suggested no effect in memory, praxis, language or attention.
TABLE 52 Summary effects on all outcomes and subgroup effects on global cognition
Analysis description Studies (n) Participants (n)
Effect estimate [standardised
mean difference (95% CI)] I2 (%)
Primary analysis 16 1420 0.36 (0.12 to 0.61) 76
Secondary analysis (longest follow-up) 16 1358 0.37 (0.12 to 0.63) 78
Subgroup analysis
Condition p < 0.01
Alzheimer’s disease only 10 622 0.62 (0.22 to 1.02) 80
Alzheimer’s disease and
non-Alzheimer’s disease
6 798 –0.01 (–0.15 to 0.14) 0
Setting p = 0.85
Residential 6 342 0.41 (–0.07 to 0.90) 77
Community 10 1078 0.36 (0.06 to 0.66) 78
Follow-up period (weeks) p = 0.26
< 20 11 758 0.26 (0.02 to 0.50) 58
≥ 20 5 662 0.67 (0.00 to 1.33) 90
Intervention duration (months) p = 0.65
< 4 10 672 0.33 (0.02 to 0.64) 73
≥ 4 6 748 0.46 (–0.00 to 0.92) 82
Intervention dose (minutes) p = 0.12
< 150 10 1049 0.20 (–0.03 to 0.44) 63
≥ 150 6 371 0.71 (0.11 to 1.30) 84
Intervention type p = 0.17
Aerobic only 8 541 0.48 (0.04 to 0.92) 81
Mixed 6 745 0.14 (–0.07 to 0.36) 33
Sensitivity analysis
Attention control 2 146 0.05 (–0.28 to 0.37) 0
Low risk of bias 2 569 0.01 (–0.18 to 0.21) 13
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Standard mean difference
IV, random, 95% CI
Standard mean difference
IV, random (95% CI)Study or subgroup Mean SD Total Mean SD
Exercise Control
Total Weight (%)
– 4 – 2 0 2 4
Favours control Favours exercise
AD
Aguiar 2014159
Hoffmann 2017164
Holthoff 2015165
Kemoun 2010166
López 2015158
Pitkälä 2013168
Venturelli 2011171
Venturelli 2016172
Vreugdenhil 2012148
Yang 2015173
Subtotal (95% CI)
Heterogeneity: τ2 = 0.31; χ2 = 46.10, df = 9 (p < 0.00001); I 2 = 80%
Test for overall effect: z = 3.02 (p = 0.003)
AD and non-AD
Arcoverde 2014160
Bossers 2015161
Cheng 2014162
DAPA trial
Miu 2008167
Underwood 2013149
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 4.99, df = 5 (p = 0.42); I 2 = 0%
Test for overall effect: z = 0.08 (p = 0.94)
Total (95% CI)
Heterogeneity: τ2 = 0.17; χ2 = 62.78, df = 15 (p < 0.00001); I 2 = 76%
Test for overall effect: z = 2.89 (p = 0.004)
Test for subgroup differences: χ2 = 8.22, df = 1 (p = 0.004); I 2 = 87.8%
21
23.9
21.99
30.38
15.17
16.44
12
13.6
– 18.5
22.8
73.3
14.62
6.05
– 22.9
18.47
12.57
4.7
3.4
2.09
7.66
1.92
5.96
2
1.9
9.8
2.8
10.9
5.61
5.31
11.6
5.27
6.3
17
102
15
16
24
61
11
20
20
25
311
10
36
39
298
36
53
472
783
21.1
23.9
21.28
23.23
13.06
15.42
6
13.8
– 30.6
19.5
12.8
5.73
5.03
– 22.4
19.65
11.73
4.6
3.9
2.09
8.37
1.16
5.7
2
1.9
17.9
3.4
12.8
5.73
5.03
9.4
3.97
6.54
17
88
15
15
36
65
10
20
20
25
311
10
36
35
145
49
51
326
637
5.5
8.3
5.2
5.0
6.2
7.9
2.6
5.9
5.7
6.0
58.2
4.1
7.0
7.1
8.8
7.2
7.6
41.8
100.0
– 0.02 (– 0.69 to 0.65)
0.00 (– 0.29 to 0.29)
0.33 (– 0.39 to 1.05)
0.87 (0.13 to 1.61)
1.38 (0.80 to 1.96)
0.17 (– 0.18 to 0.52)
2.88 (1.59 to 4.17)
– 0.10 (– 0.72 to 0.52)
0.82 (0.17 to 1.47)
1.04 (0.45 to 1.64)
0.62 (0.22 to 1.02)
0.77 (– 0.15 to 1.68)
0.13 (– 0.33 to 0.59)
– 0.03 (– 0.49 to 0.43)
– 0.05 (– 0.24 to 0.15)
– 0.26 (– 0.69 to 0.18)
0.13 (– 0.25 to 0.51)
– 0.01 (– 0.15 to 0.14)
0.36 (0.12 to 0.61)
FIGURE 19 Forest plot: global cognition by type of dementia.
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Standard mean difference
IV, random, 95% CI
Standard mean difference
IV, random (95% CI)Study or subgroup Mean SD Total Mean SD
Exercise Control
Total Weight (%)
– 4 – 2 0 2 4
Favours control Favours exercise
Aguiar 2014159
DAPA trial
Hoffmann 2017164
Holthoff 2015165
Kemoun 2010166
López 2015158
Pitkälä 2013168
Venturelli 2011171
Venturelli 2016172
Vreugdenhil 2012148
Yang 2015173
Total (95% CI)
Heterogeneity: τ2 = 0.28; χ2 = 60.68, df = 10 (p < 0.00001); I 2 = 84%
Test for overall effect: z = 2.83 (p = 0.005)
21
– 23.5
23.9
21.99
30.38
15.17
16.44
12
13.6
– 18.5
22.8
4.7
11.8
3.4
2.09
7.66
1.92
5.96
2
1.9
9.8
2.8
17
240
102
15
16
24
61
11
20
20
25
551
21.1
– 21.8
23.9
21.28
23.23
13.06
15.42
6
13.8
– 30.6
19.5
4.6
9.5
3.9
2.09
8.37
1.16
5.7
2
1.9
17.9
3.4
17
126
88
15
15
36
65
10
20
20
25
437
8.6
11.7
11.4
8.2
8.1
9.3
11.0
4.8
9.0
8.8
9.2
100.0
– 0.02 (– 0.69 to 0.65)
– 0.15 (– 0.37 to 0.06)
0.00 (– 0.29 to 0.29)
0.33 (– 0.39 to 1.05)
0.87 (0.13 to 1.61)
1.38 (0.80 to 1.96)
0.17 (– 0.18 to 0.52)
2.88 (1.59 to 4.17)
– 0.10 (– 0.72 to 0.52)
0.82 (0.17 to 1.47)
1.04 (0.45 to 1.64)
0.52 (0.16 to 0.88)
FIGURE 20 Forest plot: global cognition – Alzheimer’s disease only.
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Standard mean difference
IV, random, 95% CI
Standard mean difference
IV, random (95% CI)Study or subgroup Mean SD Total Mean SD
Exercise Control
Total Weight (%)
– 4 – 2 0 2 4
Favours control Favours exercise
73.3
23.9
30.38
18.47
12
13.6
22.8
15.17
21
14.62
– 22.9
21.99
16.44
12.57
– 18.5
10.9
3.4
7.66
5.27
2
1.9
2.8
1.92
4.7
5.61
11.6
2.09
5.96
6.3
9.8
10
102
16
36
11
20
25
220
24
24
17
36
298
15
61
53
20
500
63.8
23.9
23.23
19.65
6
13.8
19.5
13.06
21.1
13.88
– 22.4
21.28
15.42
11.73
– 30.6
12.8
3.9
8.37
3.97
2
1.9
3.4
1.16
4.6
5.73
9.4
2.09
5.7
6.54
17.9
10
88
15
49
10
20
25
217
36
36
17
36
145
15
65
51
20
349
4.5
8.8
5.5
7.8
2.9
6.3
6.5
42.3
6.7
6.7
6.0
7.5
9.3
5.6
8.4
8.1
6.1
51.0
100.0
0.77 (– 0.15 to 1.68)
0.00 (– 0.29 to 0.29)
0.87 (0.13 to 1.61)
– 0.26 (– 0.69 to 0.18)
2.88 (1.59 to 4.17)
– 0.10 (– 0.72 to 0.52)
1.04 (0.45 to 1.64)
0.58 (0.04 to 1.12)
1.38 (0.80 to 1.96)
1.38 (0.80 to 1.96)
– 0.02 (– 0.69 to 0.65)
0.13 (– 0.33 to 0.59)
– 0.05 (– 0.24 to 0.15)
0.33 (– 0.39 to 1.05)
0.17 (– 0.18 to 0.52)
0.13 (– 0.25 to 0.51)
0.82 (0.17 to 1.47)
0.12 (– 0.05 to 0.29)
0.40 (0.14 to 0.66)
Aerobic only
Arcoverde 2014160
Hoffmann 2017164
Kemoun 2010166
Miu 2008167
Venturelli 2011171
Venturelli 2016172
Yang 2015173
Subtotal (95% CI)
Heterogeneity: τ2 = 0.41; χ2 = 35.97, df = 6 (p < 0.00001); I 2 = 83%
Test for overall effect: z = 2.09 (p = 0.04)
Resistance only
López 2015158
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 4.70 (p < 0.00001)
Mixed
Aguiar 2014159
Bossers 2015161
DAPA trial
Holthoff 2015165
Pitkälä 2013168
Underwood 2013149
Vreugdenhil 2012148
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 7.51, df = 6 (p = 0.28); I 2 = 20%
Test for overall effect: z = 1.36 (p = 0.17)
Total (95% CI)
Heterogeneity: τ2 = 0.18; χ2 = 62.07, df = 14 (p < 0.00001); I 2 = 77%
Test for overall effect: z = 2.97 (p = 0.003)
Test for subgroup differences: χ2 = 18.39, df = 2 (p = 0.0001); I 2 = 89.1%
FIGURE 21 Forest plot: global cognition by type of exercise.
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– 2 – 1 0
I 2 = 0%
1 2
Attention
(a)
Study or subgroup
Arcoverde 2014160
Bossers 2015161
López 2015158
Total (95% CI)
Favours control Favours exercise
– 2 – 1 0
I 2 = 82%
1 2
Global
Favours control Favours exercise
– 2 – 1 0
I 2 = 54%
1 2
Language
(b)
Study or subgroup
Arcoverde 2014160
Bossers 2015161
DAPA trial
Hoffmann 2017164
Holthoff 2015165
Total (95% CI)
Favours control Favours exercise
– 2 – 1 0
I 2 = 0%
1 2
Global
Favours control Favours exercise
– 2 – 1 0
I 2 = 0%
1 2
Memory
(c)
Study or subgroup
Arcoverde 2014160
Bossers 2015161
Cheng 2014162
DAPA trial
Hoffmann 2017164
Total (95% CI)
Heterogeneity: τ2  
Test for overall effect:
Favours control Favours exercise
– 2 – 1 0
I 2 = 0%
1 2
Global
Favours control Favours exercise
– 2 – 1 0
I 2 = 34%
1 2
Praxis
(d)
Study or subgroup
Arcoverde 2014160
Bossers 2015161
DAPA trial
Total (95% CI)
Favours control Favours exercise
– 2 – 1 0
I 2 = 37%
1 2
Global
Favours control Favours exercise
– 2 – 1 0
I 2 = 7%
1 2
Executive
(e)
Study
Arcoverde 2014160
Bossers 2015161
Hoffmann 2017164
Total (95% CI)
Favours control Favours exercise
– 2 – 1 0
I 2 = 20%
1 2
Global
Favours control Favours exercise
FIGURE 22 Forest plot: global and specific outcomes reported within same trials.
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Chapter 7 Discussion
An overview of the study findings and key messages
The discussion focuses on the interpretation of the findings, the internal and external validity of the trial
and associated analysis, the implications for clinical practice in the NHS and further research.
The DAPA trial was a definitive, pragmatic, rigorous, well-conducted trial to estimate the effect of a
moderate- to high-intensity exercise intervention on cognitive and functional decline in community-dwelling
adults with MMD. The trial included a large sample who have demonstrated good intervention compliance
and follow-up rates over a moderate to long follow-up time period (12 months). Our primary ITT analysis
reports a small, statistically significant, negative effect upon cognitive impairment. There were no significant
effects upon any of the secondary outcomes regarding function and quality of life for people with MMD.
Neither was there an effect upon caregiver burden nor quality of life. In summary, the exercise-based
intervention did not change outcomes for participants or carers and may have made cognition slightly worse.
A secondary aim included updating and expanding a systematic review into this topic area. Upon
completion of our review, we were surprised that even the most recent publications examining exercise
interventions for people with dementia were rated as having unclear or high risk of bias. Our review’s
primary analysis suggested that there is a small to moderate positive effect upon cognitive impairment
within this population. However, this assumption is based on a less than rigorous evidence base.
The key message that emerged from the quantitative and qualitative results is that exercise may worsen
cognitive decline and does not change functional outcomes, quality of life or carer burden. However,
structured exercise sessions do seem to bring enjoyment and respite to people living with this incredibly
challenging condition and also to their carers.
External validity and generalisability of the findings
The baseline descriptive analyses demonstrated that we have recruited a representative sample of
community-dwelling adults with MMD to satisfy our sample size estimate calculation, allowing us to
perform our prespecified statistical analyses with confidence on a sample that is largely representative of
the UK dementia population. We recruited rather more sites than the seven sites originally specified in the
protocol because of the need to spread the cost and resource implication of the intervention across more
health sites, and because of the challenges of recruitment.
The intervention and control groups were well balanced at baseline. The baseline and demographic data
of our recruited participants reflect the patterns observed in the general dementia population. Our sample
included slightly higher Alzheimer’s disease diagnoses (78.8%) than that reported globally (62%).3,177
Consequently, our sample had a smaller proportion of people with vascular types (acute, multi-infarct,
mixed, other and unspecified) (11.3%) than reported globally (20%) or other aetiologies (Pick’s disease,
Parkinson’s disease, other specified and unspecified) than reported globally (20%).
Dementia prevalence is reported to be equal between genders.2 Our sample had a ratio of roughly 60 : 40
(male to female), which seems appropriate, especially when considering the demographics collected across
the studies included in our systematic review, in which the percentage of females in the study populations
ranged from 31% to 81%. The CACE analyses indicated that men were more likely to comply with the
intervention than women. The age of our participants spanned across early- to late-onset dementia
(≥ 65 years old); however, the mean (77.4 years) and median (78.3 years) both rested at late-onset dementia.
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When compared with the included studies from our systematic review, when there was no age restriction,
the age of participants was reported to range from 68 to 87 years, with a median of 77 years. Our sample
appears to be representative.
The majority of our participants were married (73.7%); however, the next largest group were those who
were widowed (17.4%). When combining those who were widowed, divorced or single (i.e. without a
long-term partner), this equated to 23.6%. The majority of participants were living with their partner
(75.5%) and nearly 20% of the participants lived alone. This is slightly lower than the observation that,
prior to 2002, one-third of people with dementia live on their own in the UK, as reviewed in Miranda-
Castillo et al.178 The qualitative chapter findings (see Chapter 4) exemplified the importance of considering
practical considerations such as travelling to and from structured exercise sessions. If a person is single
and living alone, they may lack the motivation and practical logistics to attend an exercise session. When
examining the demographic data from those who withdrew from the study, there was no pattern to
suggest that people who were without a long-term partner and/or who were living alone were more likely
to drop out or be lost to follow-up. However, the CACE analyses suggest that participants were more likely
to comply with the intervention if they were not living alone.
Our sample seems to mirror the ethnic proportions reported in the second report of the Cognitive
Functioning and Ageing Studies for dementia patients in the UK.7 The Cognitive Functioning and Ageing
Studies report identified that, in 2011, 3.7% of people with dementia in the UK were from black, Asian
and minority ethnic groups and our sample included 3.2% of participants from these groups.
Our population sample has a mean age of leaving school of 16 years, with only 16.4% having a degree
(or equivalent) level of education and the majority having no qualification (30%). This is similar to the
Office for National Statistics census data,179 which show that people > 65 years in UK are more likely to
have no qualifications (52.9%) than any other age group. However, the age range from 16 to 64 years
shows that 30% of people have a degree, or equivalent, level of education.
Our inclusion criteria stipulated that participants must have probable dementia, classified by clinician
(according to DSM-IV), which was mild to moderate in severity (sMMSE score of > 10). The systematic
review (see Chapter 6) found that the majority of included studies (13/28) classified the severity of their
study population as mild to moderate (sMMSE score of 10–26). The trial sample’s sMMSE scores range
from 11 to 30 (out of a possible maximum score of 30), with the higher scores indicating less impairment.
This range crosses the NICE guideline boundaries of mild dementia into MCI (a score of 26 on sMMSE).67
The mean sMMSE score was 21.9 (SD 4.6), which is classified as mild dementia severity. This is echoed
with the baseline ADAS-Cog scores, which find that there is a mean score of 20.9, with a large range
from 5.3 to 52 (out of a possible 70), with a higher score indicating more impairment. These scores are
indicative rather than confirmatory, and expert clinical opinion explains that many people with early-stage
dementia are likely to have mild impairment scores yet still have the disease. The quantitative description
demonstrates that our participants have a broad range in their level of cognitive impairment. Variation in
dementia symptom was witnessed in the qualitative chapter (see Chapter 4), in which one participant
clearly explained that he did not identify with the other people in his exercise classes and that their
symptoms were more severe than his.
The sample demonstrates the expected dementia population trend of a 4-point ADAS-Cog deterioration
over the 12-month79 study period, which demonstrates that the ADAS-Cog measurement is detecting
normal deterioration but that it has still not detected a change in progression as a result of the intervention.
We examined the subdomains of the ADAS-Cog composite score. The sample mean scores present
substantial memory impairment but the mean scores for language and praxis functions do not seem to
indicate, as yet, a great affect. The ability to understand commands and communicate (language) and
synthesise and sequence motor movements (praxis) remains relatively intact in our sample and these seem
to be functions that could be necessary to enable people to participate in an intervention such as exercise.
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The outcome measures for the quality of life of the participants were completed by the participants and,
when possible, their carers (proxy). The ratings of the carers were significantly lower than the participants’
own ratings, indicating that the carers perceive the participants to have a worse quality of life than the
participants believe themselves to have. This lack of patient–carer agreement on quality-of-life outcomes is
well established in dementia populations180 and in other chronic conditions.181 Carer’s ratings of the quality
of life of people with dementia is likely to be influenced by the type of carer relationship (spouse or child),
patient’s mood status and the participant’s activities of daily living.180 The majority of our carers were
spouses, who tend to give better QoL scores for their spouse than a child would for their parent. We were
able to follow the validated scoring guidelines of all measures and, when appropriate, obtained good
completion rates from the person with dementia. The conclusions of our study would not have been
altered had we chosen to use proxy responses for variables such as the EQ-5D-3L. Falls were a secondary
measure and we did not use a falls calendar, which is the gold standard method of collecting falls data,182
because of the already substantial commitment that people with dementia and their carers were making
to the study. Any under or overestimation of falls that resulted from the carer recall should be randomly
distributed across the sample.
In summary, our sample appears to be largely representative of the general dementia population in terms
of demographics. The sample also reflects those from previously published exercise intervention trials in
this target group.
Our findings are based on a sample that is representative of the population likely to engage with exercise
as an intervention for dementia. In comparison to previous trials, we recruited a substantially larger
sample size, used a sensitive measure of cognitive impairment and maintained high levels of follow-up.
We used prospective registration and robust allocation concealment, independent computer-generated
randomisation and masked outcome assessment.
Participant follow-up
For such a large and relatively long-term (12-months) trial, we achieved a good follow-up rate. The majority of
participants who withdrew from the intervention and control arms did so between the point of randomisation
and the 6-month follow-up. When examining the demographic data of those who remained in the trial, those
who withdrew, those who were lost to follow-up and those who died during the trial (at 6 and 12 months’
follow-up), there are no concerning trends. The characteristics of the sample providing data were well
matched.
When examining baseline cognitive impairment and QoL scores, those who died during the trial were,
as to be expected, older and had greater impairment and lower QoL ratings than those who did not die.
When examining those who withdrew or were lost to follow-up, they had similar cognitive impairment
scores (sMMSE and ADAS-Cog) to those who remained in the trial but their QoL ratings (EQ-5D-3L and
QoL-AD scores) indicated poorer quality of life.
The individual variation in participant ability and the challenges that this poses to the therapists leading
the sessions and to exercise prescription was reflected in the qualitative interviews. Some participants
felt that the therapists were overly cautious and underestimated their physical abilities, whereas some
other participants felt the exercises were uncomfortably hard in some situations. A key finding from the
qualitative data was the importance of maintaining a positive working therapeutic relationship and open
communication. Without this, motivation deteriorates, expectations and capabilities can be misunderstood
and compliance will deteriorate. Overall, the participants, their carers and the physiotherapists found this
to be a rewarding programme in many different ways. When asked about whether or not the intervention
had an effect, the response of participants in the qualitative study suggested that it was not improving
their cognitive functioning but that it was improving physical fitness/strength and emotional well-being.
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Some of the benefits of the intervention were attributed to enjoying the sociality of performing exercises
in a group. The data show that the mean number of participants per group was six people and only one
group had as few as three people per group.
About half of the cohort was able to maintain physical activity after cessation of the intervention.
Participant compliance
Compliance with exercise was good and 65% of participants achieved between 75% and 100% compliance
to the intervention. When we examined the CACE analysis, we see that the people who were not compliant
were more likely to be women and people living alone. Men seemed to really appreciate the physical
challenge of using the bikes and carers were very important in helping to get people to the classes. We did
not find any other statistically significant differences between the usual-care group, the intervention
compliers and the intervention non-compliers on any descriptive or outcome measurements.
Critique of the methods
The trial was designed to test an intervention that could be delivered in routine practice. The groups were
feasible and the number of AEs was small. From a physiological perspective, the protocol improved physical
fitness parameters and walking speed within a range that would be considered worthwhile.53,61,62 The sample
was diverse in baseline fitness, as selection was based predominantly on cognition. The exercise protocol
was able to account for higher levels of fitness but this was challenging. Our prespecified subgroup analyses
suggest that there is no hidden effect within the sample, for example related to baseline mobility, cognition or
broad classification of underlying disease. The choice of exercises was also driven by the underlying hypothesis
of targeting cognitive impairment. At the time of designing the intervention, most evidence/theory supported
aerobic and strength conditioning as the prime pathways to target. We did not include cognitive training or
psychomotor training (for example training reaction time) to ensure that the effects of the intervention could
be attributed to aerobic and strength training disease pathways. There was no evidence to suggest that
balance exercise could modify cognition at the time of developing the intervention and, therefore, it was not
included. Although we did not randomise the behavioural elements underpinning the programme and cannot
make robust conclusions about the effects of these elements, the good session compliance suggests that the
behavioural support was adequate, at least during the first 4 months of the programme.
We monitored the dose delivered through session records. In contrast to similar high-intensity interventions
that improve muscle function in older people without dementia,63 we started with a higher initial strength
challenge and then progressed participants at a similar rate. The strength dose was higher than that
achieved in residential care settings, in which a similar intervention was found to be ineffective in changing
cognitive and BADLS status but improved balance.183,184 Hence, it seems likely that we have delivered sufficient
dose. Greater compliance with session attendance was associated with further reduction in cognition and even
higher doses may incur greater harm.
The results of this trial disagree with those of many small single-centre studies. Study quality is likely to play a
role, with many previous studies having uncertain allocation concealment and very poor levels of masking.
There are some limitations to our work. We collected physical parameters only in the exercise arm and, hence,
cannot conclude definitively that the intervention improves physical fitness. Subgroup analyses may be
underpowered, as the proportion of people in the various strata was not distributed optimally,57,183,184 but the
direction of effect estimates support our conclusions. In the absence of definitive guidance and rationale, we
used a mixed exercise programme, and it may be that longer periods of a single training modality may be
effective. However, the feasibility of getting participants to sustain a single type of activity through an entire
session is improbable. We did not include an attention control as our intention was for a pragmatic trial.
Participants and carers were not masked to allocation and this is an unavoidable limitation.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
On a positive note, the qualitative study suggested that in the small sample interviewed, people were
able to exercise safely and they appeared to enjoy the experience and it improved confidence in movement
and self-efficacy. We found no evidence of improved mood or quality of life, suggesting that any perceived
benefits might be either positive reporting or transitory.
The changes in physical fitness did not translate into improvements in transfers, mobility or functional
activities. To achieve these outcomes may require greater motor relearning than we included in our
programme. Falls were not reduced and this may be because we did not specifically target balance within
the intervention. Carers may also be reluctant to encourage people to re-establish functional activities
through fear of their relative falling or because of well-established caring roles. Although the quality of
life of carers was not different from the general population, the carer burden was high. Two sessions per
week may have provided some respite, but these are likely to be insignificant in comparison with other
behavioural challenges.
We updated and expanded a systematic review in this topic area as part of the project. The quality of
the reviewed studies was very low and the literature was dominated by small single-centre studies.
A review published during the trial suggested that the effect of exercise on cognition may be specific to
Alzheimer’s disease.20 We were unable to support this finding within the cohort of DAPA trial patients
with Alzheimer’s disease only, which is surprising given the size of the overall effect reported across pooled
studies. Addition of the DAPA trial estimates to the systematic review reduced the estimated effect in
people with Alzheimer’s disease but did not eradicate it. There remain a number of concerns with the
synthesis of the literature for this indication and intervention. There are multiple small studies of low quality.
The chance of overestimating effects or conducting a biased experiment are high in these situations. The
level of heterogeneity reported in global measures of cognition was also well above accepted levels. When
we examined effects in specific areas of cognitive impairment, heterogeneity was much lower and effects
were null. There is some preliminary evidence that supports different dementia types (Alzheimer’s disease or
vascular dementia) influencing different specific cognitive functions (language or executive function) to
varying degrees.185
Another important finding was that this high-intensity exercise intervention was well tolerated by
participants. Participants’ carers and the physiotherapists delivering the intervention felt it was a suitable
structured activity for people with dementia. Despite the intervention group sample displaying a high level
of comorbid conditions, including nearly 50% living with a heart/circulatory condition and over 50% living
with joint or muscle pain, there were remarkably few AEs.
It was a disappointing finding that there were no changes to carers’ quality of life, considering the
enjoyment and benefits reported in the qualitative study. However, on reflection of the bigger picture, we
can see that the burden on carers is unrelenting. Carers may have found these two sessions per week to be
a respite but they then have to cope with a range of challenges throughout the day and night. It is also
worth considering that the quality-of-life measurements were taken at 6 and 12 months post intervention.
So although they may have enjoyed the intervention when it was running, the continued deterioration of
their loved one (an average of 4 ADAS-Cog points per year79) will undoubtedly compound their burden and
the deterioration of their quality of life. It could be argued that a longer period of exercise classes may have
had a better effect, but there was no signal of this within a time period that is consistent with physiological
change in muscles and the cardiovascular system. Longer-term provision will be more costly and, hence,
there is a need to demonstrate even greater benefit to achieve effects at the current levels of willingness
to pay. There is also the possibility that longer periods of moderate- to high-intensity exercise may incur
greater detriment to cognitive function.
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Cost-effectiveness
The data collected in the DAPA trial strongly support a hypothesis that exercise therapy in addition to usual
care, when compared with usual care alone, is not cost-effective.
Future research questions
This was a well-conducted and large trial with good compliance with a moderate- to high-intensity dose
of exercise. Follow-up rates were good and the sample was representative of those likely to participate.
The logistical difficulties and cost of running sessions was substantial. Motor relearning and ability to
maximise functional gains from physical fitness are a suggested focus for future research.
DISCUSSION
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Appendix 1 Health Technology Assessment
correspondence regarding 4-month restriction on the
intervention design
29 January 2010 
Dear Professor Lamb, 
09/80/04 Community physical activity programme for people with mild 
to moderate dementia (DAPA - Dementia And Physical Activity) 
Following the HTA Commissioning Board meeting on 7th January 2010. I 
am pleased to inform you that the board has asked me to invite you to 
submit a full proposal. 
A frequent observation of Commissioning Board members is that 
applicants do not address the commissioning brief. I therefore urge you to 
refer to the commissioning brief as you formulate your full proposal to 
ensure that you specifically address the research question(s) posed. A copy 
of the relevant brief is attached. 
The board considers how well projects fulfil the following criteria when 
assessing proposals. The criteria include: 
• How well the proposal addresses the issues outlined in the 
commissioning brief; 
• The quality of the methodology and science presented; 
• The extent to which the group has the necessary skill 
mix and/or experience to complete the project; 
• There is evidence of the necessary project management 
and infra-structure to enable delivery of the project; 
• How well the estimated recruitment rates are explained and justified; 
• The costs of the research represent good value for money. 
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 In addition to any individual comments provided, the board would 
like you to consider the following comments when preparing your 
full proposal: 
• The board felt that there was insufficient information about patient and 
public involvement. 
• The board would like further consideration to be given as 
to whether it is economically feasible for the exercise intervention to be 
delivered over 6 months. 
In the meantime, there are a number of actions and issues to consider when 
preparing your full proposal: 
If you need any clarification of the above comments, please send your 
queries to me via email: htacmsng@soton.ac.uk. 
 
• Project timings 
Please plan to start your project on the 1st of a month and give a realistic start date 
to allow for staff recruitment etc., bearing in mind that full proposals will be 
considered by the HTA Commissioning Board in July 2010 and a resubmission or 
revision may be required 
subsequently. 
• NHS Costs 
Applicants should note that it is in their interests to undertake a thorough, realistic 
and accurate costing of their proposal. The HTA programme expects that the costs 
identified should not differ between outline and full proposal stage. Any differences 
must be clearly explained and fully justified. The Commissioning Board will pay 
close scrutiny to any increases. 
To help you, I enclose the following documents: 
• A copy of ‘EL (97)77: Non-Commercial Externally Funded 
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 R&D in the NHS: Guidance for NHS Researchers’ and HSG(97)32 Responsibilities 
for meeting Patient Care Costs associated with Research and Development in the 
NHS 
• A copy of ‘Attributing revenue costs of externally funded non-
commercial research in the NHS ’. 
• NHS Costs Help Sheet – hints for applicants submitting primary 
research full proposals. 
Please read these enclosures carefully before completing the electronic form 
For more advice on NHS costs and funding, contact Ms Trudi 
Simmons (email: trudi.simmons@dh.gsi.gov.uk.) 
• Please supply a flow diagram illustrating the study design and the flow 
of participants. The HTA Commissioning Board values the inclusion of such a 
diagram to explain the design of your proposed study. Applicants proposing a RCT 
should refer to the CONSORT statement and website for guidance 
(http://www.consort-statement.org). 
Submitting your full proposal 
The HTA programme requires you to submit your application form and detailed 
project description in time to reach our offices by 26 March 2010. Please note 
that we cannot grant any time extensions beyond this deadline. The application 
and guidance notes can be found at 
http://www.hta.ac.uk/funding/standardcalls/howtoapply.shtml  
Full proposals must be submitted electronically and as hard copies. 
• Submit your application electronically, using the Submit 
button on the last page of the web form. 
• Two paper copies of your proposal, one of which must 
contain all appropriate original signatures should be sent to us at the address 
below. 
The HTA Commissioning Team, NETSCC 
Alpha House, Enterprise Road, 
Chilworth Science Park, 
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 Chilworth, Southampton 
SO16 7NS 
Please note that the signed paper copies should be received by the 
office no later than a maximum of 1 week after the deadline. The paper 
copies must be identical to the electronic application, as no further changes 
can be made after the deadline. 
Further assistance in completing your application can be found in our Frequently 
Asked Questions (FAQs) available online at: 
http://www.hta.ac.uk/funding/troubleshooting/index.html, or see our detailed 
guidance notes. For further guidance please contact the team on the email address 
or telephone number above. 
Finally, also enclosed is a checklist, which we would be grateful if you would 
complete and send in with your full application. 
Yours sincerely 
 
Programme Manager 
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Appendix 2 Pre-exercise assessment form
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Appendix 3 Suppliers of exercise equipment
Standard materials list for intervention Manufacturer Manufacturer’s location
Marker cones The Safety Supply Company Wembley, UK
Lap counter Silver-Line Tools Ltd Yeovil, UK
Heart rate monitor Polar Electro (UK) Ltd Warwick, UK
15-m tape measure Silver-Line Tools Ltd Yeovil, UK
Chair cushions Fitness-Mad [The Mad Group (HQ) Ltd] Evesham, UK
Fully weighted belts (mixed sizes) Rehabus Lerum, Sverige
Fully loaded 20-lb weighted vests All Pro Exercise Products Inc. Longboat Key, FL, USA
Handweights Fitness-Mad [The Mad Group (HQ) Ltd] Evesham, UK
Stopwatch Scientific Laboratory Supplies Ltd Hessle, UK
Grey crates (× 8) The Hill Company West Thurrock, UK
Flatbed trolley (× 2) Key (Family member of Manutan) Verwood, UK
Gel seat cover Selle Royal Pozzoleone, Italy
Portable bike 3D Innovations LLC Greeley, CO, USA
Recliner bike Powerhouse Fitness Glasgow, UK
Upright bike Powerhouse Fitness Glasgow, UK
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Appendix 4 Quality control forms for sites
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
175
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
DOI: 10.3310/hta22280 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 28
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lamb et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177

Appendix 5 Item response theory analysis
We made an analysis of the DAPA trial data using IRT analysis. We assumed that cognitive impairmentis a continuous score, such that higher scores on the ADAS-Cog denote higher levels of impairment.
In the original IRT analysis of the ADAS-Cog, Verma and Markey186 found that cognitive impairment is
composed of three subtraits: memory, language and praxis. This model is consistent with clinical opinion.
To create the ADAS-Cog-IRT, the ADAS-Cog items were first assessed for use in an IRT analysis. This consisted
of examining item-level frequency tables for all data collected and checking for response categories that were
sparsely used. Dichotomous items with low response rates were dealt with as follows:
l commands – ceiling and fist items were combined to create ‘easy’ commands owing to their low
incorrect response rate
l construction – circle and rectangle were combined to create ‘easy’ construction
l naming objects:
¢ flower, bed, whistle and pencil were combined into ‘high frequency’
¢ rattle, mask, scissors and comb were combined into ‘medium frequency’
l naming fingers – the thumb item was removed owing to the low number of incorrect responses
l orientation – the name item was removed owing to the low number of incorrect responses.
For polytomous items, categories with low response frequencies were merged together, and for the word
recall trials, the mean score was used (rounded to the nearest integer). Patients with any incomplete
responses to the remaining ADAS-Cog items were then removed from further analyses.
In line with the methods of Verma and Markey,186 the two-parameter model was fitted to all dichotomous
items apart from orientation – season; naming objects – funnel; and constructional praxis – cube, which were
fitted with the three-parameter model. The two-parameter models consist of parameters of characteristic
(slope) and difficulty (intercept). The characteristic of each item represents the sensitivity of the item to detect
different abilities, with lager characteristics (greater slopes) being able to detect more subtle differences in
abilities. The item difficulty (intercept or location) represents the point where half of the population affirm the
item, and is the point at which the item slope is steepest. For the three-parameter model, the third parameter
represents ‘guessing’, or the fact that respondents of lower ability may randomly guess which answer is
correct, rather than having the ability to pass the item. For the DAPA study, it represents items for which
persons with low levels of cognitive impairment find the item difficult, even though their impairment is low
enough that they should not have affirmed the item.
The graded response model was used for all polytomous items. The graded response model fits an item
response curve (probability of affirming the item) to each possible item response separately. The responses
are assumed ordered, but not at fixed intervals. This captures the fact that for each item, the interval of
cognitive impairment between ‘mild’ and ‘moderate’ is not necessarily the same as the difference in
cognitive impairment between ‘moderate’ and ‘moderately severe’.
Rather than fitting a novel model, the structure reported by Verma and Markey186 was used, as this model
had been tested on real and simulated clinical trial data and was found to have good clinical meaning.
Hence, the baseline data were then used to obtain the parameter estimates of the following item structure:
l memory trait – word recall, orientation items and word recognition
l language trait – naming objects and fingers items, spoken language, language comprehension, word
finding and remembering test instruction
l praxis trait – commands items, construction items and ideational praxis items.
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The model was estimated using the mirt package in R (The R Foundation for Statistical Computing, Vienna,
Austria) using a Metropolis–Hastings Robbins–Monro algorithm.187 Similarly to factor analysis, an oblimin
factor rotation was applied to allow each factor trait to correlate freely with each other.
This estimated model was then used to calculate the respondent’s ability for each latent trait at each
ADAS-Cog response. Baseline data were used to estimate the model, as there would be no influence from
the trial interventions on the data, and the balance between the groups was ensured by randomisation.
No patient-level data were added to the model.
Hence, the ADAS-Cog-IRT at a single follow-up point consists of the estimated ability for each of the three
traits separately. As the model allowed correlations between traits, total scores were not constructed. Scaling
factors were not applied; consequently, all trait abilities were generated using IRT standard parameters, that
is, the distribution of abilities for each latent trait is centred on a mean of 0 and a SD of 1.
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Appendix 6 Supplementary analyses
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TABLE 53 Flow of participants into the DAPA trial summarised by region
Phase and data
Region, n (%)
Total,
n (%)Berkshire
Black
Country Coventry
Devon
and Exeter
Greater
Manchester
West
Gloucestershire
and Herefordshire Leicester Northampton
North East
London Nuneaton Oxford Rugby Solent
South
Warwickshire Worcester
From entry into the trial up to pre randomisation
Total number
of patients
approached
46 180 589 26 44 27 148 274 57 382 381 174 21 172 408 2929
Excluded patients
not meeting the
eligibility criteriaa
1 (2) 9 (5) 337 (57) 2 (8) 8 (18) 5 (19) 47 (32) 57 (21) 16 (28) 236 (62) 102 (27) 75 (43) 2 (10) 24 (14) 161 (39) 1082
(37)
Randomisation
Patients satisfying
the entry inclusion
criteriaa
41 (89) 45 (25) 54 (9) 10 (38) 18 (41) 18 (67) 17 (11) 62 (23) 18 (32) 23 (6) 75 (20) 24 (14) 10 (48) 36 (21) 43 (11) 494
(17)
Patients satisfying
the entry inclusion
criteriaa
4 (9) 126 (70) 198 (34) 14 (54) 18 (41) 4 (15) 84 (57) 155 (57) 23 (40) 123 (32) 204 (54) 75 (43) 9 (43) 112 (65) 204 (50) 1353
(46)
Patients
randomised but
ineligible
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Follow-upb
No follow-up
data at any time
points
4 (10) 5 (11) 6 (11) 1 (10) 0 1 (6) 4 (24) 7 (11) 3 (17) 1 (4) 6 (8) 2 (8) 2 (20) 2 (6) 1 (2) 45 (9)
Follow-up data
available for
6 months only
6 (15) 3 (7) 5 (9) 0 1 (6) 1 (6) 1 (6) 6 (10) 1 (6) 1 (4) 3 (4) 0 1 (10) 2 (6) 0 31 (6)
Follow-up data
available for
12 months only
0 0 1 (2) 0 0 0 0 1 (2) 0 0 0 0 0 0 2 (5) 4 (1)
Follow-up data
available for both
6 and 12 months
31 (76) 37 (82) 42 (78) 9 (90) 17 (94) 16 (89) 12 (71) 48 (77) 14 (78) 21 (91) 66 (88) 22 (92) 7 (70) 32 (89) 40 (93) 414
(84)
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Phase and data
Region, n (%)
Total,
n (%)Berkshire
Black
Country Coventry
Devon
and Exeter
Greater
Manchester
West
Gloucestershire
and Herefordshire Leicester Northampton
North East
London Nuneaton Oxford Rugby Solent
South
Warwickshire Worcester
Diedb
Patient dies post
randomisation up
to 6 months’
follow-up
1 (2) 0 2 (4) 0 0 0 0 1 (2) 0 0 1 (1) 0 0 1 (3) 0 6 (1)
Patient died
during 6 to
12 months’
follow-up
2 (5) 0 3 (6) 0 0 1 (6) 1 (6) 2 (3) 0 0 1 (1) 0 0 2 (6) 0 12 (2)
Withdrawalsb
Patient
withdrew post
randomisation up
to 6 months’
follow-up
3 (7) 4 (9) 4 (7) 1 (10) 0 1 (6) 4 (24) 5 (8) 2 (11) 1 (4) 5 (7) 2 (8) 2 (20) 1 (3) 0 35 (7)
Patient withdrew
during 6 to
12 months’
follow-up
4 (10) 3 (7) 0 0 0 0 0 0 0 0 2 (3) 0 1 (10) 0 0 10 (2)
Non-responders (follow-up)b
Non-response
to 6-month
follow-up
0 1 (2) 1 (2) 0 0 0 0 2 (3) 1 (6) 0 0 0 0 0 3 (7) 8 (2)
Non-response to
6 to 12 months’
follow-up
0 1 (2) 2 (4) 0 1 (6) 0 0 5 (8) 2 (11) 1 (4) 0 0 0 0 1 (2) 13 (3)
a % calculated using the total number of participants approached in the respective region as the denominator.
b % calculated using the number of participants randomised in the respective region as the denominator.
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TABLE 54 Summary of the type of organisation providing recruits in each region
Data source
Region
Total,
n (%)Berkshire
Black
Country Coventry
Devon
and Exeter
Gloucestershire
and Herefordshire
Greater
Manchester
West Leicester
North East
London Northampton Nuneaton Oxford Rugby Solent
South
Warwickshire Worcester
Primary care 0 67 115 0 2 0 17 0 2 71 0 7 0 57 217 555
RiL 34 0 0 0 0 1 16 0 215 0 207 0 0 0 0 473
Secondary
care
6 92 111 21 20 29 68 40 0 75 71 88 19 80 30 750
Other 5 12 26 3 0 6 0 1 0 0 1 4 0 11 0 69
Total 45 171 252 24 22 36 101 41 217 146 279 99 19 148 247 1847
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TABLE 55 Randomised patients by randomisation strata and treatment (region, sMMSE category)
Region
sMMSE score
Treatment arm, < 20 Treatment arm, ≥ 20
Usual care Exercise programme Usual care Exercise programme
Berkshire 4 5 9 23
Black Country 7 12 8 18
Coventry 7 13 11 23
Devon and Exeter 1 3 3 3
Gloucestershire and Herefordshire 1 2 5 10
Greater Manchester West 2 5 4 7
Leicester 0 2 5 10
North East London 2 2 4 10
Northampton 7 8 14 33
Nuneaton 3 8 5 7
Oxford 6 17 19 33
Rugby 3 6 5 10
Solent 0 1 4 5
South Warwickshire 5 10 7 14
Worcester 3 6 11 23
Total 51 100 114 229
TABLE 56 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 6 months
Characteristic/outcome
Died
(N= 6)
Withdrew
(N= 35)
Lost to
follow-up
(N= 8)
Completed
follow-up
(N= 445)
p-value for difference
between completers
and non-completersa
Age (years)
Mean (SD) 80.1 (4.3) 77.8 (8.7) 78.1 (6.6) 77.3 (7.9) 0.464
Range 74.1 to 87.4 51.1 to 92.2 65.9 to 88.6 50.4 to 94.6
Gender (male), n (%) 4 (66.7) 24 (68.6) 4 (50.0) 269 (60.5) 0.508
Marital status, n (%)
Single 0 1 (2.9) 1 (12.5) 7 (1.6) 0.013
Married 3 (50.0) 25 (71.4) 4 (50.0) 332 (74.6)
Separated 0 2 (5.7) 1 (12.5) 4 (0.9)
Divorced 2 (33.3) 2 (5.7) 0 11 (2.5)
Widowed 1 (16.7) 4 (11.4) 2 (25.0) 79 (17.7)
Cohabiting 0 1 (2.9) 0 11 (2.5)
Missing 0 0 0 1 (0.2)
continued
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TABLE 56 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 6 months (continued )
Characteristic/outcome
Died
(N= 6)
Withdrew
(N= 35)
Lost to
follow-up
(N= 8)
Completed
follow-up
(N= 445)
p-value for difference
between completers
and non-completersa
Living arrangements, n (%)
Live alone 3 (50.0) 8 (22.9) 4 (50.0) 82 (18.4) 0.195
Live with relatives 0 1 (2.9) 0 22 (5.0)
Live with wife/husband/
partner
3 (50.0) 26 (74.2) 4 (50.0) 340 (76.4)
Living with friends 0 0 0 1 (0.2)
Ethnicity, n (%)
White 5 (83.3) 33 (94.2) 8 (100.0) 432 (97.1) 0.05
Other 1 (16.7) 2 (5.8) 0 13 (2.9)
Age (years) left full-time education
Mean (SD) 16.8 (2.4) 16.1 (1.8) 15.6 (0.7) 16.2 (2.7) 0.919
Range 14 to 21 14 to 20 15 to 17 7 to 31
Missing 0 0 0 8
Highest level of education, n (%)
Degree/degree equivalent
(including higher degree)/
NVQ4/NVQ5
1 (16.7) 5 (14.3) 1 (12.5) 74 (16.6) 0.884
Higher education below
degree
1 (16.7) 5 (14.3) 0 38 (8.5)
NVQ3/GCE A-level
equivalent
0 1 (2.9) 1 (12.5) 22 (4.9)
NVQ2/GCE O-level/GCSE-
level equivalent/school
certificate
1 (16.7) 8 (22.8) 1 (12.5) 79 (17.8)
Other vocational/work-
related qualifications
0 5 (14.3) 3 (37.5) 95 (21.4)
No qualification 3 (49.9) 11 (31.4) 2 (25.0) 132 (29.7)
Missing 0 0 0 5 (1.1)
ADAS-Cog (imputed)
Mean (SD) 27.4 (12.5) 22.7 (8.0) 21.5 (6.5) 21.4 (9.1) 0.209
Range 12 to 41.7 8.7 to 43.4 15 to 35.7 5.3 to 52.7
Missing 0 0 0 2
ADAS-Cog (raw score)
Mean (SD) 27.4 (12.5) 21.6 (6.8) 21.5 (6.5) 20.7 (8.5) 0.219
Range 12 to 41.7 8.7 to 33.3 15 to 35.7 5.3 to 52
Missing 0 2 0 26
sMMSE score
Mean (SD) 18.2 (5.2) 21.1 (4.3) 22.6 (3.7) 21.9 (4.7) 0.157
Range 12 to 25 13 to 27 15 to 26 11 to 30
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
186
TABLE 56 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 6 months (continued )
Characteristic/outcome
Died
(N= 6)
Withdrew
(N= 35)
Lost to
follow-up
(N= 8)
Completed
follow-up
(N= 445)
p-value for difference
between completers
and non-completersa
EQ-5D-3L score (self-reported)
Mean (SD) 0.76 (0.42) 0.75 (0.19) 0.67 (0.39) 0.84 (0.18) < 0.001
Range –0.02 to 1 0.19 to 1 –0.02 to 1 –0.07 to 1
Missing 0 2 0 6
EQ-5D-3L VAS score (self-reported)
Mean (SD) 79.3 (27.0) 74.3 (22.8) 71 (20.3) 78.9 (17.8) 0.105
Range 30 to 100 20 to 100 49 to 100 20 to 100
Missing 0 1 0 9
QoL-AD score (self-reported)
Mean (SD) 43 (4.6) 37.0 (6.0) 38.4 (5.5) 39.0 (5.4) 0.267
Range 36 to 49 27 to 48 30 to 47 21 to 52
Missing 1 5 1 63
A-level, Advanced Level; GCE, General Certificate of Education; GCSE, General Certificate of Secondary Education;
NVQ, National Vocational Qualification; O-level, Ordinary Level.
a The p-value for continuous covariates was estimated using a univariate linear regression model. The p-value for categorical
covariates was estimated using either chi-squared test or Fisher’s exact test.
TABLE 57 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 12 months
Characteristic/outcome
Died
(N= 18)
Withdrew
(N= 45)
Lost to
follow-up
(N= 13)
Completed
follow-up
(N= 418)
p-value for difference
between completers
and non-completersa
Age (years)
Mean (SD) 81.0 (5.3) 77.6 (8.4) 77.0 (7.9) 77.2 (7.9) 0.260
Range 70.0 to 88.8 51.1 to 92.2 63.5 to 88.6 50.4 to 94.6
Gender (male), n (%) 13 (72.2) 27 (60.0) 7 (53.8) 254 (60.8) 0.860
Marital status, n (%)
Single 0 1 (2.2) 2 (15.4) 6 (1.4) 0.008
Married 14 (77.9) 32 (71.1) 3 (23.1) 315 (75.3)
Separated 0 2 (4.4) 1 (7.7) 4 (1.0)
Divorced 2 (11.1) 3 (6.7) 1 (7.7) 9 (2.2)
Widowed 1 (5.5) 6 (13.4) 5 (38.4) 74 (17.7)
Cohabiting 1 (5.5) 1 (2.2) 1 (7.7) 9 (2.2)
Missing 0 0 0 1 (0.2)
continued
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TABLE 57 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 12 months (continued )
Characteristic/outcome
Died
(N= 18)
Withdrew
(N= 45)
Lost to
follow-up
(N= 13)
Completed
follow-up
(N= 418)
p-value for difference
between completers
and non-completersa
Living arrangements, n (%)
Live alone 3 (16.7) 11 (24.4) 7 (53.8) 76 (18.2) 0.244
Live with relatives 0 2 (4.4) 2 (15.4) 19 (4.6)
Live with wife/husband/
partner
15 (83.3) 32 (71.2) 4 (30.8) 322 (77.0)
Living with friends 0 0 0 1 (0.2)
Ethnicity, n (%)
White 15 (83.3) 43 (95.6) 13 (100.0) 407 (97.4) 0.022
Other 3 (16.7) 2 (4.4) 0 11 (2.6)
Age left full-time education (years)
Mean (SD) 17.4 (3.0) 15.9 (1.7) 15.5 (1.0) 16.2 (2.7) 0.996
Range 14 to 25 14 to 20 14 to 18 7 to 31
Missing 1 0 0 7
Highest level of education, n (%)
Degree/degree equivalent
(including higher degree)/
NVQ4/NVQ5
3 (16.6) 5 (11.1) 0 73 (17.5) 0.566
Higher education below
degree
5 (27.7) 5 (11.1) 0 34 (8.1)
NVQ3/GCE A-level
equivalent
1 (5.6) 1 (2.2) 1 (7.7) 21 (5.0)
NVQ2/GCE O-level/
GCSE-level equivalent/
school certificate
1 (5.6) 11 (24.4) 2 (15.4) 75 (17.9)
Other vocational/work-related
qualifications
1 (5.6) 9 (20.0) 6 (46.1) 87 (20.8)
No qualification 6 (33.3) 13 (29.0) 4 (30.8) 125 (29.9)
Missing 1 (5.6) 1 (2.2) 0 3 (0.8)
ADAS-Cog (imputed)
Mean (SD) 26.1 (11.2) 22.0 (8.6) 21 (9.1) 21.3 (8.9)
Range 12 to 52.7 5.3 to 44.7 8.7 to 42.7 5.7 to 52
Missing 0 0 0 2
ADAS-Cog (raw score)
Mean (SD) 23.5 (8.5) 21.3 (7.7) 21 (9.1) 20.8 (8.5) 0.372
Range 12 to 41.7 5.3 to 44.7 8.7 to 42.7 5.7 to 52
Missing 2 4 0 22
sMMSE score
Mean (SD) 19.1 (5.2) 21.2 (4.7) 21.5 (4.2) 22.1 (4.6) 0.023
Range 11 to 29 13 to 29 13 to 28 11 to 30
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TABLE 57 Baseline characteristics of participants who died, withdrew, were lost to follow-up or completed
follow-up at 12 months (continued )
Characteristic/outcome
Died
(N= 18)
Withdrew
(N= 45)
Lost to
follow-up
(N= 13)
Completed
follow-up
(N= 418)
p-value for difference
between completers
and non-completersa
EQ-5D-3L score (self-reported)
Mean (SD) 0.71 (0.35) 0.77 (0.18) 0.65 (0.26) 0.85 (0.18) < 0.001
Range –0.07 to 1 0.19 to 1 –0.02 to 1 –0.07 to 1
Missing 2 2 0 4
EQ-5D-3L VAS score (self-reported)
Mean (SD) 73.6 (24.2) 74.9 (22.5) 69.8 (20.1) 79.3 (17.5) 0.104
Range 30 to 100 20 to 100 36 to 95 20 to 100
Missing 2 1 0 7
QoL-AD score (self-reported)
Mean (SD) 37.2 (7.3) 36.7 (6.1) 37.5 (5.2) 39.2 (5.3) 0.003
Range 23 to 49 21 to 48 26 to 43 25 to 52
Missing 5 7 3 55
A-level, Advanced Level; GCE, General Certificate of Education; GCSE, General Certificate of Secondary Education;
NVQ, National Vocational Qualification; O-level, Ordinary Level.
a The p-value for continuous covariates was estimated using a univariate linear regression model. The p-value for
categorical covariates was estimated using either chi-squared test or Fisher’s exact test.
TABLE 58 Descriptive statistics of trait scores at all time points
Trait Time point n Mean SD Minimum Q1 Median Q3 Maximum
Memory Baseline 451 0 0.91 –2.08 –0.71 –0.03 0.67 2.68
6 months 403 0.06 0.88 –2.61 –0.62 0.02 0.69 3.31
12 months 386 0.02 0.82 –2.23 –0.52 0.01 0.64 2.39
Language Baseline 451 0 0.89 –1.94 –0.68 –0.1 0.68 2.77
6 months 403 0.06 0.93 –2.29 –0.65 –0.06 0.8 3.6
12 months 386 0.02 0.82 –1.99 –0.59 –0.01 0.69 2.76
Praxis Baseline 451 0 0.87 –1.73 –0.69 –0.1 0.65 2.93
6 months 403 0 0.85 –2.15 –0.64 –0.1 0.62 2.99
12 months 386 –0.02 0.81 –1.85 –0.64 –0.11 0.52 2.59
Q1, quarter 1; Q3, quarter 3.
Higher scores denote higher levels of cognitive impairment for that trait.
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TABLE 59 Abilities summarised by trial arm at baseline
Trait Arm n Mean SD p-value
Memory 1 301 0 0.89 0.932
2 150 0 0.94
Language 1 301 –0.01 0.88 0.753
2 150 0.02 0.92
Praxis 1 301 –0.02 0.85 0.499
2 150 0.04 0.91
Higher scores denote higher levels of cognitive impairment for that trait.
TABLE 60 Abilities summarised by trial arm at 6 months
Trait Arm n Mean SD p-value
Memory 1 276 0.1 0.89 0.205
2 127 –0.02 0.85
Language 1 276 0.1 0.94 0.228
2 127 –0.02 0.93
Praxis 1 276 0.04 0.88 0.097
2 127 –0.1 0.78
Higher scores denote higher levels of cognitive impairment for that trait.
TABLE 61 Abilities by group at 12 months
Trait Arm n Mean SD p-value
Memory 1 261 0.01 0.83 0.763
2 125 0.04 0.82
Language 1 261 0.02 0.81 0.826
2 125 0.04 0.86
Praxis 1 261 0 0.8 0.554
2 125 –0.06 0.83
Higher scores denote higher levels of cognitive impairment for that trait.
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FIGURE 23 Box plots of respondent ability scores at each follow-up point for each latent trait. (a) Memory;
(b) language; and (c) praxis.
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TABLE 62 Adjusted regression model for the memory trait at 12 months’ follow-up
Variables Estimate 95% CI p-value
Baseline score 0.000 –0.09 to 0.10 0.98
Arm: arm 2 0.002 –0.16 to 0.18 0.801
sMMSE score: score of ≥ 20 0.16 –0.02 to 0.35 0.082
Model includes region as a random effect.
TABLE 63 Adjusted regression model for the language trait at 12 months’ follow-up
Variables Estimate 95% CI p-value
Baseline score 0.00 –0.09 to 0.09 0.998
Arm: arm 2 0.004 –0.15 to 0.22 0.678
sMMSE score: score of ≥ 20 0.23 0.05 to 0.42 0.015
Model includes region as a random effect.
TABLE 64 Adjusted regression model for the praxis trait at 12 months’ follow-up
Variables Estimate 95% CI p-value
Baseline score –0.05 –0.22 to 0.14 0.607
Arm: arm 2 0.05 –0.05 to 0.15 0.286
sMMSE score: score of ≥ 20 –0.06 –0.24 to 0.12 0.512
Baseline score 0.09 –0.08 to 0.28 0.346
Model includes region as a random effect.
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
192
Appendix 7 Serious adverse event details
SAE
number Event details Description
1 Participant was participating in ‘Walks for Health’ as part of follow-on physical activity
after cessation of exercise classes. Fell, suffered lacerations to face, may need surgery.
Admitted to hospital same day
Fall
2 Participant reported gradual worsening of hip pain over 2 weeks – initially did not feel
the class was the cause and happy to continue. Pain got worse so he saw an osteopath
privately who recommended he cease all physical exercise. Two weeks later wife
reported he is still in a lot of pain and will not be returning to the class, as he is awaiting
urgent MRI scan
Pain
3 Last exercise session therefore shorter session, only two PRT exercises completed. Sitting
awaiting refreshments, spoke to participant who reported start of chest pain and has
taken GTN spray. Sat with patient – pain not resolving with GTN. Asked centre staff
to assist. Monitored pain for few minutes then noted participant’s colour changing.
HR reduced to high 48s (normal 60s) and closing eyes. Was able to respond to me but
intermittent. Asked centre staff to call for help – patient lowered to floor. Resuscitate
officer arrived in minutes – defibrillator applied but not required. Taken to A&E for
monitoring. Plan to admit
Hospital admission
4 Participant on walk, fell, required hospitals admission for facial injury. Diagnosed with
urinary tract infection, discharged home after approximately 1 month. Has returned to
previous level of functional ability, but walking is slightly more unsteady
Hospital admission
A&E, accident and emergency; GTN, glyceryl trinitrate; MRI, magnetic resonance imaging; PRT, Progressive Resistance Training.
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Appendix 8 Semistructured interview guides for
participants, carers and physiotherapists
Participants 
This interview schedule is for participants in the DAPA trial and has been designed on the 
basis of analysis done on 3 observations of the DAPA exercise classes, 15 exploratory 
interviews with participants, their careers and physiotherapists. The questions are focused on 
three emerging themes which have been used to code the transcripts which are: Exercise, 
Burden and The elephant in the room.  
Exercise This is used when participates, carers or physio’s talk about their experiences 
of doing the exercises, delivering the exercise intervention and perceived 
impact (or lack of) of the intervention. 
Burden Burden is used where a participant, carer or physio’s talks about the (lack 
of) burden due to participating in the trial, daily life and or delivering the 
intervention. 
The 
elephant in 
the room 
Used when participants, carers or physio's talk about or fail to talk explicitly 
about Dementia, Alzheimer’s or any other formal diagnosis. May be used to 
highlight where euphemisms like 'memory problems' are used in their place 
(or in addition to) formal diagnosis. 
 
• Do you like going to the exercise classes? 
Prompts: what do you like about them, what don’t you like, what’s your favourite part, 
what do you like least, what do you find easy/difficult? 
• How do you feel during the classes? 
• How do you feel after the classes? 
Prompts: what do you do afterwards if you feel tired/full of energy/normal 
• How do you get to the classes 
Prompts: is it difficult, easy, no problem, a worry? 
• If you were able to change some things about the class what would they be? 
• Can you tell me what your day-to-day like was like before you started the DAPA 
classes? 
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Prompts: how did you get around, did you do regular activities/exercises? Were you 
busy enough, wanted to do more, bored? 
I would now like to ask you about why you think you are taking part in the exercise classes 
• Can you tell me why? 
Prompts: some older people have memory problems, do you have memory problems, 
and do you think you have Dementia or Alzheimer’s? 
•  If patient acknowledges their diagnosis and ask: Can you tell me what your main 
symptoms are?  
• How do they impact on your day-to-day life? 
Prompts: how do you manage your symptoms with close family and friends, 
acquaintances, in the exercise class, in public and with strangers? 
• Would you mind if the people instructing you in the class talked about the fact that 
everyone is having memory problems? 
• Do other people say to you that you are repeating yourself or that they have already told 
you something that you have no memory of? 
Prompts: how does that make you feel when that happens? Would you rather people 
didn’t bring your attention to your memory problems or is it helpful? Do you find it 
embarrassing?  
• Do you think that the exercise classes will make you physically fitter? 
Prompts: in what way, how would you know if you were fitter? 
• If you were to become fitter would your day-to-day life change in anyway 
Prompts: is there anything you would like to do that you are currently unable to? 
• Do you think that the exercise classes can help with your memory? 
Prompts: how would you know if your memory had improved? 
• Do you think that the exercise classes can help with your sense of well-being? 
Prompts: how would you judge if your well-being had improved? 
• What are your hopes for the future? 
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Carers 
This interview schedule is for carers in the DAPA trial and has been designed on the basis of 
analysis done on 3 observations of the DAPA exercise classes, 15 exploratory interviews with 
participants, their careers and physiotherapists. The questions are focused on three emerging 
themes which have been used to code the transcripts which are: Exercise, Burden and The 
elephant in the room.  
Exercise This is used when participates, carers or physio’s talk about their experiences 
of doing the exercises, delivering the exercise intervention and perceived 
impact (or lack of) of the intervention. 
Burden Burden is used where a participant, carer or physio’s talks about the (lack 
of) burden due to participating in the trial, daily life and or delivering the 
intervention. 
The 
elephant in 
the room 
Used when participants, carers or physio's talk about or fail to talk explicitly 
about Dementia, Alzheimer’s or any other formal diagnosis. May be used to 
highlight where euphemisms like 'memory problems' are used in their place 
(or in addition to) formal diagnosis. 
 
• How did you get involved in the trial? 
has it been a burdensome process, are you happy to be involved 
• Can you tell me about you and your partner’s activity levels before taking part in the 
trial? What was a typical day/week like? 
• What does it mean to you to be involved in the trial? 
• How do you cope with your loved one’s dementia? 
Day to day, week to week, planning for the future, do you talk openly about the disease, 
in public, in private, with friends and family 
• What separates a good day from a bad day? 
• Do you think the exercise is having any effect on your wife/husband 
How tired are they, what do they do after the class or the next day 
• Do you think you will manage to do exercise after the exercise classes stop? If not why, 
if so, how? 
• Thinking about the classes is there anything about them that you would change about 
them  
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• Would you be comfortable if it was someone other than a physio leading the exercise 
class an exercise instructor for example? 
• Is there anything else you think we should know? 
 
Physiotherapists 
• Could you describe your role in the DAPA trial 
• How did you come to be part of the DAPA team 
• Can you tell me about your previous experiences of running classes 
• How does running classes with dementia patients differ to working with other groups? 
• Tell me about how you learnt the protocol 
Prompts: what about any specific training given around Dementia, did you learn 
anything new about Dementia?  
• How would you describe your approach to this patient group, does it differ from other 
patients that you have worked with, how? 
• Do you speak directly with participants about the fact that they have dementia? 
Prompts: if not why,  
Moving on now to talk about your experiences with participants in more detail 
• Could you please describe the symptoms of dementia that you have encountered so far? 
• Thinking about times when you have encountered them, how have you reacted? 
• Would you like to react differently in the future? 
• Which symptoms most interfere with compliance with the intervention 
Prompts: how do you negotiate them? 
• What effect do you think the intervention will have on participants? 
• How can you tell if a patient is working hard enough, what have you done if they are 
not, or what do you imagine doing if they are not? 
Moving on now to talk about your experiences with participants carers 
• How much and what sort of contact have you had with carers so far 
Prompts; do they seek your advice/support? 
• Do carers talk openly about participants condition 
How and in what way? 
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
198
 Moving on now to talk about follow ups 
• Have you done any? What were they like? 
• Do you think the intervention will get a positive result 
• Do you think your participants might deteriorate 
• How do you think you will react if they have at 6 months 
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Appendix 9 Systematic review search strategy
Search strategy for update (inception to September 2016)
MEDLINE In-Process & Other Non-Indexed Citations (PubMed)
Search strategy
1. dementia [MeSH]
2. alzheimer*
3. lewy bod*
4. fronto-temporal
5. picks
6. korsako*
7. binswanger
8. ‘primary progressive aphasia’
9. ‘kluver bucy’
10. ‘cognition disorders’
11. cognitive impair*
12. memory impair*
13. OR/1-12
14. aged [MeSH]
15. old*
16. elder*
17. ‘middle aged’
18. ‘frail elderly’
19. OR/14-18
20. exercise [MeSH]
21. physical activit*
22. ‘resistance exercise’
23. ‘strength training’
24. ‘weight training’
25. ‘anaerobic exercise’
26. ‘aerobic exercise’
27. run*
28. swim*
29. walk*
30. danc*
31. cycling
32. yoga
33. ‘tai ji’
34. OR/20-33
35. randomised controlled trial [pt]
36. controlled clinical trial [pt]
37. randomised [tiab]
38. placebo [tiab]
39. randomly [tiab]
40. trial [tiab]
41. groups [tiab]
42. OR/35-41
43. 13. AND 19. AND 34. AND 42.
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